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Abstract 
Human respiratory syncytial virus is a leading cause of lower respiratory tract infection 
in infants. Current prophylaxis with Palivizumab, a humanised anti-fusion glycoprotein 
monoclonal antibody, has only achieved moderate success. In animal models, 
immunization with G glycoprotein has led to largely genotype specific immunity. This 
suggests the hypothesis that anti-G antibodies to the infecting virus genotype, either 
acquired transplacentally or induced by immunisation, may contribute to protection of 
the infant in the early months of life.  
The aim of this study has been to test this hypothesis by measuring levels of maternally 
acquired antibody to the G glycoprotein of the infecting virus genotype in an index 
group of infants with severe HRSV infection and, to the same genotype, in a 
comparison group of infants with no history of HRSV infection. As only 2% of infants 
suffer severe disease on primary HRSV infection, the comparison group are assumed to 
be destined to be resistant to severe infection. A deficiency of anti-G antibodies in the 
index group will thus indicate a protective role for these antibodies.  
A phylogenetic study was carried out in Newcastle upon Tyne from autumn 2007 to 
spring 2010 revealing three circulating genotypes of HRSV, namely GA2, GA5 and 
BA4 although GA5 was not detected in the third epidemic. The G genes of GA2 and 
BA4 and the F gene of GA2 were cloned and expressed individually in modified 
vaccinia Ankara virus. The recombinant proteins were used in the development of a 
concanavalinA capture ELISA sufficiently sensitive to detect maternal antibodies in the 
acute sera of infants under 6 months of age. An attempt was made to refine the assay in 
order to separately detect antibodies to the conserved and variable epitopes of the G 
glycoprotein. However, mapping of conserved and variable epitopes revealed overlap 
epitopes precluding the development of a differentiation in a simple ELISA assay. 
An index group of infants with severe HRSV infection and a comparison group of 
infants of similar age with no history of HRSV infection were recruited with consent by 
their legal carer during the epidemic of 2009/2010. The infecting virus lineage of each 
infant in the index group, either GA2 or BA4, was identified by reverse transciptase-
polymerase chain reaction of virus recovered from nasal secretions. Sera were collected 
from both groups, at the acute stage of infection for the index group, and screened for 
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HRSV specific IgA by ELISA. Only those without detectable IgA were included in the 
study.    
IgG maternal antibodies to the recombinant G glycoprotein of the infecting virus 
genotype and the F glycoprotein of the GA2 genotype were measured in the sera of 
index and comparison group infants whilst maternal antibody levels to both F and G 
glycoproteins in the sera of both index and control sera decayed at similar rates with age, 
the index group possessed significantly more anti-G and anti-F antibody at all ages 
suggesting that infants hospitalized with severe HRSV infection were not deficient in 
antibodies to either glycoprotein contrary to the hypothesis under test. However, mean 
maternal antibody levels at birth have been shown to fall across the winter epidemic and 
the above analysis may be susceptible to bias introduced by uneven sampling of  infants 
across the epidemic. To avoid this potential error, anti-F/anti-G antibody ratios, which 
give a measure of anti-G immunity independent of age and time of collection, were also 
compared in the sera of index and comparison group infants. Mean ratios were not 
significantly different between the two groups also rejecting the hypothesis that severely 
affected infants have a deficiency in maternal anti-G antibodies. These studies, therefore, 
fail to establish a role for anti-G glycoprotein antibodies in the protection of infants 
against severe lower respiratory tract disease.  
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Chapter 1 Literature Review 
 2 
 
1.1 Origin 
A novel virus was isolated from a colony of chimpanzees suffering from coryza in 1956 
and named chimpanzee coryza agent (CCA). Following the discovery, antibodies to 
CCA was detected in the serum of a laboratory worker suffering from a cold, providing 
evidence that CCA or CCA-like agents were capable of crossing species barrier from 
chimpanzee to human. This was further confirmed with the isolation of CCA-like 
viruses from 2 infants with bronchopneumonia and laryngotracheobronchitis with 
respiratory tract infections named Long virus and Synder virus respectively (Chanock et 
al., 1957) both Long virus and Synder virus exhibited identical cytopathogenic effect 
(CPE) with CCA virus which was described as the formation of syncytial areas although 
round cell degeneration also occurred in KB cells. A population study revealed that, by 
the age of 4 years, 80% of the children had been exposed to this infecting agent by the 
presence of neutralizing antibodies to the Long virus. Thus the these agents were 
grouped together and the term respiratory syncytial virus was introduced (Chanock and 
Finberg, 1957). 
1.2 Classification and morphology  
 
Figure 1 The taxonomy of HRSV  
Adapted from The International Committee on Taxonomy of Viruses (ICTV). 
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The HRSV is the prototype strain of the genus pneumovirus within the 
Paramyxovirinae subfamily as shown in Figure 1. HRSV contains two serologically 
distinct subgroups, A and B which cocirculate during HRSV epidemics. Other members 
include bovine respiratory syncytial virus, ovine pneumonia virus and murine 
pneumonia virus. Within the subfamily is the genus Metapneumovirus which contains 
avian metapneumovirus and the recently found human metapneumovirus (HMPV) (van 
den Hoogen et al., 2001). The clinical symptoms caused by HMPV ranges from upper 
respiratory tract infection to severe bronchiolitis and pneumonia, indistinguishable from 
the clinical symptoms caused by HRSV(van den Hoogen et al., 2001). 
The HRSV is a Baltimore Class V virus which contains a single-strand, non-segmented, 
negative sense RNA with the molecular weight of approximately 5.0 x 106Da (Y. T. 
Huang and Wertz, 1982). The actual size of the genome is strain dependent but the 
typical length is about 15k nucleotides (nt).  
The HRSV virions are either spherical, filamentous or pleomorphic particles. The 
spherical particles are about 90-130nm in diameter (Norrby et al., 1970) but particles 
with the diameter between 150-500nm have also been observed. (Bachi and Howe, 
1973). Filamentous particles are predominantly observed having diameters ranging 
between 100 to 120nm. They can be as long as 10µm in length.  
Peripheral spikes with the length of 10nm can be observed in all of the particles 
comprising one or all of the three transmembrane viral envelope proteins: the 
attachment (G), the fusion (F) and the small hydrophobic (SH) glycoproteins. 
1.3 Genome, transcription and replication 
The genome of HRSV is neither capped nor polyadenylated and carries 10 viral genes 
(P L Collins et al., 1984a; P. L. Collins et al., 1986) as shown in Figure 2. Genes are 
separated from one another by intron-like regions called the intergenic regions which 
vary in length from 1 to 53nt without any significant conservation (P. L. Collins et al., 
1986).  
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Figure 2 Diagram depicting the RSV genome and its transcription and replication 
products.  
The virus genes are depicted as grey rectangles; the L gene, which comprises almost 
half of the genome, has been truncated. The GS and GE signals are shown as white and 
black boxes, respectively. The encoded antigenome and mRNAs are indicated by 
hatched rectangles. Arrows indicate the location of the promoters (Cowton et al., 2006). 
Each gene is flanked by the gene start (GS) and gene end (GE) sequences which direct 
the polymerase during transcription. The GS sequence for the first nine genes is 
conserved except the GS for the L gene. The function of each GS and GE is 
independent of the gene it flanks and can be attached to foreign genes to direct 
transcription into subgenomic mRNA (Kuo et al., 1996). At the 3’- and 5’- ends of the 
genome are short extragenic regions known as the 44nt leader sequence (Le) and a 
155nt trailer sequence (Tr) respectively (P. L. Collins et al., 1991; Mink et al., 1991).  
 
Figure 3 The negative sense RNA genomic sequence of Le and NS1 GS of HRSV.  
Adapted from (McGivern et al., 2005; Cowton et al., 2006), based on strain A2. The 
polymerase binding site, U-rich region and region important for encapsidation is shown. 
HRSV is monocystronic in nature with the sole promoter for transcription located in the 
Le where the polymerase binds to nt 1-11 and moves along the length of the genome 
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(Cowton and Fearns, 2005). There is an uracyl-rich (U-rich) region at the end of the Le 
sequence (Figure 3), just before the NS1 GS which determines the efficiency of 
transcription. The U-rich and NS1 GS sequence can tolerate up to 80nt foreign 
nucleotide insertion upstream without any significant inhibitory effect to transcription. 
However, deletions in the sequence upstream of the U-rich region cause inhibitory 
effects on transcription (Fearns et al., 2000; McGivern et al., 2005). The NS1 GS 
sequence is part of the sequential-transcription system (Cowton et al., 2006) whereby 
mutation to this sequence causes up to 90% reduction of downstream genes transcript 
(Kuo et al., 1996). 
The GS sequence is believed to hold the template-bound polymerase for a sufficient 
time to allow the initiating nucleotides to enter the polymerase active site and to initiate 
RNA synthesis (Cowton et al., 2006). When the polymerase reaches the GE sequence, it 
polyadenylates and releases the nascent mRNA. It then reinitiates RNA synthesis at the 
next GS sequence and caps (Liuzzi et al., 2005) and methylates the 5’-of the RNA. 
Thus, the GS and GE signals help to produce polycistronic mRNAs for individual 
protein translation (P. L. Collins and Wertz, 1983). The GE sequence contains the 
UCAAU motif which is conserved in nine of the ten GE sequences. The GE motif is 
probably designed to be of moderate efficiency to ensure polymerase readthrough 
during transcription (P. L. Collins and Wertz, 1983) resulting in read through mRNAs 
in HRSV infected cells.  
The M2-1 protein helps to enhance processivity of the polymerase which in turn ensures 
read through at the GE sequence (Sutherland et al., 2001) and prevents inappropriate 
dissociation at the U-rich intergenic region (Hardy and Wertz, 1998; Sutherland et al., 
2001). 
With sufficient processivity and GE read through capability, the polymerase will still 
have the tendency to dissociate from the genome resulting a gradient of expression, with 
the gene at the 3’- end being transcribed more frequently compared to those at the 5’- 
end of the genome (Krempl et al., 2002). Thus, proteins that are required in vast 
quantity are positioned near the 3’- end while those needed in minute quantity are near 
the 5’-end (P. L. Collins and Crowe, 2001). 
The polymerase has a dual function in transcription (as transcriptase) and replication 
(replicase) but the actual mechanism controlling these two functions is not yet 
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understood. During replication, the polymerase binds to the Le region and initiates full 
length antigenome synthesis from the 3’-end disregarding the GS and GE motifs. The 
first 34nt of the Le region are important for antigenome synthesis but the polymerase 
binding site remains the same as during transcription revealing a dual function for the 
first 11nt. The central region of the Le sequence (nt 16-34) is believed to mediate 
encapsidation nucleation of the antigenomic RNA and to ensure readthrough at the GE 
sequences (McGivern et al., 2005) 
At the end of the antigenome (positive strand genome) is the complement for the trailer 
(TrC) (Figure 2) which contains a promoter to generate the negative sense genomic 
RNA at a significantly higher level of replication than the Le resulting in higher 
concentration of negative sense genomic RNA (product of TrC promoter) compared to 
positive sense antigenomic RNA (product of Le promoter) in infected cells (Mink et al., 
1991).  
The first 36nt in TrC is sufficient to initiate replication and to direct transcription when 
positioned upstream to a GS sequence. TrC and Le promoters have identical strength 
when the Le sequence was replaced with the TrC sequence in a minireplicon 
experiment. However, then the length of the introduced TrC sequence was increased to 
147nt, replication was increased four-fold with almost total silencing of transcription 
suggesting that there is a non-essential cis-acting element which enhances replication. 
This element is thought to reside in nucleotide residues 36-97 but the exact location and 
mechanism has not been mapped to date. However, this cis-acting element is believed to 
accelerate polymerase binding to the promoter and speed up initiation of RNA synthesis 
and promoting encapsidation of the nascent RNA which might facilitate replication 
processivity (Fearns et al., 2000). The genomic RNA is encapsidated with nucleoprotein 
immediately upon synthesis (Cowton et al., 2006). 
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1.4 Viral proteins 
1.4.1 Non-structural proteins (NS)  
HRSV encodes for 2 nonstructural proteins from 2 open reading frames producing NS1 
and NS2. They are synthesized in high quantity in infected cells but are not packaged 
into the matured virions (Bitko et al., 2007). 
NS proteins act as host range determinants. Bovine respiratory syncytial virus (BRSV) 
and HRSV grow in an identical manner in both human and bovine cells lacking intact 
interferon (INF) functions. However, when grown in INF competent human cells, the 
growth of BRSV was retarded and vice versa. Similarly, the growth of HRSV was 
insensitive to exogenous INF when grown in human cell line but growth was retarded 
by exogenous INF when grown in cells from bovine origin. (Bossert and Conzelmann, 
2002). 
The nonstructural proteins function by inhibiting host innate immunity especially the 
type I interferon (IFN) to ensure uninhibited growth in the host cells with NS1 playing a 
greater role compared to NS2 (Spann et al., 2004). NS1 and NS2 are functionally 
related and were shown to form a heterodimer in immunoprecipitation experiment but 
can function individually or in concert in the inhibition of the IFN synthesis pathway 
and IFN function. (Swedan et al., 2009). The deletion of NS1 and M2-2 caused 
attenuation of the virus in a primate model (Teng et al., 2000) and severely retarded the 
viral replication, producing smaller plaques in Vero cell culture. NS2 is relatively 
unstable with the half life of 30 minutes suggesting that it plays an important role in the 
early phase of the life cycle. (Evans et al., 1996).  
NS2 alone can inhibit the INF production mediated by the retinoic acid induced gene I 
(RIG-I) and Toll-like receptor 3 (TLR3) pathways (Ling et al., 2009). It also reduces the 
level of signal transducer and activator of transcription 2 (STAT2), a transcription factor 
for INF-inducible antiviral genes by proteasome-dependent degradation but increases 
the level of inhibitor of NF-kappaB kinase ε (IKKε) (Swedan et al., 2009). However, 
NS1 is known to reduce the production of IKKε (Swedan et al., 2009) suggesting a 
negative regulatory effect on NS2. 
Both NS1 and NS2 work together in reducing the level of TRAF3 (Tumour Necrosis 
Factor receptor-associated factor 3) with NS1 playing a greater role (Swedan et al., 
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2009). TRAF3 functions downstream of multiple (Tumour necrosis factor) TNF 
receptors and receptor that induces INF-, INF-β and INF-λ synthesis, including 
Toll-like receptor 3 (TLR3) (Pérez de Diego et al., 2010) and is a negative 
regulator for NF-KappaB activation (Ikeda et al., 2010). The genetic deficiency in 
TRAF3 ablates the ability of individuals to activate INF upon stimulation and is 
associated with increased susceptibility to herpes simplex virus-1 encephalitis (HSE) 
(Pérez de Diego et al., 2010). The expression of both NS proteins prevent the early 
apoptosis of infected cells (Bitko et al., 2007). 
Although NS1 is not packaged into the matured virion, it might be involved in the 
virion packaging process as it was shown to be associated with the matrix protein in a 
co-immunoprecipitation experiments (Teng et al., 2000). The absence of NS1 reduces 
the efficiency of the virion assembly and budding (Jin et al., 2000).  
1.4.2 NPL complex 
The HRSV nucleoprotein (B. Garcia-Barreno et al., 1996), phosphoprotein, polymerase 
(Khattar et al., 2001) and M2-1 (Mason et al., 2003) proteins work in concert in RNA 
synthesis.  
Nucleoprotein (N) 
Common with all other members of Mononegavirales order, HRSV encodes for a 
nucleoprotein, in this case of 391 amino acids (aa) in length,which forms a nuclease 
resistant helical ribonucleoprotein complex with the genomic RNA forming the 
nucleocapsid (P. L. Collins and Crowe, 2001). N forms a decameric ring like structure 
with each nucleoprotein subunit held together by van der Waals interaction between the 
highly hydrophilic N-terminal domain (aa36-253) and C-terminal domain (aa257-360). 
The decameric structure is further stabilised by the genomic RNA belt which runs 
within a basic surface groove surrounding the periphery of the ring with every 7 
nucleotides interacting with one N subunit (Tawar et al., 2009). 
The C-terminal end of N was shown to bind to the phosphoprotein using monoclonal 
inhibition assay and peptide interference assays (Murray et al., 2001).  
With the resolution of the crystal structure of N, it was postulated that the polymerase 
can read along the RNA without the need to dissociate N from the genomic RNA by 
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transiently moving the N-terminal domain (NTD) like a lever exposing the bases during 
transcription (Tawar et al., 2009). Encapsidation of the genomic RNA prevents the 
formation of secondary structure, eliminatinig the need of helicase and reduces the 
formation of double stranded RNA to avoid triggering host’s antiviral response (Le 
Mercier et al., 2002). 
Phosphoprotein (P) 
The phosphoprotein is a 241 amino acid protein which is folded into oligomer of ~500 
kDa, possibly a homotetramer. It contains a central structured domain (aa100-200) 
flanked by two essentially disordered regions (aa1–99 and aa201–241) (Llorente et al., 
2006). P is heavily phosphorylated in Ser232 and the absence of phosphorylation at this 
site yielded a partially synthesized RNA transcript suggesting that phosphorylation is 
essential in the activation or stabilization of the polymerase (Dupuy et al., 1999).  
RNA dependent RNA polymerase (L protein) 
The RNA dependent RNA polymerase is the largest protein encoded by HRSV which 
gives it the abbreviation L protein. The L gene of HRSV strain A2 is 6578nt long 
encoding a protein of 2165aa with a molecular weight of 250kDa as determined by 
electrophoretic mobility (Stec et al., 1991; P. L. Collins and Crowe, 2001). The L 
protein sequence is rather similar to that of other paramyxoviruses but with a 70 aa 
extension at the N-terminus which is probably due to the adoption of a new translational 
start codon which overlaps with the upstream M2 gene. The N-terminus half of the L 
protein shares 20% homology with the equivalent regions of other negative stranded 
virus polymerases and contain 6 isolated segments that are colinear and highly 
conserved with 3 segments match sequence motifs also found in other RNA-dependent 
RNA and DNA polymerases (Stec et al., 1991). 
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1.4.3 Matrix protein (M) 
The matrix protein association with the NS1 protein suggests that it requires the NS1 for 
maturation, assembly (Teng et al., 2000) and are responsible for connecting the viral 
membrane to the nucleocapsid and plays a role in RNA regulation (Ghildyal et al., 
2006). The M protein was shown to translocate into the nucleus of infected cells 
through the action of importin β1 nuclear import receptor and exit into the cytoplasm 
through the nuclear export receptor Crm1 directed by the nuclear export signal (NES) 
located in residues 194-206 of the M protein. Mutation of NES in recombinant HRSV 
resulted in reduced virus production (Ghildyal et al., 2009).  
The mRNA coding the M2 protein contains two overlapping open reading frames 
(ORFs) ORF1 encodes the 22kDa structural protein, M2-1 and ORF2 encodes a 10kDa 
protein (M2-2) (Hardy and Wertz, 1998). 
M2-1 
The M2 gene of HRSV encodes for a protein of 194aa in length with the molecular 
weight of 22kDa, thus previously known as the 22k protein. The M2-1 proteins coexist 
in 2 isoforms and can be distinguished by western blot whereby a 24kDa species can be 
observed (Routledge et al., 1987). The 24k species is phosphorylated at Ser58 and 
Ser61 by casein kinase I (Cartee and Wertz, 2001). Interestingly the 24k species 
dominates when expressed alone but the 22k species dominates when co-expressed with 
other HRSV components. M2-1 self assembles into oligomers, possibly tetramers in 
infected cells (Tran et al., 2009), a phenomenon which was initially described 2 decades 
ago when resolving the M2-1 through polyacrylamide gel in non-reducing condition 
(Routledge et al., 1987). 
The M2-1 protein serves as a transcription factor which increases polymerase 
processivity, and acts as a transcription anti-terminator by promoting readthrough of 
intergenic junctions during virus transcription (Hardy and Wertz, 2000). The M2-1 
protein contains a Cys3-His1 motif (C-X7-C-X5-C-X3-H) near the N-terminus and this 
pattern is conserved in all human, bovine, and ovine RSV. This motif, known as the 
zinc finger motif is known to bind zinc in another molecule and maintains the integrity 
and function of M2-1. It is believed that the binding of zinc to this site alters the 3 
dimensional structure of M2-1 making it more accessible to cellular kinase for 
phosphorylation. Site directed mutagenesis experiments ablating the binding site of M2-
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1 with the nucleocapsid have shown that M2-1 can function alone (Hardy and Wertz, 
2000).  
M2-2 
Transcription of M2-2 is initiated by any of the three start codons upstream of the stop 
codon of M2-1 with the first two being more important. Studies have shown that the 
location of the M2-1 termination codon is crucial in regulating the translation of M2-2 
suggesting that M2-2 is accessed by ribosomes that are leaving the ORF1 (Gholamreza 
Ahmadian et al., 2000).  
M2-2 is expressed as a separate protein from M2-1 but its expression is believed to be 
highly regulated by M2-1 (Cheng et al., 2005) as the concentration of M2-2 is relatively 
low compared to that of other viral proteins (G. Ahmadian et al., 1999). 
M2-2 was initially found to be inhibitory to RNA transcription and transcription by 
RSV minireplicons and overexpression of the M2-2 protein completely inhibited the 
RSV replication (Cheng et al., 2005). However, recent studies have shown that M2-2 
acts as a regulatory factor for the RNA replication and transcription of HRSV in 
infected cells rather than being solely inhibitory. Experiments with the M2-2 knockout 
mutant (∆M2-2), where the second start codon of the M2 gene is silent show that M2-2 
increases RNA replication and regulates transcription. M2-2 promotes transcription in 
the early stage post infection and allows the mRNA to accumulate to a certain 
concentration. M2-2 downregulates transcription and upregulates replication when the 
threshold mRNA concentration is reached to favour genomic RNA synthesis. The 
absence of M2-2 attenuates the virus by the factor of 103, accelerates cytopathology in 
vitro but somehow increases gene expression. The deletion of the M2-2 can be an useful 
feature in vaccine design as it allows infection of the respiratory tract at low MOI but 
with the enhancement of viral protein production (Bermingham and Collins, 1999). 
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1.4.4 Surface glycoproteins 
HRSV expresses three glycoproteins which are displayed on the surface of the infected 
cells. They are the small hydrophobic protein (SH), the attachment protein (G) and the 
fusion protein (F). 
The small hydrophobic (SH) protein 
The small hydrophobic protein is a 64-65aa long depending on strain (64aa for 
subgroup A and 65aa for subgroup B). It is a type II integral transmembrane 
glycoprotein in which the N-terminus of the glycoprotein is anchored via a 
transmembrane region and the C-terminus located extracellularly (Peter L. Collins and 
Mottet, 1993). The exact extent of the transmembrane domain is controversial. Collins 
and Mottet, (1993) suggested aa14-41 but aa20-42 has recently been suggested (Gan et 
al., 2008). There are several forms of the SH protein present in infected cells which 
differ in their amount of glycosylation. The unglycosylated form (SH0) (7.5kDa), which 
accumulates in abundance, a minor truncated species (SHt) (4.5kDa) produced as the 
result of a second AUG translation initiation codon at methionine-23 (M23). SH0 
undergoes N-glycosylation at Asparagine-52 (N52) to form SHg (13kDa) while SHp 
(21-40kDa) is a post translational modification of SHg with the addition of 
polylactosaminoglycan to the N carbohydrates (R. A. Olmsted and Collins, 1989; Peter 
L. Collins and Mottet, 1993). SH accumulates in abundance in the compartments of the 
secretory pathway, such as the endoplasmic reticulum (ER) and the Golgi complex and 
associates closely with lipid raft structures within the Golgi complex (Rixon et al., 
2004). 
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Figure 4 Molecular model of full-length SH protein as a hexamer.  
W15/H22 residues within the trans-membrane domain are shown within the putative 
channel lumen. (Carter et al., 2010). 
Purified recombinant SH protein synthesized in E. coli were shown to form pentamers 
and hexamers (Figure 4) with a central channel measuring 1.9 and 2.6 nm respectively 
(Carter et al., 2010). This model shows the location of a conserved Tryptophan-15 
(W15) positioned at the channel entrance with a proximal Histidine-22 (H22). This 
structure is similar to that of the M2 protein of influenza virus type A which acts as an 
ion channel controlled by ‘tryptophan gates’. Gate movement is triggered by 
protonation of the histidine residue (Schnell and Chou, 2008). This tryptophan gate 
hypotheses had been further enhanced as the transmembrane domain of the HRSV SH 
protein forms pentameric -helical bundles producing cation selective ion channels in 
planar lipid bilayer (Gan et al., 2008). 
It has been suggested that the SH protein might also be involved in the enhancement of 
syncytium formation in cells (Heminway et al., 1994). However, recombinant HRSV 
lacking the entire SH gene replicated as efficiently as the wild type recombinant virus in 
cell culture, although it grew less efficiently in the lungs of mice (A. Bukreyev et al., 
1997; Techaarpornkul et al., 2001). Further studies of deletion mutants suggest that SH 
has a negative effect on virus fusion in cell culture (Techaarpornkul et al., 2001). In the 
absence of the G gene, virus expressing both the F and SH proteins display relatively 
smaller plaques, reduced fusion activity and slower viral entry compared to the virus 
expressing the F protein alone.  
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The G glycoprotein 
The G gene of HRSV strain A2 is 918nt in length which varies from strain to strain. The 
single gene encodes for two different types of glycoprotein, one being a type II integral 
transmembrane glycoprotein (Gm) (Satake et al., 1985; Gail W. Wertz et al., 1985), 
which is incorporated into mature virions and displayed on the infected cell surface, and 
a soluble form (Gs) which is secreted into the environment. 
The soluble form of G glycoprotein is the result of a second in frame translation 
initiation codon at methionine-48 (M48) (Lichtenstein et al., 1996) (see Figure 5). Gs is 
formed by proteolitic cleavage at the N-terminal during maturation to remove the 
truncated signal/anchor domain producing a polypeptide with the amino terminal 
asparagine residue corresponding to codon 66 (N66) of the full length G. The presence 
of the full length signal anchor domain prevents the cleavage of Gm suggesting the type 
II signal sequence (Roberts et al., 1994). Hence, Gs represents the ectodomain of Gm 
without the signal sequence and hydrophobic transmembrane region. Gs exist as a 
soluble monomer (Escribano-Romero et al., 2004).  
Gm of strain A2 has the predicted molecular weight of 32.5kDa and the mature 
molecular weight of 84-90 kDa which appears as a heterogeneous band in western blots 
although less glycosylated bands of approximately 45-80 kDa can accumulate to a 
significant amount (Gail W. Wertz et al., 1985). Gs is 6-9 kDa smaller compared to Gm 
in electrophoretic mobility (Lichtenstein et al., 1996). This information suggests that 
more than half of the molecular weight of the G glycoprotein consists of carbohydrates 
especially the O-linked oligosaccharides (Gail W. Wertz et al., 1985). Matured Gm 
oligomerizes into a homotetramer or homotrimer in the endoplasmic reticulum 
(Escribano-Romero et al., 2004). 
A new variant of subgroup B HRSV known as the Buenos Aires strain (BA) was 
isolated in 1999 which contains an exact repetition of 60 nucleotides in the G gene 
subsequent to residue 791. This repetition is flanked by a repeat of four nucleotides 
(GUGU) and can fold into a relatively stable secondary structure. The predicted 
polypeptide is extended by another 20aa (residue 260-279), reflected in the slower 
electrophoretic mobility of the G protein precursor of BA viruses compared with related 
viruses (Trento et al., 2003). The antigenic significance of the repetition is currently not 
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known but has served as a useful natural tag in the epidemiological study of HRSV 
(Trento et al., 2010). 
 
Figure 5 Schematic and 2-dimentional diagram of HRSV G glycoprotein. 
A scheme of the 298 amino acid Gm protein from Long strain HRSV is presented in the 
upper part of the figure, denoting the hydrophobic region (▬), the potential N- (▼) and 
O-glycosylation sites (|), and the cysteine residues (●). Also indicated are the two 
mucin-like regions. Formation of the Gs form occurs by translation initiation at Met48 
and subsequent cleavage after residue 65 (Roberts et al., 1994). A 3D structure of the 
mature Gm shown as a homodimer rather than a homotetramer at the bottom of the 
figure for illustration purpose (Escribano-Romero et al., 2004; Melero and Cane, 2006). 
The first 37aa at the N-terminus form a cytoplasmic tail and is followed by the 26 
hydrophobic residues of the transmembrane region. The first hypervariable region 
before the cysteine residues is a stiff shaft-like structure extending the polypeptide 
backbone towards the environment possibly due to steric interaction between the 
heavily clustered O-glycosylation of the region and the polypeptide (Jentoft, 1990). 
Both hypervariable regions are serine, threonine and proline rich which resembles the 
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amino acid composition of mucins as secreted by epithelial cells, and are named mucin-
like regions (I. Martinez et al., 1997). 
The epitopes of the G glycoproteins were grouped into three regions namely the 
conserved, subgroup specific and strain specific epitopes based on the sequence analysis 
of escape mutants selected against a panel of monoclonal antibodies. Briefly, virus 
plaques were passaged in the presence of monoclonal antibodies in the form of 
hybridoma supernatant which were raised against a subgroup A HRSV strain Mon/3/88 
and the G gene of the resulting escape mutants were sequenced and analysed (I. 
Martinez et al., 1997). Other methods such as competitive ELISA have been used for 
topological mapping of epitopes in the G glycoprotein and ten distinct epitope regions 
were identified based on the panel of monoclonal antibodies used (B Garcia-Barreno et 
al., 1989). 
The central unglycosylated region contains both conserved epitopes for all HRSV and 
subgroup specific epitope which are unique among HRSV from the same subgroup. The 
central unglycosylated region contains a 13aa sequence which is highly conserved 
among all HRSV strains and the ‘cysteine noose’ region overlaps four cysteine residues 
(aa 173, 176, 182, 186), also conserved in BRSV, which forms disulphide bonds 
between C173-C186 and C176-C182 holding this region like a hairpin loop (I. Martinez 
et al., 1997; Melero et al., 1997). The cysteine noose starts with a single -helix 
followed by a 1.5 -helical turn formed by residue P180-W185 in which the inner 
disulphide bridge (aa176-182) adopts the left hand conformation but the outer 
disulphide bridge (aa173-186) is less defined. The outer disulphide bridge probably 
adopts both left and right hand conformation which exist in equilibrium. The two -
helices are connected by a reverse type I turn (aa Cys176-Asn179) and form a 9Å thick 
disk with a diameter of approximately 20Å with Asn179 extending into the 
environment. A hydrophobic pouch of approximately 4Å is thought to attach to small 
ligands or amino acid side chains. The hydrophobic pouch is lined by Cys176-Cys182 
(top), Ile185-Cys186 (right), Val171 and Pro172 (bottom) and Cys173 (left). The 
Cys182 has the most surface accessibility with the backbone oxygen atom being the 
only exposed hydrophilic atom in the pouch and is hydrogen bonded with the amide 
hydrogen of Cys186 (Doreleijers et al., 1996).  
The C-terminal hypervariable region of the Gm after the cystine noose contains strain 
specific epitopes (I. Martinez et al., 1997). This region is prone to host protease 
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degradation and viruses grown in Vero cells exhibit a mature G protein which lacks the 
C-terminus and has a molecular weight of 55 kDa as compared to 80-90 kDa in HRSV 
grown in Hep-2 cells (Kwilas et al., 2009). The C-terminal hypervariable region is also 
highly O-glycosylated as with the first hyperviariable region and host cell specific 
glycosylation affects the expression of some strain specific epitope (Garcia-Beato and 
Melero, 2000). Thus, infection of a HRSV strain in different individuals might produce 
G glycoprotein with different carbohydrate side chain due to individual polymorphisms 
which alter the expression of epitopes in the G glycoprotein (Melero et al., 1997). The 
glycosylation of the C terminal hypervariable region seems to reduce the reactivity to 
human sera suggesting that glycosylation in this region is important as part of the viral 
immune evasion strategy (Rawling and Melero, 2007). 
The G glycoprotein was shown to play a role in attachment of HRSV. The use of G 
specific monoclonal antibodies blocks the attachment of wild type (wt) HRSV to HeLa 
monolayer (S. Levine et al., 1987). However, G gene deletion mutant viruses remained 
capable of infecting cells but with reduced efficiency of entry by 3 to 4-fold (Schlender 
et al., 2003).  
The G glycoprotein contains a heparin binding domain spanning from aa 184-198 in 
subgroup A and aa 183-197 in subgroup B (Feldman et al., 1999). Treatment of HRSV 
with heparin blocks in vitro infection of Hep-2 cells monolayer but only with the 
presence of heparin during the time of inoculation. Further experimentation with 
immobilized heparin and affinity chromatography confirms the binding of G to heparin 
(Krusat and Streckert, 1997). The G glycoprotein also binds to heparin-like 
glycosaminoglycans (GAGs) such as heparan sulphate expressed on the cell surface 
(Isidoro Martinez and Melero, 2000) which is also abundant in the lung.  
The Gs is produced in much larger quantity compared to the membrane bound G (Gm) 
(Roberts et al., 1994) in the first 24 hours p.i. and comprises 20% of the total G 
glycoprotein produced during infection. Gs was shown to play a role as an antigen 
decoy to facilitate immune evasion. Although the initial amount of Gs in the inoculum 
is insufficient to protect the virus from G specific antibodies from maternal transfer or 
previous infections, the local concentration of Gs surrounding the infected epithelial cell 
would be significant after one or two cycles in replication and may be enough to quench 
G specific antibodies (Alexander Bukreyev et al., 2008). 
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The central conserved cysteine noose contains a CX3C chemokine motif at amino acid 
position 182-CWAIC-186 which binds to CX3CR1, a specific receptor for the CX3C 
chemokine fractalkine (CX3CL1) which regulates leukocyte adhesion, activation, and 
trafficking (Tripp et al., 2001). This finding suggests that the CX3C motif is involved in 
the induction of pathology in RSV infected tissues in vivo. The CX3C motif was proven 
to be important in the development of enhanced disease caused by FI-RSV. Mice 
immunized with FI-RSV vaccine with an ablated CX3C motif or the deletion of the 
whole G did not exhibit enhanced pulmonary disease characterised by pulmonary 
eosinophilia with significant inflammatory response (Haynes et al., 2003). 
Immunization of cotton rats with recombinant HRSV without the G glycoprotein 
(G∆HRSV) induced long lasting protection with the antibody titer comparable with 
cotton rats immunized with wtHRSV. The G∆HRSV detectability in the nose and lungs 
of cotton rats was negligible compared to wtHRSV but low levels could be detected in 
nasal washes showing G∆HRSV is highly attenuated in vivo but indistinguishable in 
vitro (Widjojoatmodjo et al., 2010). 
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The Fusion glycoprotein  
The F gene of HRSV strain A2 is 1903 nucleotides in length and contains a single ORF 
which encodes a protein of 574 aa with the calculated molecular weight of 63.5kDa (P. 
L. Collins et al., 1984b). Unlike the SH and G protein, the fusion (F) glycoprotein is a 
type I integral membrane protein whereby its N-terminus is oriented extracellularly 
while the C-terminus remains in the cytoplasm (P. L. Collins et al., 1984b). There are 
three hydrophobic regions in the F glycoprotein as shown in Figure 6. First, the signal 
sequence in the N terminus of the F2 chain, second is the fusion peptide at the N-
terminus of the N-terminus of F1 chain, and the third is the transmembrane regions 
located near the C-terminus of F1 chain. Adjacent to the fusion peptide and 
transmembrane regions are two heptad sequences namely, HRA and HRB. HRA and 
HRB peptides are known to form trimeric complexes in solution (Matthews et al., 2000; 
Xun Zhao et al., 2000).  
 
Figure 6 Schematic diagram of the F glycoprotein.  
Diagram of the F protein primary structure denoting cysteine residues (●), potential 
glycosylation sites (▴), hybrophobic regions (■), heptad repeat sequences (▨) and 
cleavage sites by fur-sequence motifs (boldface) the cleavage sites I and II (Gonzalez-
Reyes et al., 2001) and the antigenic sites (Ag) I, II, IV,V,VI) are indicated (Lopez et al., 
1998).  
F is initially synthesized as an inactive precursor (F0) and translocated through the 
membrane into the lumen of the endoplasmic reticulum initiated by the signal sequence 
at aa1-22 where high mannose sugar chains are covalently added to the asparagine 
residues. There are a total of 5 and 6 potential N-glycan acceptor residues in the F0 (A2 
and Long respectively). Then F is exported to the distal cisternae of the trans Golgi 
compartment and the more distal trans Golgi network where the furin like protease will 
recognise the highly conserved basic motifs, 106-RARR-109 (Site I) and 131-
KKRKRR-136 (Site II) and cleaved at both residues 109 and 136 (Figure 6) resulting in 
two phenomenon; first, the release of a 27 aa peptide (pep27) the exact function of 
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which is not yet determined, second, the formation of polypeptides (F2) from the N-
terminus and F1 from the C terminus which are held together by a disulphide bond. The 
mature F protein can be resolved under reducing condition in SDS-PAGE as bands of 
50 kDa (F1), 20 kDa (F2) and 58 kDa (cleavage intermediates) (Zimmer et al., 2001). 
The cleavage intermediates resulting from inefficient protease activity can also be found 
in HRSV infected cells (Gonzalez-Reyes et al., 2001). No F0 residue is found on the 
cell surface and export of F to the cell surface solely depends on cleavage and not 
glycosylation (Peter L. Collins and Mottet, 1991).  
 
Figure 7 Homotrimeric fusion glycoprotein.  
Diagrammatic representation of the pre-fusion structure of the homology model of 
RSV-F. The protein is colored by chain, with the F1 subunits in orange, green, and 
violet and the F2 subunits in red, yellow, and blue. The division of the structure into 
head, neck, and stalk (or core) regions is indicated, as are the attachment points for the 
three viral anchor peptides and three fusion peptides, which are not included in the 
model. (Morton et al., 2003). 
The prefusion mature F glycoprotein folds into a homotrimer (Calder et al., 2000) as 
depicted in Figure 7 before being exported onto the cell membrane with the 
transmembrane anchor residues 525-550 embedded in the lipid bilayer (P. L. Collins et 
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al., 1984b) the fusion peptide protruding from the N-terminus of the F2 (Matthews et 
al., 2000).  
The trimeric structure can be divided into three segments namely the stalk/core, neck 
and head. The core is made up by a six-membered antiparallel helical coiled coil 
structure where the HRA and HRB interacts (Xun Zhao et al., 2000).  
The head region of each monomer is made up by two β-coiled domains, namely I and II 
which form the upper walls of a radial channel at intersection of the head and the neck 
layers. Domain I is a highly twisted 7-stranded β barrel-like assembly and domain II is 
an immunoglobulin-like sandwich domain and it forms the opposite wall of the radial 
channel. A central void accessible from the exterior of the protein through a channel 
down the axis of the protein can be observed by electron microscopy (Lin Chen et al., 
2001). The head is supported by the protruding neck region (Morton et al., 2003) made 
up of a triple-helical coiled coil encircling three copies of residue G171-F221 and 
extended to the HRA region by 21 residues (Lin Chen et al., 2001). The HRA coiled 
coil continues towards the N terminus, out of the base of the neck and onwards to the 
base of the stalk where the remaining visible HRA region is well packed around the 
molecular axis (Lin Chen et al., 2001). 
 
 
Figure 8 Membrane fusion mechanisms (McLellan et al., 2010) 
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The fusion mechanisms of the F glycoprotein are depicted in Figure 8 . In the prefusion 
state, the fusion peptide is always kept at the end of HRA (Figure 8A and B) and upon 
attachment to a cell, the fusion protein is activated and forms a prehairpin intermediate 
resulted in the release of the fusion peptide through the head of the fusion protein into 
the target cell membrane (Figure 8C). The target cell membrane and viral membrane are 
pulled into close proximity when the prehairpin intermediate structure collapses into the 
hairpin intermediate and the six helix bundles begins to form resulting in the formation 
of post fusion conformation where the membrane fuses together (Figure 8D) (Morton et 
al., 2003; McLellan et al., 2010).  
The initial work to map the epitopes of the fusion glycoproteins revealed three distinct 
types of epitopes namely; neutralizing and fusion inhibiting, neutralizing, and non-
neutralizing (Edward E. Walsh et al., 1986). Later, these antigenic sites were mapped 
into domains called I, II, IV, V, and VI (('Recovery from infants with respiratory illness 
of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of 
infection in infants and young children.,' ; Arbiza et al., 1992) and the locations are 
shown in Figure 6.  
Antigenic site II is located in the protease resistant region (aa255-275) within the F1 
(Lopez et al., 1998) and antibodies that bind to antigenic site II are highly neutralizing 
and possess protective fusion inhibitory property ('Recovery from infants with 
respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. 
Epidemiologic aspects of infection in infants and young children.,' ; C. E. Taylor et al., 
1989). Antigenic site II is made up by two -helices which require a certain level of 
conformational protein folding for the correct presention of the functional epitope, thus 
mapping antigenic site II with shorter overlapping peptides tend to give negative results 
(Lopez et al., 1993). The humanized murine monoclonal antibody (Palivizumab) which 
is currently used as a passive immune prophylaxis against HRSV infection (Melero and 
Cane, 2006) binds to this site. 
Antigenic site IV, V and VI are neutralizing epitopes and binding of recombinant 
murine monoclonal ch101F which was mapped to aa 422-438 within this site 
neutralized the wild type HRSV (Sheng-Jiun Wu et al., 2007b). Site I is a group A 
specific epitope which is partially neutralizing with one log unit reduction in infectivity 
with Long strain but escape mutants to this site can be recovered after passaging the 
virus under selective pressure with monoclonal antibodies to this site. Escape mutants 
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derived from Mabs to this site revealed at least two distinct epitopes. (Lopez et al., 
1998). 
1.5 Epidemiology 
RSV epidemics occur each winter in temperate climates such as in the UK starting 
around week 40 reaching a peak in between week 48-52 as shown in Figure 9. During 
the peak of the epidemic, there can be more than 1000 cases of HRSV infection reported 
every week in the UK with a majority of the patients aged <1 yr followed by those of 1-
4 yrs (Patricia. A.  Cane, 2001). HRSV is also recognized as a major respiratory 
pathogen in some adult populations (A.R. Falsey et al., 2005) especially those with 
cardiopulmonary diseases, and among the immunocompromised hosts such as those 
with human immunodeficiency virus (Dianne Murphy and Rose, 1989; van der Ven et 
al., 1996), renal transplant patient(s) (Janet A. Englund et al., 1988; Morales et al., 
2003) and pancreas transplant patients (Janet A. Englund et al., 1988). The 
epidemiologic study revealed that HRSV is responsible in 2-5% of pneumonia in the 
adult population. The HRSV attack rate in the nursing home was estimated at 5-10% 
annually with 10-20% HRSV associated pneumonia and 2-5% mortality (Ann R. Falsey 
and Walsh, 2000). Patients scheduled for bone marrow transplant are at a very high risk 
due to the administration of immunosuppresive drugs prior to marrow engraftment (Ann 
R. Falsey and Walsh, 2000) although early administration of ribavirin might prevent the 
progression of URTI to LRTI and reduced mortality rate in those who developed 
pneumonia (Hattington et al., 1992; Bowden, 1997). 
  
 24 
 
 
Figure 9 Prevalence of HRSV infection in the UK.  
The graph was adapted from http://www.hpa.org.uk/ updated on the 1st September 2010 
as reported by the microbiology laboratories of NHS and HPA over 6 seasons based on 
the date of specimen. 
In equatorial countries such as Malaysia, HRSV is endemic throughout the year with a 
periodic peak between November to January annually (see Figure 10) corresponding to 
the annual monsoon season which is characterized by a dramatic increase in rainfall 
(Chan et al., 2002). However, it is noteworthy that the percentage of cases of HRSV 
reported in the drier months may not be significantly lower than those reported during 
the monsoon season. The epidemics seem to emerge in the equatorial regions and 
radiates in both direction north to the northern hemisphere and south to the southern 
hemisphere (Stensballe et al., 2003).  
The compilation of published epidemiological data revealed a distinct epidemic pattern 
according to region with countries from each region sharing similar seasonality and 
epidemic peak. In every region, the annual temporal peak occurs in a relatively fixed 
epicenter in the same month with spreads over the following months away from the 
epicenter corresponding to the gradual climatic change. Nevertheless, all epidemic 
peaks are associated with factors such as population crowding, reduced herd immunity 
especially among child bearing females which leads to infants with reduced immunity 
and seasonal immunosuppression (Stensballe et al., 2003).   
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Figure 10 Prevalence of HRSV infection in Malaysia for 180 months between 
January 1982 to December 1997  
Only patients with LRTI were included (n=5691, age<24 months). 
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1.5.1 RSV subgroups 
HRSV isolates can be categorized into 2 subgroups identified as subgroups A and B. 
They are effectively 2 different serotypes which can be distinguished with polyclonal 
antibodies in plaque reduction neutralization assays where polyclonal raised against one 
subgroup can effectively neutralize its homologous subgroup but is less effective 
against the heterologous subgroup (Coates et al., 1966). Later, the subgrouping was 
standardized by the reactivity profile with a panel of monoclonal antibodies directed 
against the P, F and G proteins by IFA or ELISA (Anderson et al., 1985), G, F, M, N by 
radioimmunoprecipitation analysis and IFA (Mufson et al., 1985), F and P by IFA and 
immunoblotting (H. B. Gimenez et al., 1986) F, G, N and P by IFA (Tsutsumi et al., 
1988). 
During an epidemic, both subgroups of HRSV are normally present with varying 
proportion with either one subgroup dominating or in equal proportions (Mufson et al., 
1988; Hendry et al., 1989; Hall et al., 1990; Freymuth et al., 1991). Attempts to 
measure and compare the severity of disease caused by both group of viruses have not 
yielded a clear cut differences in virulence (G.  McIntosh et al., 1993; Martinello et al., 
2002; Oliveira et al., 2008). Nevertheless, it was tempting to speculate that subgroup A 
causes more severe disease compared to subgroup B (Hall et al., 1990; Edward E. 
Walsh et al., 1997; Papadopoulos et al., 2004).  
The antigenic relatedness between sugroup A and B was estimated from antibody 
response by cotton rats immunized with either subgroup A or subgroup B HRSV. It was 
shown that the fusion glycoprotein shares 50% relatedness while the G glycoprotein 
shares only 5% relatedness in murine model. Both subgroups shared only 53-56% 
amino acid identity in G between subgroups A (strain A2) and B (strains 18537 and 
8/60) (Wayne M. Sullender et al., 1990). The authors suggested that the fusion 
glycoprotein is responsible for most of the observed cross subgroup neutralization and 
protection in the murine model (Anderson et al., 1985; P. R. Johnson, Jr. et al., 1987). 
Their work was further confirmed in the human model by Hendry et al.,(1988) where 
serum from infants infected with HRSV responded to the fusion protein of both 
homologous and heterologous strains of HRSV without any significant difference. 
However, the authors reported a significant difference when assayed on the G 
glycoprotein with only 7.3% relatedness between subgroups A and B. Nevertheless, the 
similarities in the amino acid sequence can be summarised as in Table 1. The authors 
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did not state the HRSV strains used for comparison and the interpretation of this table 
should be done with care. 
Table 1 Percentage (%) amino acid sequence identity for proteins in HRSV 
 NS1 NS2 N P M SH G F M2-1 M2-2 L 
% 
identity 
87 92 96 91 91 76 53 89 92 72 93 
Data was adapted from Collin and Crowe (2001) 
Molecular evolutionary studies on the G glycoprotein gene of subgroups A and B 
revealed a very similar evolutionary rate of 1.83 x 10–3 nucleotide substitutions/site/year 
(Zlateva et al., 2004) and 1.95 x 10–3 nucleotide substitutions/site/year (Zlateva et al., 
2005) respectively. However, the analysis of the G gene of the BA viruses alone 
revealed a higher evolutionary rate of 4.7 x 10–3 nucleotide substitutions/site/year 
(Trento et al., 2010), more than double the evolutionary rate of the regular subgroup B 
viruses. The evolutionary rate for the fusion glycoprotein was estimated to be 1.3-1.5 x 
10-3 nucleotide substitutions/site/year showing a higher selective pressure against the G 
glycoprotein than F glycoprotein suggesting the immunologic pressure exerted on the G 
glycoprotein is the main factor behind the diversification of HRSV lineages (Gaunt et 
al., 2011).  
Probabilistic models of codon substitution that allow for variable 
nonsynonymous/synonymous substitution rate ratios among sites revealed that both 
subgroups A and B differ in positively immune-selected codons in the G glycoprotein 
(Zlateva et al., 2004; Zlateva et al., 2005) except codon 226 in subgroup A which 
corresponds to codon 227 in subgroup B (Woelk and Holmes, 2001) suggesting a 
different selective pressure between subgroups and probably utilizing a different host 
immune evasion strategy.  
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1.5.2 Genotypes 
The variation between isolates from the same subgroup was initially demonstrated with 
monoclonal antibodies raised against the prototype strain (Patricia. A.  Cane, 2001). 
This was followed by other methods and the most commonly used being the 
phylogenetic analysis of the G nucleotide sequence which can accurately define the 
number of genotypes within a subgroup (Peret et al., 2000; Trento et al., 2006; Trento et 
al., 2010). 
In any one epidemic, more than one genotype from each subgroup may circulate (Lim et 
al., 2003). One genotype may be dominant in one epidemic but forms a minority 
genotype in the following epidemic and may disappear altogether in the third epidemic, 
perhaps replaced by a new genotype (Peret et al., 2000; Patricia. A.  Cane, 2001). 
Clinical severity between the genotypes of subgroup A HRSV has been evaluated and 
genotype GA3 seems to produce more severe disease compared to GA2 and GA4 
(Martinello et al., 2002) but recent reports showed no correlation between severity of 
disease with genotype (Rong-Fang Zhang et al., 2010a) although the genotypes 
evaluated were not the same with the previous. Comparing disease severity between 
genogroup might not be entirely possible due to the shift of the predominant group in 
each epidemic and the existence of heterogenous genotypes across the globe. 
  
 29 
 
1.6 Infection, Pathogenesis and Immunity 
1.6.1 Spread 
HRSV can be considered as the one of the highly prevalent viruses that affects humans 
and is mainly spread through self inoculation by contact with surfaces contaminated by 
RSV-infected nasal secretions (Hall et al., 1980). HRSV is more labile when compared 
to rhinovirus but survived long enough outside host environment for transmission. In an 
experiment done back in 1980 shows that HRSV from nasal secretions remains 
infectious on countertops up to 6 hours and on hands up to 25 minutes (Hall et al., 
1980). The spread through aerosols seems unlikely as the virus was quickly inactivated 
upon drying (Rechsteiner and Winkler, 1969) and infectious particle transmission are 
often through large droplets (Hall et al., 1978). Infection can be efficiently established 
by self inoculation through the eyes or nose but not through the mouth (Hall et al., 
1981). 
1.6.2 Infection 
Virus replication starts in the nasopharynx with the incubation time around 3-5 days 
(Sterner et al., 1966) with the highest detectable virus titer at day 6-8 p.i (Kim et al., 
1971) with the peak illness occurred around day 8-10 post infection (Sterner et al., 
1966; Wright et al., 2002). 
HRSV only causes upper respiratory tract (URT) infection in most infants ranging from 
mild medical manifestation such as poor feeding, rhinorrhea, coughing, fever, apnea, 
lethargy wheezing, respiratory distress (Baker and Ryan, 1999), and otitis media (T. 
Heikkinen et al., 1995; Terho Heikkinen et al., 1999). However, in some HRSV naïve 
infants, infection can quickly spread to the lower respiratory tract (LRT) resulting in 
bronchiolitis and pneumonia, and such cases are responsible for about 1-2% infant 
hospitalizations of which 2-5% required mechanical ventilation (Glezen et al., 1986; C. 
L. Collins and Pollard, 2002).  
The clinical manifestation of HRSV infection correlates with the pathology caused by 
the virus in the LRT. In acute bronchiolitis, the main pathology is epithelial necrosis of 
the small airways. The bronchiolar lumen may be blocked by dense mucus plugs 
leading to trapping of air and mechanical interference with ventilation. In pneumonia, 
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there is a widespread inflammation and necrosis of the lung parenchyma, and severe 
lesions of the bronchial and bronchiolar mucosa (Aherne et al., 1970). 
Clinical recovery usually corresponded to the termination of virus shedding although 
some infants continue to shed virus for many weeks after recovery (Wright et al., 2002). 
HRSV only causes localized respiratory infection in normal infants and adults but 
systemic infection and spread to other organs such as liver, heart and kidney in immune-
compromised individual had been documented (M Fishaut et al., 1980; Milner et al., 
1985; Padman et al., 1985).  
1.6.3 Innate immunity 
The first line of innate defence mechanism is associated with the surfactant protein (SP), 
a member of collectin family in the respiratory system. It was shown in infants that the 
amount of surfactant protein present the bronchioaveolar lavage fluid in children with 
severe HRSV associated LRTI shows a marked reduction in concentration suggesting 
the importance of surfactant protein in keeping infecting HRSV at bay (Kerr and Paton, 
1999; Barreira et al., 2010; Kawasaki et al., 2011). Later, HRSV infection of the 
pulmonary bronchiolar epithelial cells shows an inhibitory effect to the translation of 
SP-A mRNA although SP-A mRNA transcription was not impaired (Bruce et al., 2009). 
In vitro experimentation has shown a virus neutralizing effect of SP-A which recognizes 
the fusion glycoprotein rather than G glycoprotein (Ghildyal et al., 1999). In vivo 
studies with SP-A deficient mice (Ann Marie LeVine et al., 1999) and SP-D deficient 
mice (Ann Marie LeVine et al., 2004) showed the importance of SP-A and SP-D in the 
enhancement of virus clearance. 
When infection sets in the airway epithelial cells of mice, these cells together with 
dendritic cells (DC) and macrophages are the first cells to respond to HRSV infections 
(Sung et al., 2006). The presence of different DC subsets will determine the course of 
the immune response. For example, the expansion of plasmacytoid DC (pDC) and 
conventional DC (cDC) was shown to have a protective impact to the airway by reduced 
pathophysiology characterized by decreased airway hypersensitivity, reduced Th2 
cytokines, increased Th1 cytokines and a reduction in airway inflamation and mucus 
overexpression. All these protective responses can be reversed by the selective depletion 
of pDC (Smit et al., 2008) which resulted in decreased HRSV clearance and leads to the 
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manifestation of immune-mediated pathology caused by HRSV infection in BALB/c 
mice (Smit et al., 2006). 
HRSV infection is detected thorugh a series of pattern recognition receptors (PRR) 
comprising of Toll-like receptors (TLR) and cytoplasmic sensors of viral RNA, such as 
retinoic-acid inducible protein I (RIG-1) and melanoma-differentiation associated gene 
5 (MDA-5) in mice (Kato et al., 2006). The initial detection of HRSV in the airway 
epithelial cells is recognised by RIG-1 receptors due to the presence of single stranded 
virus RNA (Ping Liu et al., 2007) which contains uncapped unmodified 5’-triphosphate 
RNA (Pichlmair et al., 2006). The synthesis of double stranded RNA later in HRSV 
replication process stimulates the TLR3 (Ping Liu et al., 2007). Upon stimulation , RIG-
I and TLR3 activates NF-kappaB through a MyD88 (adaptor protein shared by all TLR) 
dependent pathway, activates mitogen-activated proteins (MAP) kinases independent of 
MyD88 pathway, which stimulates the production of type I interferons, (INFs) and 
promotes the maturation of DCs (Alexopoulou et al., 2001). Type I INF like INF-, 
INF-β and INF-ω are key cytokines to antiviral response (Muller et al., 1994), induce 
apoptosis in murine fibroblast cells, limits virus replication in infected cells and 
prevents the spread of infection to non infected cells (Balachandran et al., 2000). 
The F glycoprotein of RSV was shown to stimulate the synthesis of interleukin 6 (IL-6) 
by purified human monocytes expressing TLR4, essential receptor for the recognition of 
lipopolysaccharides from Gram negative bacteria, mycoplasmas, spirochetes and fungi. 
The G glycoprotein and nucleocapsid protein stimulates weaker cytokine response than 
F (Kurt-Jones et al., 2000). The interation between the F glycoprotein and TLR4 is host 
species specific which is not activated upon stimulation by BRSV derived F 
glycoprotein (Lizundia et al., 2008). The deficiency of TLR4 results in prolonged 
infection (Kurt-Jones et al., 2000) in human and reduced NF-kappaB activity in mice 
(Haeberle et al., 2002). Genetic polymorphism studies have shown mutation in 
autosomal gene encoding TLR4 being associated with severe HRSV disease in human 
(Mailaparambil et al., 2008). HRSV infection in the airway epithelial cells induces the 
numerous cytokine upregulation genes resulting in the accumation of an array of 
cytokines such as CC [RANTES, Macrophage chemoattractant protein (MCP)-1, -1β], 
CXC [inducible neutrophil chemotactic factor (GRO)-, -β, -γ and IL-8) and CX3C 
(fractalkines) which promotes the recruitment of neutrophils, monocytes, DC and T 
cells into the respiratory tract, possibly contributes to a more severe disease (Sheeran et 
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al., 1999; Allison et al., 2004). High levels of TNF-, RANTES, MIP-1, IL-6, IL-8, 
and IL-10 were detected in the nasal wash and tracheal aspirates of patients with severe 
HRSV infection (Olszewska-Pazdrak et al., 1998; Sheeran et al., 1999; Gill et al., 
2008). However, single nucleotide polymorphisms (SNP) studies have revealed the 
association of SNPs in the gene loci of IL-4 (Forton et al., 2009), IL-8 (Hacking et al., 
2004; Lu et al., 2010), IL-9 (Schuurhof et al., 2010), IL10 (Wilson et al., 2005) and 
TNF- (Puthothu et al., 2009) as a genetic determinants of severe HRSV disease in 
infants. 
1.6.4 Adaptive immunity 
The stimulation of the adaptive immunity by HRSV is incomplete and reinfections is 
common and occurs throughout life (Hall et al., 1991). After HRSV infection is 
established, cDC migrates to the lymph nodes presenting the HRSV derived antigens to 
the naïve T and memory specific T cells. Some migratory DC might have been infected 
by HRSV but HRSV antigens derived from infected epithelial cells might have 
contributed to the antigen display to the T cells (Lukens et al., 2009) as human DC 
infected with HRSV was shown to be a poor inducer for T-cell proliferation (de Graaff 
et al., 2005).  
Two novel CD4+ T cell epitopes had been identified to date in the M and M2 protein 
corresponding to the sequence 213-FKYIKPQSQFI-223 and 27-YFEWPPHALLV-37 
respectively. Peptides containing these epitopes can stimulate the proliferation of 
mainly lung CD4+ T cells in greater ratio compared to the spleen CD4+ T cells to 
produce INF-γ, IL-2 (Jie Liu et al., 2009) and IL-10 (F. Eun-Hyung Lee et al., 2005) in 
murine models. CD4+ T cells were found to mediate the synthesis of Th2 related 
chemokines and the depletion of CD4+ T cells induced reduced airway 
hyperresponsiveness (AHR), lower Th2 cytokines and reduced Gob5 production in mice 
model (Neupane et al., 2007). CD4+ T cells associated cytokines promotes the 
recruitment and infiltration of neutrophils and eosinophils into the lung tissues (Bueno 
et al., 2008). Following this INF-γ promotes cytotoxic T cells function by stimutating 
CD8+ T cells and Natural Killer (NK) cells to clear virus infected cells, stimulate 
macrophage phagocytic activity to eliminate dead cells and induce the production of 
IgG antibodies by B cells (Kidd, 2003). However, when immune response to HRSV 
infection is skewed towards the Th2 cells mediated pathways, IL4 and IL5 was secreted 
by innate immune cells into the blood and directs strong pulmonaric eosinophil 
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response as observed in FI-RSV enhanced disease in murine models (P. J. M. 
Openshaw et al., 2001; Becker, 2006) leading to enhanced pathology to the lungs. 
Meanwhile, CD8+ T cells undergo rapid expansion and 50-70% were virus specific as 
estimated with LCMV infection in mice (Murali-Krishna et al., 1998). CD8+ cytotoxic 
lymphocytes (CTLs) activity peaks around day 6 post immunization by predominantly 
recombinant M2 protein in mice with residual activity detected 45 days post 
immunization showing the resistance induced by M2 protein was mainly mediated by 
primary pulmonary CTLs supporting the observation of frequent HRSV reinfection in 
humans (Kulkarni et al., 1993). Depletion of CD8+ CTLs in HRSV challenged mice 
showed elevated AHR, production of IL-13 and increased mucus associated gene 
(Gob5) expression (Neupane et al., 2007). In sufficient numbers, CD8+ CTLs inhibits 
Th2 associated chemokines and prevents the progression of eosinophilia BALB/c mice 
(Olson et al., 2008) and are not associated with severe HRSV disease (Lukens et al., 
2010). However, the contribution of neutrophils influx into the lung tissues due to Th1 
mediated cytokines to the lung pathology have not been established in mice (Lukens et 
al., 2010). 
Thus, it is clear that severe HRSV disease is not solely caused by virus mediated 
pathology but a great proportion was driven by immune response by the Th2>Th1 
skewed adaptive immunity. Other than that, SNPs to key genes in the innate immune 
systems might predispose individuals to genetic mediated risk during HRSV 
pathogenesis. Nevertheless, most experiments had been done in mouse model which is 
not a natural host for HRSV and may represent a totally different picture in human 
humoral response. 
Infants acquire maternal IgG starting from week 26 to birth. Although some infants do 
develop severe HRSV disease, maternal antibodies seem to offer some protection and 
are associated with milder disease outcome in infants (Glezen et al., 1981a). Premature 
infants tend to be at a higher risk of acquiring severe disease, and full term infants tend 
to be spared to a certain extent in the first month of life (P. L. Collins and Crowe, 2001). 
The sensitivity of very young infants in developing infectious disease such as HRSV 
infection might be due to the lack of preexisting immunological memory and delayed 
neonatal B cell responses (Adkins et al., 2004). Healthy institutionalised elderly have 
intact humoral response and are not associated with severe HRSV disease (Ann R. 
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Falsey and Walsh, 1992) but frail elderly have waned HRSV antibody which might 
exposed them to a higher risk of HRSV reinfection (Terrosi, 2009). 
The humoral response in infants 2 months and below is mainly restricted to IgA 
response but is not neutralizing  (Wright et al., 2000). However the initial appearance of 
IgA antibody to HRSV marked the termination of an infection and continued to rise 
thereafter (Kenneth McIntosh et al., 1978). The detection of HRSV specific IgE in 
HRSV infants during bronchiolitis have been associated with wheezing and asthma later 
in life (Welliver and Duffy, 1993) but IgE was not detected in a separate groups of 
infants (Rakes et al., 1999; de Alarcon et al., 2001) suggesting the production of IgE, a 
product of Th2 lymphocytes response is not mandatory in all HRSV infections. 
.  
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1.7 Vaccines 
1.7.1 Formalin inactivated RSV (FI-RSV) 
This method involved the formalin inactivation of Bernett strain of RSV grown from 
vervet monkey kidney cell followed by concentration by centrifugation and absorption 
into adjuvant aluminium hydroxide. FI-RSV lot 100, Pfizer was administered 
intramuscularly (Delgado et al., 2009) in three injections to children aged 4 months to 7 
years prior to the annual RSV epidemic. However, the increase in neutralizing antibody 
of the vaccinees to HRSV infections was not promising (47%) and failed to protect the 
vaccinees from the natural infection of environmental RSV. However, all vaccinees 
shown at least four-fold increased in serum complement fixation (CF) antibody 
(Fulginiti et al., 1969). To make things worse, RSV-naïve vaccinees experienced 
respiratory disease enhancement when exposed to the natural infection in the epidemic 
post-vaccination (Chin et al., 1969). No children previously exposed to wild type HRSV 
infection developed disease enhancement after acquiring HRSV infection post 
vaccination (Fulginiti et al., 1969). None of those who experienced with disease 
enhancement acquired a second disease enhancement in the following epidemics. This 
was probably due to the B cells elicited by wtHRSV outcompeting the pathogenic B 
cells primed by FI-RSV and establishing a normal response to future reinfections 
(Delgado et al., 2009). Enhanced disease was also reported in cynomolgus macaques 
vaccinated with FI human metapneumovirus (FI-HMPV) showing the similar drawback 
consequences as FI-RSV (de Swart et al., 2007).  
The alteration to the protective epitopes by formalin was thought to be the main reason 
in the lack of neutralizing antibodies in HRSV naïve vaccinees (Brian R. Murphy et al., 
1989; Connors et al., 1992) resulting in low avidity antibodies to protective epitopes 
(Delgado et al., 2009), poor Toll-like receptor (TLR) stimulation; suboptimal 
maturation of dendritic cells; decreased germinal center formation in lymph nodes; and 
the production of nonprotective antibodies (Ubol and Halstead, 2010). 
Delgado et al., (2009) have attempted to fix the first generation FI-RSV by the 
incorporation of TLR agonists in adjuvants which later promotes dendritic cell 
maturation, T helper activation and B cell affinity maturation in Myd88+/- murine 
model but to what extent the deficiency in TLR activation which leads to the Th2 bias 
in the disease enhancement still remains to be answered. The authors suggested that if 
the FI-RSV can elicit high neutralizing antibodies against HRSV, the progression to 
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enhanced disease would be prevented in HRSV-naïve vaccinees upon subsequent wild 
type HRSV (wtHRSV) reinfection. 
The role of the G glycoprotein as the cause of enhanced disease through the Th2 biased 
pathway have been suggested (Peter J. M. Openshaw et al., 1992; G. E. Hancock et al., 
1996; Bembridge et al., 1998; Teresa R. Johnson et al., 1998) with Gs seems to play a 
significant role in eosinophilia compared to Gm (Bembridge et al., 1998; Teresa R. 
Johnson et al., 1998) upon challenge with wild type RSV. The epitope in the G 
glycoprotein which contributes to the Th2 biased response and eosinophilia had been 
mapped to aa184-198 (Tebbey et al., 1998) and aa193-203 (Sparer et al., 1998) 
corresponsing to the amino acid of the G glycoprotein of subgroup A HRSV. The 
inclusion of neutralizing anti-HSRV-G monoclonal antibody 1 day prior to challenge in 
FI-RSV vaccinated BALB/c mice demonstated the reduction of enhanced disease by 
30% (Radu et al., 2010), a practice which is not feasible in infants. However, enhanced 
disease was recently demonstrated by immunizing BALB/c mice with formalin 
inactivated recombinant RSV lacking the G glycoprotein (Polack et al., 1999; Teresa R. 
Johnson et al., 2004). Vaccination of BALB/c mice with Newcastle disease virus-like 
particles containing HRSV G glycoprotein demonstrated protection upon challenge with 
wtHRSV with no evidence of immunopathology (Murawski et al., 2010). 
1.7.2 Live Attenuated HRSV vaccines 
As a next step into developing a safe and immunogenic HRSV vaccine, the feasibility of 
using live attenuated HRSV as a vaccine candidate was explored. The generation of live 
attenuated HRSV vaccine candidate involved serial passages of HRSV strain A2 in 
bovine cell line at low temperature and a cold passaged (cp) temperature sensitive (ts) 
RSV mutant, designated as RSV cpts530 was derived at passage 52 which is 10-fold 
less efficient in replication in mice compared to strain A2. Other group have reported 
the similar generation of cold passaged attenuated HRSV mutants by low temperature 
serial passages in Vero cells (Randolph et al., 1994). Further attenuation was added to 
the cp mutants by mutagenesis with 5-fluorouracil rendering it more attenuated in 
primates and more stable in vivo. All the resulting mutants including cpts248/404, 
cpts248/955 and cpts530/1009 (with mutation at amino acid position 1009 in the 
polymerase) showed high attenuation in chimpanzees, immunogenic and confers 
significant protection upon challenged with wtHRSV (Crowe Jr et al., 1994; Crowe et 
al., 1995). Crowe et al., (1995) also reported that the administration of anti-HRSV 
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antibodies to chimpanzees prior to vaccination resulted in a significantly higher 
production of neutralizing antibodies to the challenged virus compared to the control 
group not receiving the immunoglobulins. Further attempts to attenuate the cold 
passaged mutants by recombinant means have yielded two candidates 
rA2cp248/404∆SH and rA2cp248/404/1030∆SH. Both candidates were highly 
attenuated in adults and in HRSV seropositive infants. They were immunogenic and 
well tolerated in HRSV naïve infants with the later exhibiting reduced replication of 
HRSV in naïve infants showing the important attenuating effect of missense mutation in 
aa1030 in the polymerase (Karron et al., 2005). No disease enhancement was observed 
in all of the vaccinees although seroconversion upon wild type reinfection was low (20 
of 54) in younger infants (1-3months) compared to (18 of 51) older infants. 
Nevertheless, virus shedding was negligible in vaccinees showing high attenuation of 
the vaccines and the low occurrence of URT disease among the vaccinees compared to 
the control group indicated the protective effect of the live attenuated vaccine (Wright et 
al., 2007). Nevertheless, more work is needed to improve the immunogenicity as to 
obtain a higher seroconversion rate among vaccinees. 
1.7.3 Subunit vaccines 
The work on the development of anti-HRSV subunit vaccines concentrated mainly on 
the fusion glycoprotein due to its conservation between subgroups A and B. 
Nevertheless, a chimeric FG fusion had been described by expressing the fusion 
glycoprotein (aa1-489) as the N-terminus of the ectodomain of the G glycoprotein 
(aa97-279) using the baculovirus expression system (Wathen et al., 1989b). The 
intramuscular immunization of mice with affinity purified FG subunit vaccine induced 
relatively low level of neutralizing antibody but surprisingly showed a marked >90% 
reduction in pulmonary HRSV upon intranasal challenge with wtHRSV (Prince et al., 
2000), a level which contradicts with the results previously reported (Connors et al., 
1992). Despite the impressive level of protection, immunized mice exhibited mild 
alveolitis and interstitial pneumonitis which can be eliminated by the addition of 
monophosphoryl lipid A (MPA) to the adjuvant. MPA is known to direct immune 
response to the Th1 pathway avoiding the Th2 biased pathway which is associated with 
the enhanced disease (Prince et al., 2000). Nevertheless, these vaccine associated 
disease enhancement in parenteral administration of subunit FG or immunoaffinity 
purified F glycoprotein in cotton rats were not observed in cotton rats immunized with 
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vaccinia virus expressed recombinant HRSV fusion protein after challenged with wild 
type HRSV (Connors et al., 1992).  
Purified whole fusion glycoprotein (PFP) vaccine had been evaluated in clinical trials. 
PFP-1 and PFP-2 were prepared from HRSV strain A2 purified by immunoaffinity and 
ion exchange chromatography respectively (Dudas and Karron, 1998) and was shown to 
reduce the overall HRSV related incidence (Simoes et al., 2001). PFP-2 had been 
shown to be safe and immunogenic in healthy institutionalized elderly (Ann R. Falsey, 
1998), healthy adults over 60 years of age (Ann R. Falsey and Walsh, 1996) showing 
four-fold or higher rise in serum neutralizing antibody titer in 61% of the vaccinees. 
However frail institutionalized elderly showed reduced immunologic response to PFP-2 
(Ann R. Falsey and Walsh, 1997). Trials on HRSV seropositive children shown that 
PFP-1 and PFP-2 are immunogenic without any disease enhancement upon wtHRSV 
challenge (Paradiso et al., 1994; Piedra et al., 1995; Jessie R. Groothuis et al., 1998) but 
the neutralizing antibody titer was not long lasting and requires annual vaccination for 
continuous protection (Tristram et al., 1994). No trials had been done on seronegative 
infants but maternal immunization with PFP-2 had been carried out in order to arm the 
newborn infant with high titered HRSV neutralizing antibody although the protective 
role of maternal antibody in protection against severe HRSV disease is still inconclusive. 
Nevertheless, pregnant women immunised with PFP-2 had HRSV specific antibodies 
detected in their expressed breast milk which might offer some degree of protection in 
breast fed infants (Janet Englund et al., 1998). To minimize the possible risk of the 
subunit vaccine to the developing foetus, maternal vaccination was scheduled at the 
third trimester when the foetus is fully formed (Munoz and Englund, 2000) but this 
might prove to be suboptimal as the accumulation of IgG post infection happens in the 
first two trimesters and is suppressed in the third trimesters (Nandapalan et al., 1986). 
Nevertheless, the inclusion of G glycoprotein with PFP in the subunit vaccine 
formulation showed marked increase in neutralizing antibodies suggesting the 
importance of G glycoprotein in the subunit vaccine strategy against HRSV (Gerald E. 
Hancock et al., 2000). 
The evaluation of the G glyocoprotein as a sole vaccine candidate had been evaluated. 
The amino acid 130-230 of HRSV strain A was fused to streptococcal protein G (BB) as 
a carrier protein and designated as BBG2Na.(Goetsch et al., 2001). The administration 
of BBG2Na was not associated with enhanced disease upon challenge with wild type 
HRSV in mice (Plotnicky et al., 2003; Power et al., 2003) but low level of eosinophilia 
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had been reported in 2 of 4 seronegative macaques vaccinees (de Waal et al., 2004). 
Parenteral immunization of healthy elderly elicited protective neutralizing antibodies 
which protected SCID mice from intranasal wild type challenge after passive transfer of 
antibody (Hélène Plotnicky-Gilquin et al., 2002).  
1.8 Treatment 
1.8.1 Ribavirin 
Ribavirin (Virazole® or 1-(β-D-Ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide was 
licensed in the 1986 for the treatment of disease associated with the HRSV infection in 
hospitalized children (Ohmit et al., 1996). Ribavirin acts by inhibiting the enzyme IMP 
dehydrogenase and the phosphorylated form inhibits the RNA polymerase (Nichols et 
al., 2008).  
The use of ribavirin remains controversial (Committee on Infectious Diseases, 1996) . 
Recent studies have shown that the administration of ribavirin during the HRSV 
bronchiolitis reduced the risk of asthma and allergen sensitization in high risk children 
but the length of hospitalization among the patients was significantly extended (Chien-
Han Chen et al., 2008) which agrees with the results of previous researchers (Ohmit et 
al., 1996). However, the administration of aerosol ribavirin showed marked reduction in 
the duration of hospital stay (by 7 days) (Smith et al., 1991) and reduction in the 
dependency for mechanical ventilation by 5 days for previously normal infants 
requiring mechanical ventilation due to severe HRSV infection (Hall et al., 1983; Smith 
et al., 1991). 
Ribavirin had been administered to high risk adults with HRSV infections but the 
mortality rate remains high. The administration of intravenous ribavirin (IV-R) to 
HRSV infected bone marrow transplant (BMT) recipients is virtually ineffective and 
have been associated with 80% (2 of 10) mortality rate (Lewinsohn et al., 1996) but the 
mortality rate was reduced to zero (0 of 10) when IV-R was co-administered with oral 
pnednisolone, a type of corticosteroid used in lung transplant recipients (Glanville et al., 
2005). The administration of aerosolized ribavirin to BMT recipients with HRSV 
related pneumonia resulted in approximately 28% (5 of 18) mortality (Hattington et al., 
1992) and 50% (3 of 6) mortality (Janet A. Englund et al., 1988). The co-administration 
of aerosolised ribavirin with IVIG (RespiGam), an IgG preparation with high 
concentrations of HRSV neutralizing antibody to BMT recipients with HRSV related 
 40 
 
pneumonia resulted in 9.1% (1 of 11) mortality (DeVincenzo et al., 2000) and 6.25% (1 
of 16) mortality (Small et al., 2002). It is clear that ribavirin alone is poor in its efficacy 
as a prohylaxis against HRSV infection in the high risk groups unless supplemented 
with either anti-inflamatory corticosteroids or IVIG but IVIG alone is highly effective 
against HRSV infection. Following this, ribavirin is rarely administered to infants due 
to technical difficulty in delivery by aerosol inhalation (Clercq, 2004) coupled with the 
potential teratogenic effects of the drug (Lewinsohn et al., 1996). Ribavirin has been 
associated with hepatoxicity in a stem cell transplant recipient with Hodgkin lymphoma 
suffering from HRSV infection suggesting a possible toxicity of ribavirin in 
immunocompromised adults (Chaves et al., 2006). 
1.8.2 Immunoglobulin as prophylaxis 
The administration of intravenous immune globulin (IVIG) obtained from adult donors 
to high risk infants proved to be safe and effective in an outpatient setting but the titer of 
the HRSV neutralizing immunoglobulins are relatively low to offer prophylaxis against 
HRSV. The high HRSV neutralizing titer of IVIG found previously in individual IVIG 
preparation seems to be absent in 40 individual lots of IVIG from different suppliers 
suggesting the use of donor pools failed to ensure reproducibility, standard and efficacy 
of IVIG (J. R. Groothuis et al., 1991). Due to this, high titered immune globulins (RSV-
IG) were then prepared from adult human plasma with the minimum neutralizing titer 
three times higher (1:3000) than those in IVIG (1:1000). RSV-IG undergoes further 
processing and purification including steps to inactivate blood borne pathogens to make 
it more suitable for intravenous administration (Oertel, 1996). RSV-IG was approved by 
the US FDA in the early 1996 under the name RespiGam™ after the proven 
effectiveness in two major clinical trials involving National Institute of Allergy and 
Infectious Diseases (NIAID) (Ellenberg et al., 1994) and Prophylaxis of Respiratory 
Syncytial Virus in Elevated risk Neonates (PREVENT). Although RespiGam was 
shown to be effective as passive prophylaxis in premature infants and infants under 2 
years of age with bronchiopulmonary dysplasia (BPD) (Oertel, 1996), the risk of the 
transmission of blood borne viruses cannot be ruled out and obtaining reproducible 
batches of highly neutralizing antibodies from donor pools will prove to be a challenge. 
Following this, the administration of anti-F monoclonal antibodies were shown to be 
protective, neutralizing, anti-fusogenic and eliminates virus from lungs of infected mice 
and cotton rats (G. Taylor et al., 1984; Edward E. Walsh et al., 1987; Routledge et al., 
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1988; G. Taylor et al., 1992; Skaricic et al., 2008) and this passive protective effect was 
also observed in the gnotobiotic calves against BRSV infection (Thomas et al., 1998). 
To this a humanised murine monoclonal antibody palivizumab (Synagis, Abbott, UK) 
was developed. Palivizumab is recombinant based, eliminating the risk of blood borne 
virus transmission and ensured highly reproducibility between batches. Palivizumab is 
the only monoclonal antibody licenced for prophylaxis of HRSV (Sandritter, 1999; 
Herren Wu et al., 2007a) and can be delivered through intramuscular route rather than 
intravenous as with RespiGam™. The efficacy of Palivizumab was demonstrated in a 
large clinical trial, known as The Impact RSV Study Group, (1998) which involved 
1502 children with prematurity or with BPD. The study showed reduced hospitalization 
rates of HRSV high risk groups following the administration of intramuscular 
Palivizumab. These studies also reported that infants receiving Palivizumab had reduced 
HRSV hospital days, oxygen supplementation and moderate to severe lower respiratory 
tract infection (LRTI) (Thwaites et al., 2008). However, the administration of 
Palivizumab only reduced the hospitalization rate by 55% (Group, 1998) and 45% 
(Feltes et al., 2003) with no significant reduction in the rate of mechanical ventilation or 
length of stay in the Intensive Care Unit (ICU). This raised the question of the cost 
effectiveness and efficacy of Palivizumab (Landau, 2006).  
Recently, Palivizumab resistant HRSV strains were isolated from infants receiving 
Palivizumab treatment and their characterization revealed a mutation in codon 272 and 
276 in the F gene in which resulted in a complete loss of binding to Palivizumab 
(Adams et al., 2010). Also, HRSV from nasopharyngeal secretions and low passages of 
virus isolates have been was shown to be significantly resistant to neutralization by F 
protein specific monoclonal antibodies including palivizumab (Marsh et al., 2007). 
These resistant viruses replicated poorly in cell culture and upon cell culture adaptation, 
the higher passage viruses were shown to increase in susceptibility to Palivizumab 
without any change of the binding of Palivizumab to the isolated F protein in 
BIAcore™ assay (Marsh et al., 2007). 
A second generation immune prophylaxis involving the affinity maturation of 
humanized monoclonal antibodies derived from Palivizumab has been developed. This 
humanized monoclonal named motavizumab (MEDI-524, Numax) developed by 
MedImmune Inc., a subsidiary of AstraZeneca targets antigenic site A of the F 
glycoprotein only differs from its predecessor by 13 amino acids. Motavizumab shows 
approximately 20-fold improvement in virus neutralization in vitro and up to 100-fold 
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reduction in virus titer in cotton rats compared to Palivizumab at equivalent 
concentration. Unlike Palivizumab, motavizumab is potent in the inhibition of viral 
replication in the upper respiratory tract (Herren Wu et al., 2007a). Motavizumab 
exhibited 70-fold enhancement in binding to the F glycoprotein, 11-fold faster 
association and 6-fold slower dissociation rate compared to Palivizumab (Weisman, 
2009). Clinical trials have shown that motavizumab to be comparable to Palivizumab in 
both safety and efficacy in the reduction of incidence of RSV-related hospitalizations. A 
detailed summary of the progression of the clinical trials from phase1/2 to phase 3 was 
reviewed by Cingoz (2009). However, motavizumab was not approved by the US FDA 
and the licensing application had been withdrawn by AstraZeneca. 
Additional work on passive immunization of Mabs to the G glycoprotein showed 
similar protective effect in mice and cotton rats (G. Taylor et al., 1984; E E Walsh et al., 
1984; Stott et al., 1986; Routledge et al., 1988) but most anti-G Mabs especially those 
recognizing subgroup specific epitopes involving the conserved cysteine noose region 
of the G glycoprotein do not neutralize the virus in vitro (Trudel et al., 1991; Simard et 
al., 1997; Helene Plotnicky-Gilquin et al., 1999) and significantly less effective than 
anti-F Mabs. Mekseepralard et al. (2006b) by using a aglycosyl mutant to the CH2 
domain which renders the antibody defective in complement activation and FcγR 
binding have shown the reduced protective effect of a subgroup specific monoclonal 
antibody in BALB/c  mice upon challenged with HRSV showing the complex 
involvement of both Fc and non-Fc mediated interactions in protection.  
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Chapter 2 Background of project 
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2.1 Introduction 
Pneumonia is the leading cause of mortality in children below five years old which 
accounts for 1.6 million children annually or 18% of the total number of children in that  
age group worldwide with the main viral etiological agent being human respiratory 
syncytial virus (WHO, 2010). As reviewed  above, the only treatments licensed to treat 
or prevent HRSV related respiratory illneses are the administration of aerosolized 
ribavirin and/or intramuscular administration of Palivizumab but the efficacy and the 
reduction of hospital stay associated with the treatments are not satisfactory (Committee 
on Infectious Diseases, 1996; Landau, 2006).  It is possible that the administration of a 
single monoclonal antibody targeting the highly conserved fusion protein alone as a 
means of prophylaxis is insufficient in vivo and the inclusion of anti-G monoclonal 
antibody specific to the contemporary genotype or cross reactive as a complement to 
Palivizumab may boost the efficacy of Palivizumab in reducing the hospital stay and 
duration  of dependency on mechanical ventilation. 
The F glycoprotein exhibits a lower evolutionary rate compared to the G glycoprotein as 
reviewed in section 1.5.1. The relative conservation of the fusion glycoprotein suggests 
that the fusion glycoprotein either cannot tolerate changes or is a relatively unimportant 
antigen compared to the G glycoprotein (Xiaodong Zhao et al., 2004). In line with the 
latter possibility, escape mutations occur in the F gene and can be readily selected by 
exposure of the virus to anti-F antibody in cell culture systems. Prolonged treatment of a 
4 year old girl with severe combined immune deficiency disease (SCID) with IVIG 
resulted in the emergence of an escape mutant carrying a novel mutation to the G 
glycoprotein but not the F glycoprotein (Lazar et al., 2006).  
The finding that antibodies to the F glycoprotein can be protective in infants favours the 
first alternative, F is an important antigen but is unable to vary antigenically. However, 
the facile creation of antigenic variations in F in culture under immune pressure argues 
for the alternative hypothesis that F cannot change and must therefore not be under 
immune pressure in vivo. These apparently conflicting views can be resolved if anti-F 
antibodies are important in protecting the infant lung but unimportant in preventing 
transmission of the virus from the upper respiratory tract. Immune pressure is exerted 
on virus transmission, selecting escape mutants able to carry infection from one 
individual to another. The ability of anti-F antibodies to protect the infant lung is 
irrelevant to transmission.  
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If anti-G antibodies are important in controlling transmission of HRSV in the 
population resulting in a high evolutionary rate and emergence of G glycoprotein 
antigenic variants, anti-G antibodies may also play a role in protecting the infant lung, 
and therefore might have prophylactic potential.   
In an epidemiological study Scott et al., (2006) showed that infants with primary HRSV 
infection lost their subgroup specific immunity 2-4 months after infection but retained 
their infecting genotype specific immunity for up to 7-9 month suggesting that genotype 
specific antibodies, which are mainly anti-G antibodies following primary infection in 
infancy (McGill et al.,2004b) are protective longer than group specific antibodies, 
which are predominantly anti-F and to a lesser extent anti-G. 
Antibodies elicited against the G glycoprotein of HRSV can be either subgroup specific, 
cross-reactive or genotype/strain specific, targetting different regions of the G 
glycoprotein as depicted in Figure 5 in section 1.4.4. Nearly 45% of adults shown 
seroconversion to the central unglycosylated region of G which contains cross-reactive 
epitopes (Murata et al., 2010) and these antibodies are therefore likely to be passed 
across the placenta to at least a proportion of infants. It has not been possible, hitherto, 
to assess the importance of cross-reactive anti-G antibodies in protection against 
primary HRSV. However, demonstration of the presence of high titered cross-reative 
and protective maternal antibody would indicate the possibility of designing a single 
potent pan-HRSV vaccine or immunoprophylaxis against the G glycoprotein. Previous 
conclusions that anti-F antibodies are protective in infants were derived from the 
correlation of maternal antibody level to the membrane bound glycoproteins at the time 
of infection with the evidence of HRSV infection (Glezen et al., 1981b; Ogilvie et al., 
1981). Kasel et al., (1987) also showed a significant correlation of anti-F but not anti-G 
antibodies with immunity although there was no significant correlation between reduced 
severity of illness among hospitalized infants and antibody to the purified glycoproteins 
of the subgroup A genotype of HRSV (Toms et al., 1989). In the latter studies prototype 
strains (A2 and Long) were employed, which were isolated about two decades 
previously. It is likely that only an undefined fraction of the anti-G antibodies would 
have been detected in contemporary sera by these antigens potentially masking any 
protective effect of anti-G antibodies. Similar studies, aiming to demonstrate a 
correlation of anti-G antibodies with reduced incidence of HRSV bronchiolitis, must 
necessarily measure anti-G antibodies against contemporary genotypes of the virus 
utilising assays which measure either all antibody species reacting with the G 
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glycoprotein of the infecting strain or, to assess the role of cross-reactive antibodies, 
exclusively all of the antibody species reacting with the conserved epitopes of the G 
glycoprotein. 
2.2 Hypothesis 
Anti-G antibodies, measured against the G glycoprotein of the infecting virus genotype, 
are important in the protection of infants against severe HRSVdiseases.  
2.3 Aims 
I. To establish the molecular epidemiology of HRSV in Newcastle upon Tyne over 
three seasons. Molecular epidemiology by phylogenetic analysis will accurately 
define the contemporary genotypes and predict the genotypes in the subsequent 
epidemic. This will also provide contemporary genotypes of HRSV for the 
expression of F and G glycoproteins. The utilization of contemporary genotypes 
to generate recombinant glycoproteins is preferable as previous research has 
shown that antibodies in covalescent sera exhibit reduced binding to the fusion 
glycoprotein derived from strain A2 compared to contemporary viruses of  
heterologous genotypes.  
II. To isolate and express the F and G glycoprotein genes of contemporary HRSV 
strains and to develop a lectin capture ELISA to measure anti-F and total anti-G 
antibodies to the infecting virus genotype in infant sera.  
III. To develop an assay for the measurement of antibody exclusively to the 
conserved epitopes of the G glycoprotein.  
IV. To compare anti-G glycoprotein maternal antibody levels between hospitalized 
infants with severe HRSV disease and a comparison group of uninfected infants 
hospitalized with no evidence of HRSV infection to test the hypothesis that anti-
G glycoprotein antibodies correlate with protection against severe HRSV 
disease. 
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Chapter 3 Materials and methods 
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3.1 General 
3.1.1 Materials 
All chemicals were from SIGMA unless stated otherwise. 
All chemicals, reagents, plasticware and glassware are sterile unless stated otherwise. 
3.1.2 Sterilization  
All sterilizations were carried out in an autoclave machine (AMA252, Astell Scientific 
Ltd) with moist heat at 121 °C for 15 minutes unless stated otherwise. 
3.1.3 Water 
All tissue culture reagents were prepared and diluted in Milli-Q water, Milli-Q synthesis 
(Millipore). 
Non-tissue culture related reagents and chemicals were prepared and diluted in distilled 
water. 
3.1.4 Surface Decontaminations 
Work surfaces were decontaminated before and after experiments with either Virkon or 
Trigene Advance. Surface was wet with the decontamination solution and wipe dry with 
paper towel. 
3.1.5 Incubation 
All incubations in this section was done in a moisture enhanced incubator supplemented 
with 5 % CO2 at 37 °C. 
3.2 Cell count 
Trypsinised cells were resuspended in λ ml of medium and 15-20 µl was spotted onto an 
Improved Neubauer Haemocytometer. The total number of cells in all four cell corners 
were counted (β cells). 
The cell concentration, Mcell= 


×104 cells/ml 
Total cells per flask, ∑=
	
×104×λ. 
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3.3 Preparation of Chicken cell fibroblast (CEF) 
Ten fertilized hen’s eggs were grown at 38 °C for 10 days in a moisture supplemented 
incubator with twice daily rotation. The eggs were sterilized with methanol in the tissue 
culture hood and air dried. Sterile sharp scissors were used to stab open the egg over the 
air sac and the shell was carefully cut away. The membranes were peeled back using a 
curved forceps and the embryo was lifted out from the egg. The embryos were 
decapitated and placed in a 50 ml centrifuge tube containing 20 ml of embryo washing 
buffer to remove erythrocytes from the embryo. All the embryos were rinsed further 
with embryo washing buffer and placed into the barrel of a 20 ml syringe, and forced 
through with the plunger into a Duran bottle containing 200 ml of digestion buffer and 
incubated at room temperature for 30 minutes with gentle stirring with a sterile 
magnetic stirrer. The stirring was stopped and the suspension kept still for 5 minutes to 
sediment large undigested fragments. The suspension was then transferred into 50 ml 
centrifuge tube containing 5 ml of FCS to inactivate the trypsin before being filtered 
through a sintered glass filter (No 3). The flow through was spun at 1000 rpm for 10 
minutes and the pellet was resuspended in 10 ml of GM1. The cell concentration was 
adjusted to 107 cells/ml in cryo buffer and frozen down at 1°C/hour in “MrFrosty” 
(Cat~5100-0001) (Nalgene) at -80 °C freezer for 16 hours and stored in liquid nitrogen 
until use. 
3.4 Human epithelial carcinoma cell line (HeLa) 
HeLa cell line was obtained from Dr. Sarah Elizabeth Welsh, Newcastle University, UK 
without any recorded passage number. This cell line has been in continuous use for the 
isolation and culture of HRSV in Newcastle upon Tyne virus diagnostic laboratories, 
Royal Victoria Infirmary for at least 34 years (Herrnstadt et al., 2002). 
3.5 Japanese Quail fibrosarcoma cell line (QT35) 
QT35, passage 26 was a gift from Dr Barbara Blacklaw, Cambridge University. 
3.6 Baby Hamster Kidney cell line (BHK21) 
BHK21 was a gift from Dr C.R Madeley, Health Protection Agency, Newcastle upon 
Tyne. 
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3.7 Routine cell culture 
All routine cell culture methods described in this section are identical to all cell lines 
unless stated otherwise. 
3.7.1 Maintenance of stock 
The medium from a confluent monolayer in a T75 tissue culture flask was aspirated and 
rinsed once with 5 ml PBS. The monolayer was treated with 5 ml of Trypsin/versene 
and 4 ml was removed followed by incubation at 37 °C for 5 minutes, the flask was 
knocked a few times to dislodge the cells which were then resuspended in 5 ml of the 
appropriate growth medium (GM). A third of the volume was transferred into a new 
flask and volume of GM adjusted to 10 ml. GM was replaced every two days.  
HeLa cells were grown in 4 oz glass bottles and maintained as described above. 
3.7.2 6 well plate 
Each well was seeded with 1.6×106 cells/well in 2 ml of GM and incubated overnight to 
achieve a confluent monolayer the next day. 
OR 
One newly confluent cell monolayer in T75 tissue culture flask was trypsinised as 
described above and resuspended in 26 ml of GM and seeded 2 ml/well for 2 plates 
followed by overnight incubation to achieve a confluent monolayer the next day.  
3.7.3 24 well plate 
Each well was seeded with 4×105 cells/well in GM and incubated overnight to achieve a 
confluent monolayer the next day.  
OR 
One newly confluent cell monolayer in T75 was resuspended in 50 ml of GM and seed 
1ml/well for 2 plates and incubated overnight to achieve a confluent monolayer the next 
day. 
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3.7.4 96 well plate 
HeLa cells grown in 96 well plates were used for HRSV virus titration. One newly 
confluent HeLa cell monolayer in 9 oz glass bottle were resuspended in 50 ml of GM 
and seed 200 µl/well and incubated overnight to achieve a confluent monolayer the 
following day. 
3.7.5 HeLa tubes 
In the morning when HRSV isolation is to be carried out, 1 flask of confluent HeLa 
cells in 4 oz glass bottle was dissociated as described above and resuspended in 18ml of 
GM2 and used to seed 1ml/tube in glass test tubes. The test tubes were placed on a test 
tube rack, sealed with a sterile silicone bung and incubated with approximately 10° 
elevations ensuring that the medium does not wet the bung. After approximately 6 hours 
of incubation, the monolayer should achieve 50-60 % confluency and are ready to be 
used. 
3.8 Diff-quik Staining 
The nucleus and cytoplasm of cell monolayer was stained with Diff-quik® 
(Cat#F07528/71) (Dade Behring). The monolayer in 24 well plate was rinsed with 500 
µl/well of PBS and fixed with 200 µl/well of Fixative Solution [0.002 g/L (w/v) Fast 
green in Methanol] by dispensing the volume onto the cell and immediately removed by 
aspiration. This procedure was repeated for 3 times. The fixed monolayer was air dried 
and stained with 200 µl/well of Stain Solution I [1.22 g/L (w/v) Eosin G in phosphate 
buffer, pH 6.6] as described above and followed with Stain Solution II [1.1 g/L (w/v) 
Thiazine Dye in phosphate buffer, pH 6.6]. The stained monolayer was washed once 
with 500 µl/well of distilled water, air dried and visualized under the microscope. 
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3.9 Immunological reagents 
 
Table 2 Lists of primary antibodies 
Antibodies Antigen/Specificity Concentrationφ 
(µg/ml) 
References 
HRSV Mab pool HRSV F, M2, P and 
N 
N/A Novocastra 
Laboratories 
1A12 HRSV F 573 (Routledge et al., 1985) 
IC2 HRSV G 
Subgroup A  
540 (Morgan et al., 1987) 
133 HRSV G 
Conserved 
25 (M. J. Robinson, 2007) 
21 HRSV G 
Conserved 
15.8 (M. J. Robinson, 2007) 
4G4 HRSV G 
Subgroup A  
19.6 (Morgan et al., 1987) 
3F43 HRSV G 
Strain A2 specific 
600 (Morgan et al., 1987) 
φ concentrations were  determined by Ms Fiona Fenwick, Newcastle University 
Table 3 Secondary antibodies 
Name Abbreviation Dilution Reference 
Goat anti-mouse-HRPψ 
Cat#NCL-GAMP 
GAMPx 1/1000φ Novocastra 
Polyclonal Rabbit anti-human IgA-HRP 
Cat#P216 
RAHAPx 1/200φ Dako 
Polyclonal Rabbit anti-human IgG-HRP  
Cat#P0406 
RAHGPx 1/800φ Dako 
Sheep anti-mouse FITC (Novocastra) SAM-FITC 1/20γ Novocastra 
φ Dilution in PTF, γ diluted in Evan’s blue counterstain, ψ Horse radish peroxidise 
conjugate 
3.9.1 Cord blood 
Cord blood from 17 donors was obtained from archived frozen stock stored at -20 °C 
collected in 1980/1981 by Dr. Ron Scott. 
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3.10 Immunofluorescence 
3.10.1 Microscope slides 
All PTFE coated multispot microscope slides (Hendley Ltd) were treated with 10 % 
(v/v) Decon90 (Decon Laboratories Ltd) in distilled water for 2 hours and washed with 
running tap water for 4 hours. Slides were soaked in distilled water overnight, air dried 
and stored at ambient temperature until use.  
3.10.2 Slide preparation 
Monolayers from the tissue culture flasks or plates were scraped into the original 
volume of the appropriate maintenance medium with a a cell scraper (Corning) and 15 
to 20 µl of the cell suspension was spotted onto microscope slide (section 3.10.2), air 
dried in a biological safety cabinet. 
3.10.3 Specimen fixation 
The dried specimens were fixed by immersing specimen slides into ice-cold acetone for 
10 minutes and then air dried. The slides were either used immediately or stored at -
20 °C until use. 
3.10.4 Indirect immunofluorescent staining 
The slides were equilibrated to ambient temperature and air dried if water of 
condensation occured. 10 µl of the primary antibody was spotted onto the fixed cells 
and incubated for 30 minutes in a moist chamber at 37 °C. The primary antibody was 
removed by immersing the slide in PBS for 5 minutes and the slide was air dried. 10 µl 
of SAM-FITC antibody and spotted onto the primary antibody stained cells and 
incubated for 30 minutes and then washed as above. The spots on the slide were 
covered with a drop of immersion oil (Cat# 16212) (Cargille Laboratories Ltd) 
visualized via a 50X oil immersion lens (Nikon Plan) in a fluorescence microscope 
Eclipse E400 (Nikon). The intensity of the fluorescence was recorded based on arbitrary 
four scale fluorescence with 1+ being the lowest and 4+ being the highest. Photographs 
were captured using a built-in Coolpix 4500 4 megapixels digital camera (Nikon).  
 54 
 
3.11 ELISA 
3.11.1 ELISA plates 
F96 Maxisorp Nunc-immunoplate (Cat#442404) (Thermo) was used and refered to as 
Maxisorp plates. 
3.11.2 Washing 
Wells of the Maxisorp plate was filled with the appropriate wash buffer, decanted and 
blot dried. This process is repeated trice for each washing. 
3.11.3 Incubation 
All incubation was done at 37 °C with the Maxisorp plate covered with a plastic lid to 
minimize evaporation. 
3.11.4 Preparation of HRSV ELISA antigens  
The maintenance medium was removed from 4 infected 4oz bottles of HeLa monolayers 
exhibiting 3+ to 4+ CPE and replaced with SAF. Cultures were incubated for a further 
16 hours before cells were scraped into the medium and the cell suspension was pooled 
into a 50 ml sterile centrifuge tube and pelleted by centrifugation at 1000 rpm for 5 
minutes. The pellet was resuspended in 2 ml of ice cold SAF and sonicated on ice using 
a SANYO MSE Soniprep sonicator, with amplitude of 10 microns, 3x30 seconds bursts 
with 30 seconds interval between each burst. The sonicated cell lysate was snap frozen 
in liquid nitrogen, thawed and aliquoted as 200 µl aliquots, snap frozen and stored at -
80 °C until use. A parallel experiment was carried out with uninfected HeLa cell control. 
The total protein concentrations for the virus lysate and cell control antigens were 
estimated as described in section 3.14. 
3.11.5 Preparation of recombinant ELISA antigens 
Four flasks of confluent HeLa in T225 were prepared by seeding one confluent T75 
flask of HeLa into one T225 flask and cultivated in 40 ml of growth medium per flask. 
The growth medium was removed by aspiration and inoculated with MVA adjusted to 
the MOI of 3 in 5 ml of MM2 an incubated for 1 hour. 20 ml of fresh MM2 was added 
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and incubated for 48 hours. The cells should show 4+ CPE and most have detached 
from the flask into the medium. 
Two flasks worth of monolayer was scraped into the medium and transferred into a 50 
ml centrifuge tube and pelleted by centrifugation at 1000 rpm for 5 minutes. The 
medium was removed by aspiration and the pellet resuspended in 50 ml of PBS and 
held on ice for 5 minutes. The cell was pelleted by centrifugation was above and PBS 
removed by aspiration. The cells were resuspended in 6 ml of ice cold lysis buffer 
prepared as described in section 3.13 and sonicated on ice bath 3 x 30 seconds at 10 
microns with 30 seconds interval using Sanyo MSE sonicator. The lysed antigen was 
stored as 500 µl aliquot in 2 ml vial at -20 °C until use. 
3.11.6 Direct ELISA protocol 
HRSV virus antigen and uninfected cell antigens were adjusted to 10 mg/ml in SAF and 
dilutions were made in 1X bicarbonate coating buffer to the desired dilutions. Half of 
the plate was coated with HRSV virus antigen and the other half with uninfected cell 
antigens at the volume of 50 µl/well followed by overnight incubation. 
The following day, unbound antigens were decanted and washed. No dedicated 
blocking step was carried out unless stated otherwise. The Maxisorp plate was either 
used immediately or stored frozen at -20 °C. 
Primary antibody was diluted in PTF to the desired dilutions and dispensed at the 
volume of 25 µl/well. The plate was incubated for 90 minutes followed by washing step 
with PBST. 
The primary antibody stained wells were then stained with the appropriate secondary 
antibody dilution and incubated for 60 minutes followed by washing step with PBST. 
Colour was developed using 50 µl/well of OPD and incubated for 30 minutes. Reaction 
was stopped with 50 µl/well of 3M H2SO4 and absorbance read at 492 nm in an ELISA 
plate reader. 
3.11.7 ConA capture ELISA  
Stock ConA prepared as described in section 12.2.4 was diluted to 50 µg/ml in PBS and 
coated on Maxisorp plate at 50 µl/well followed by overnight incubation. 
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Excess ConA was decanted, washed with PBSTx and blocked for an hour with 100 
µl/well of PTF. PTF was decanted and washed with PBST. 
The subsequent steps from the primary antibody staining onwards were carried out as 
described in section 3.11.6. 
3.11.8 Additive binding ELISA 
HRSV antigen was titrated twofold horizontally in BCB on a Maxisorp plate and 
incubated at 37 °C for 2 hours. Uninfected HeLa cell antigen was coated in parallel. The 
Maxisorp plate was washed and monoclonal antibody was twofold titrated vertically in 
PTF and direct ELISA was performed as described in section 3.11.6 using GAMPx as 
the secondary antibody. The saturating antigen concentration with the excess antibody 
dilution was chosen for the additive binding ELISA.  
Half of a Maxisorp plate was coated with the saturating HRSV antigen concentration 
and the other half with the equivalent uninifected HeLa cell concentration. The 
monoclonals were assayed individually as a control. Additive binding ELISA was 
prepared by diluting the antibody in PTF yielding double the desired concentration and 
combined at equal volume to get the test dilution. ELISA was carried out described in 
section 3.11.6 with GAMPx as the secondary antibody. 
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3.12 SDS-PAGE and Western blot 
3.12.1 Preparation of polyacrylamide gel 
BIORAD cell II system was used throughout. The glass slab was assembled with 0.1 
mm spacer on the cast system and each glass slab was filled with 5 ml of 10 % 
resolving gel formulation and carefully overlayed with distilled water and let to 
polymerise at 37 °C for 1 hour. Water overlay was decanted, rinsed with distilled water 
and blot dry with filter paper. The polymerised resolving gel was overlayed with 5 % 
stacking gel and comb was inserted and polymerised at 37 °C for 30 minutes. The comb 
was removed by lifting it vertically out from the gel and the wells were rinsed 
vigourously with distilled water. 
The gel cast was then transferred onto the electrophoresis set and filled with ice cold 1X 
electrode running buffer.  
3.12.2 Protein sample preparation 
Protein sample was diluted in 4X reducing sample buffer (150 µl of protein plus 50 µl 
of 4X reducing sample buffer), vortex mixed and boiled for 10 minutes in a boiling 
waterbath. The protein sample was immediately cooled on ice for 1 minute followed by 
centrifugation at 13000 rpm for 10 minutes in a microfuge to pellet any insoluble 
protein particles.  
3.12.3 SDS-PAGE 
Protein samples prepared in section 3.12.2 was loaded into a well in the polyacrylamide 
gel (section 3.12.1) and resolved at 120V until the bromophenol blue dye front reaches 
about 1cm from the end of the gel. 
3.12.4 Transfer of SDS PAGE gel. 
Hybond-P Polyvinylidene fluoride (PVDF) transfer membrane (GE Healthcare) was cut 
to the size of the SDS-PAGE gel and soaked in methanol for 1 minutes and stored in ice 
cold 1X Towbin buffer until use. 
The glass plates’ holding the SDS-PAGE gel was removed from the electrophoresis set 
and a glass plate was removed exposing the gel. The gel was rinsed with ice cold 1X 
Towbin buffer and sandwiched together in a Biorad transfer apparatus with 1 sheet of 
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Whatman filter paper and one sponge in either side of them and inserted into the 
electrophoresis cell. An ice pack was inserted and the electrophoresis set was flooded 
with ice cold 1X Towbin buffer and transfer was done at 100V for 1 hour. The 
temperature of the electrophoresis cell was regulated with the help of contant stirring 
with a magnetic stirrer. The membrane was removed from the set and blocked overnight 
in blocking buffer. 
3.12.5 Western blots staining 
The membrane resulting from section 3.12.4 was incubated for 1 hour with 10 ml of 
primary antibody diluted in blocking buffer in a 50 ml centrifuge tube on a rotating 
mixer. The membrane was washed 3 times in PBST and subsequently incubated with 
GAMPx  in blocking buffer and incubated as above in a fresh 50 ml centrifuge tube. 
The membrane was washed three times in PBST, dried on a piece of filter paper and 
stained in 20 ml of Substrate A and B n the dark for 1 hour on an orbital shaker. The 
membrane was soaked in distilled water overnight and air dried.  
3.13 Modified Lowry 
This method was originally described by (Lowry et al., 1951) and modified by 
(Markwell et al., 1978). 
3.13.1 Standard curve 
Due to the presence of Triton X-100 in PBSTx used to extract the fusion glycoprotein, 
recombinant antigens cannot be estimated by using the Biorad protein Assay. Thus 
Modified Lowry Assay (Markwell et al., 1978) was chosen for the estimation of total 
protein from the assay as described in section 3.13.2. 
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Figure 11 Standard curve for BSA based on modified Lowry protein assay. 
A BSA standard curve was prepared from 10 mg/ml down to 0 mg/ml and assayed as 
described in modified Lowry Assay. From the standard curve in Figure 11, the curve 
shows two linear ranges between 0-0.5 mg/ml and 5-10 mg/ml. Due to practicality, 
BSA standard curve was prepared within the first linear range and graph ploted in 
Microsoft Excel 2007 with equation displayed for calculation. 
Proteins assayed was serially diluted in PBSTx and assayed together with the standard. 
The actual concentration was calculated based on the lowest dilution where the optical 
density falls into the linear range of the standards.  
3.13.2 Procedure 
100 µl of standard/sample was aliquoted into a fresh ependorf tube and combined with 
300 µl of Reagent C. The mixture was vortex mixed and incubated for 30 minutes at 
37 °C in an incubator. 30 µl of Reagent D was added, vortex mixed and incubated for 
30 minutes at 37 °C in an incubator. The mixture was dispensed at 100 µl/well into a 96 
well plate and read at 630 nm on a ELISA plate reader. 
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3.14 Biorad Protein Assay 
3.14.1 Procedure 
10 µl of protein sample was diluted to 150 µl with 0.1 % (w/v) SDS and dispensed with 
equal volume of working Biorad Assay Reagent, mixed well by pipetting and optical 
density read at 600 nm in a microwell plate reader. The protein standard was treated in 
parallel and a protein standard curve was ploted in Microsoft Excel 2007 and equation 
was displayed for calculation. 
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3.15 Molecular biology 
3.15.1 Oligonucleotides 
All primers were synthesized by Eurofins MWG Operon. All cloning oligonucleotides 
were high performance liquid chromatography (HPLC) purified and all regular PCR 
primers were high purity salt free (HPSF) purified.  
Table 4 Oligonucotides used for genotyping 
Pr
im
er
 
Se
qu
en
ce
 
Po
la
rit
y 
Lo
ca
tio
n
 
R
ef
er
en
ce
 
GC1 GCAGCATATGCAGCAACA + 533–
551  
(Roca et al., 2001) 
F164 GTTATGACACTGGTATACCAA
CC 
- 186–
164  
(W. M. Sullender et al., 
1993) 
GB1 CCTGCAGGCAATGATAATCTC
AACCTC 
+ 153-
173β 
(A. McGill, 2001) 
GB2 GAATTCTCGGAGTGGAGGGA
TTTGCTGTTGG 
- 818-
798β 
(A. McGill, 2001) 
G1 (GGATCCC)GGGGCAAATGCA
AACATGTCC 
+ 1-21  (P. A. Cane and Pringle, 
1992) 
 sequence corresponding to strain A2, β sequence corresponding to strain 8/60, +and –
polarity also represents forward primer and reverse primer respectively. 
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Table 5 Oligonucleotides used for cloning G genes and F gene into pSC11 
Primer Sequence (5’-3’) Group  Gene 
gpGA_For TAACCCCGGGGCAATTGCAAACATGTCCA
AA 
A G 
gpGA_Rev TGGTCCCGGGTTTCCTCAGGAATACGCTTT
TTAATGACTA 
A G 
gpGB_For TCAAAAACAACCCCGGGGCAATTGCAAAC
ATGTCCAAA 
B G 
gpGB_Rev TCTCTGCCCCGGGGTACCTCAGGAATAACT
AAGCATATGACT 
B G 
gpFA_For TCAACCCCGGGGCAAATAACAATGGAGTT
GCCAATCCTC 
A F 
gpFA_Rev ATGACCCGGGCCTAAGGCATTGTAAGAAC
ATGATTAGGTGC 
A F 
Underlined: Cfr9I RE site, Boxed: ATG transcription start codon, italised: BSu36I RE 
cleavage site. 
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Table 6 Oligonucleotides used in colony PCR 
Primer Sequence (5’-3’) Vector 
M13_For CGCCAGGGTTTTCCCAGTCACGAC pGEM-T Easy 
M13_Rev TCACACAGGAAACAGCTATGAC pGEM-T Easy 
pSC_For TATACATAAACTGATCACTAATTCC pSC11 
pSC_Rev TTGAAATGTCCCATCGAGTG pSC11 
pTM_coFor TCGGTGCACATGCTTTACAT pTM3 
pTM_coRev CCCCAAGGGGTTATGCTAGT pTM3 
 
Table 7 Oligonucleotides used for the design of the colony PCR primer 
Primer Sequence (5’-3’) 
SH Forward CGCATAGCCGGCATGAAAACATTAGATGTCATAAAAAG
TGATG 
SH Reverse CGCATAGCCGGCCCTGAGGCGAATGTTCTCCACTCTTAC
TTC 
MCS_upstream CATCACTTTTTATGACATCTAATGTTTTCAT 
MCS_downstream GAAGTAAGAGTGGAGAACATTCGCCTCAGG 
pTMvec_F CCG GGGAGCTCACTAGTGGATCCCTGCAG 
pTMvec_R CTGCAGGGATCCACTAGTGAGCTCCCCGG 
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Table 8. Oligonucleotides used in the for the cloning of the G gene and its 
truncated products into pTM3 
Primer Sequence (5’-3’) 
GNcoIF CGCAATTGCAACCATGGCCAAAACCAA 
G-N151F AAGTCCACCACCATGGAACGCCAAAACAAACCACCAAAT 
G-N155F AAACAACGCCCCATGGAACCACCAAATAAACCCAACAAT 
G-N158F CAAAACAAACCCATGGATAAACCCAACAATGATTTTCAC 
G284R TGTGATGGATCCTCAGATGTTGTATAGAC 
G190R CTTTCCAGGGGATCCTCATGGTATTCTTTTGCAGAT 
G-177R CCAGCAGGTGGATCCCTAGCATATGCTGCAGGGTACAAA 
G-172R GTTGCTGCAGGATCCCTAGGGTACAAAGTTGAACACTTC 
G163R GTTGAACACGGATCCTCAAAAATCATTGTTGGGTTTA 
Boxed-transcriptional start codon which is also part of the engineered NcoI restriction 
site, Italicised-engineered BamHI restriction site, Underlined-engineered stop codon. 
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3.15.2 RNA extraction 
RNA extraction was performed using the RNeasy Mini Kit (Cat#74106) (Qiagen) with 
modification where virus stock in maintenance medium was used instead of serum free 
infected cell pellet. Three buffers namely Buffer RLT, RW1, RPE and RNase free water 
were supplied with with the kit. 
500 µl of frozen virus stock was thawed in 1 volume of Buffer RLT (lysis buffer) 
followed by the addition of 1 volume if 70 % (v/v) ethanol diluted in DEPC water. The 
lysate was filtered through an RNeasy mini column by brief centrifugation and washed 
once with 700 µl of buffer RW1 and twice with 500 µl of Buffer RPE. The total RNA 
was eluted in 2x30 µl of RNase free water supplemented with 60 units of 
Ribolock™RNase inhibitor (Cat#EO0381). 
HeLa cell was concurrently extracted with the virus stock as a cell control. Maximum of 
9 reactions were permitted at any one time for optimal loading into the centrifuge. 
3.15.3 Reverse transcription 
All reagents in this section were purchased from Fermentas unless stated otherwise. The 
first strand cDNA synthesis was carried out in 30µl reaction volume in a 24 well PCR 
plate containing 5 mM MgCl2, 1mM of each dNTP,  
20 pmol of forward primer,  
40 units of Ribolock™ RNase Inhibitor (Cat#EO0381),  
200 units of RevertAid™ H Minus Reverse Transcriptase (Cat#EP0451),  
1X reverse transcription buffer  
10 µl of total RNA extract 
The reaction was carried out in a PTC-200 Peltier thermal cycler (M.J. Research Inc.) at 
42 °C for 30 minutes followed by a denaturation step at 99 °C for 5 minutes. The cDNA 
was used immediately or being stored at -20 °C. 
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3.15.4 Polymerase Chain Reaction 
All reagents were purchased from Bioline unless stated otherwise.  
All PCR reactions use identical formulations as described below. The reaction was 
carried out in a 100 µl reaction volume in a 24 well PCR plate containing  
10 µl of cDNA (section 3.15.2) 
10 µl of the 10X PCR buffer  
0.25 mM of each dNTP  
20 pmol/µl of forward primer  
20 pmol/µl of reverse primer  
4 mM of MgCl2  
0.5 unit of Immolase™ (Cat#BIO-21046)  
The polymerase Chain Reaction was carried out in an automated thermal cycler (PTC-
200 M.J Research Inc) according to the respective programme as described below. 
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Programme PCR55 
This programme is used for the amplification of partial G gene from cDNA, nested PCR 
and heminested PCR. 
Step 1  Initial denaturation 95 °C 10 minutes 
Step 2  Denaturation   93 °C 0.75 minutes 
Step 3  Annealing   55 °C 0.75 minutes 
Step 4   Elongation  72 °C  0.75 minutes 
Step 5   Repeat step 4 for 35 times 
Step 5  Final Elongation 72 °C 0.75 minutes 
Step 6  Keep   4 °C  ∞ 
Step 7   End 
 
Programme PCR50 
For glycoprotein gene amplification and colony PCR 
Step 1  Initial denaturation 95 °C 10 minutes 
Step 2  Denaturation   93 °C 1 minutes 
Step 3  Annealing   50 °C 1 minutes 
Step 4   Elongation  72 °C  1 minutes 
Step 5   Repeat step 4 for 35 times 
Step 5  Final Elongation 72 °C 1 minutes 
Step 6  Keep   4 °C  ∞ 
Step 7   End 
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3.15.5  Plasmids 
pSC11 plasmid (Chakrabarti et al., 1985; Chiam et al., 2009) was a gift from Dr 
Rachael Chiam, Cambridge University.  
pTM3 was a gift from Dr. Bernard Moss, Laboratory of Viral Diseases, National 
Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 
USA. 
3.15.6 Colony PCR 
Colony PCR was developed for rapid screening of bacterial clones containing the 
positive inserts in pGEM-T Easy (Cat#A1360) (Promega), pSC11 (Chakrabarti et al., 
1985) and pTM3.  
A target colony was picked using a 200 µl yellow tip (S1111-0006) (Starlab Group) and 
resuspended in 100 µl of DEPC water in 0.6 ml microfuge tube, vortex mixed and 10 µl 
was used as the template for PCR using Programme PCR50.  
The PCR products were resolved in agarose gel as described in section 3.15.9. 
The remaining bacterial suspension was stored at 4 °C for culture 
3.15.7 Ethidium bromide decontamination 
Used EtBr in TBE buffer was decontaminated through BondEX-50 Ethidium bromide 
decontamination column, (Cat#740-703), Macherey-Nagel according to the 
manufacturer’s instructions.  
3.15.8 DNA molecular weight markers 
GeneRuler™ 100bp Plus DNA Ladder (Cat#0321) (Fermentas) or GeneRuler™ 1kb 
DNA Ladder (Cat#SM0311) (Fermentas) was diluted and used according to the 
manufacturer’s instructions.  
3.15.9 Agarose gel electrophoresis 
1 % (w/v) SEAKEM® LE Agarose (Cat#50004) (LONZA) was hydrated for at least 1 
minute in 1X TBE solution and solubilised in a 750 W microwave oven at maximum 
power in bursts of 5 seconds with swirl mixing in between until fully dissolved to a 
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crystal clear solution. Ethidium bromide was added to the final concentration of 10 
µg/ml and poured immediately into a gel cast of Mini-sub® cell (Bio-rad) with the 
appropriate gel comb and let to solidify at ambient temperature. 
The gel together with the gel cast was placed in the electrophoresis cell and submerged 
in TBE with 10 µg/ml EtBr. 5 parts of DNA was mixed with 1 part of 6X loading dye, 
loaded into a well and electrophoresed at a contant voltage of 120 V using a power pack 
(Northumbria Biologicals Ltd) until the desired resolution was achieved. 
3.15.10 Gel purification  
Following resolution by gel electrophoresis, the resolved DNA band to be extracted was 
excised from the Agarose gel using sterile surgical scalpel blade No.22 (Cat#0308) 
(Swann-Morton® Ltd) and extracted using QIAGEN Gel Extraction Kit (Cat#28706) 
according to the manufacturer’s instructions. DNA was eluted in 2x15 µl of EB buffer 
(10 mM Tris-Cl, pH 8.5 elution buffer supplied with the kit) and stored at -20 °C until 
use. 
3.15.11 Column purification 
Column purification was performed using the QIAquick Gel extraction kit with 
modification (refer section 3.15.10). Three buffers namely Buffer QG, PE and EB were 
supplied with the kit. Firstly, 1 part (100 µl) of DNA combined with 3 parts (300 µl) of 
buffer QG and 1 part (100 µl) of isopropanol. The mixture was passed through the spin 
column by centrifugation at 13000 rpm for 1 minute and the flow through decanted and 
the column was incubated for 5 minutes at ambient temperature with 750µl of Buffer 
PE. Buffer PE was removed by centrifugation as described above and washed 
immediately with the same volume of Buffer PE. The column was combined with 
another fresh collection tube and centrifuged for 1 minute to dry the column. DNA was 
eluted in 2x30 µl of Buffer EB (10mM Tris-Cl, pH8.5) into a 1.5 ml microfuge tube 
with the lid cut off. Purified DNA was hold on ice or stored frozen at -20 °C. 
3.15.12 DNA concentration  
The concentration of DNA was determined using a Nanodrop ND-1000 
spectrophotometer (Coleman Technologies Inc.) and analysed using the default 
parameters in the Nucleic acid measurement module in NanoDrop version 3.0.0. 
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3.15.13 Sequencing 
The DNA concentration determined as described in section 3.15.12 and diluted with 
DEPC water to 50 ng/µl and sequenced using the Sanger dye termination method by 
GATC Biotech. 
3.16 Nucleotide sequence analysis 
3.16.1 Electropherograms 
The electropherograms (file with extension .abi) were analysed manually using GENtle 
version 1.9.4 (http://gentle.magnusmanske.de/).  
3.16.2 Reverse complement 
Reverse compliment of sequences were created online using reverse complement tool 
Bioinformatics Organization (http://www.bioinformatics.org/sms/rev_comp.html).  
3.16.3 Sequence assembly 
Sequence assembly were done using the CAP3 Sequence Assembly Program (Xiaoqiu 
Huang and Madan, 1999). Sequences were manually trimed to the desired length in 
fasta format (file extension .fas) in text files. 
3.16.4 Sequence alignment 
Sequence alignment was done using ClusterW module and alignment file was saved in 
MEGA format (.MEG extension).  
3.16.5 Phylogenetic tree 
The phylogenetic tree was constructed based on the sequence alignment (section 3.16.4) 
using the neighbour joining method, maximum likelihood model with the bootstrap 
value of 1000 and default random seed value of 31332. The phylogenetic tree generated 
was saved as .MTS file and edited using the same software MEGA4 Software (Tamura 
et al., 2007). All other parameters not mention here were carried out as defaulted by the 
software. 
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3.17 Bacterial production of recombinant plasmids 
3.17.1 Escherichia coli  
E. coli strain TG1 [K12, D (lac-pro) sup E, thi, hsd, 5/F’ traD36, proA+B+, lacIq, 
lacZDM15] was provided by Prof Geoffrey Toms, Newcastle University. TG1 was used 
to prepare chemically competent cells for the transformation of pSC11, pTM3 and their 
chimeric constructs. 
E. coli strain JM109 [endA1, recA1, gyrA96, thi, hsdR17 (rk–, mk+), relA1, supE44, 
∆( lac-proAB), [F´ traD36, proAB, laqIqZ∆M15] chemically competent cell was 
purchased as a ready to use frozen competent cell. 
3.17.2 Preparation of competent E.coli  
The protocol was kindly provided by Dr. Seok-Mui Wang, University of Malaya which 
was initially optimized for BL21(DE3) and XL1Blue strains of E. coli.  
The surface of a frozen TG1 stock (section 3.17.1) was scraped with a flame sterilized 
platinum loop, streaked on an antibiotic free agar plate and cultured overnight at 37 °C 
as described in section 3.17.13. A single colony was isolated using a sterile 200 µl 
yellow tip (S1111-0006) (Starlab Group) and inoculated into a 2 ml LB broth in a bijou 
bottle and grown overnight at 37 °C with vigorous shaking (200 rpm) in an orbital 
incubator (Weiss-Gallenkamp) 
The overnight culture was diluted 1/100 into 60 ml of prewarmed SOB medium in a 250 
ml conical flask and grown to an OD600 of 0.6 at 37 °C with vigorous shaking. The 
flask was removed from the incubator and held on ice for 10 minutes. The culture was 
transferred into a 50 ml centrifuge tube and spun at 4000rpm for 10 minutes at 4 °C in a 
pre-cooled MSE Chilspin 2 bench centrifuge (Fisons). 
The pellet was resuspended in 20 ml of ice cold Tfb1 by gentle swirling and incubate on 
ice for 10 minutes and spun down as above. The pellet was gently resuspended in 4 ml 
of Tfb2 and dispensed by 200 µl/vial in screw-cap vial, held on ice for 4 hours and 
frozen by immersion in liquid nitrogen. The frozen competent cells were stored at -
80 °C until use. 
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3.17.3 Restriction digest of purified products for ligation 
Cfr91 was used for pSC11 and corresponding gene inserts with Cfr91 restriction site 
engineered. 
Purified DNA was digested with 10 units of Cfr9I (Cat#ER0171) in 1X Buffer Cfr9I 
(10 mM Tris-HCl (pH7.2), 5 mM MgCl2, 200 mM sodium glutamate,0.1mg/ml BSA) 
supplied in a 50 µl reaction at 37 °C in automated thermal cycler (PTC-200 M.J 
Research Inc) for 4 hours. The digested vector was column purified and eluted in 50 µl 
EB buffer. 
NcoI/BamHI digestion was carried out for pTM3 and corresponding gene inserts. 
Double digestion was not carried out due to the incompability of the digestion buffers 
for the respective enzymes. Thus, the following proceduce was developed and used. 
Purified DNA with 10 units of BamHI (Fermentas) in 1X Buffer BamHI supplied. The 
digestion was done at 37 °C in an automated thermal cycler. BamHI was removed by 
column purification (section 3.15.10) and eluted in 50 µl of EB buffer. Then the vector 
was digested with 10 units of NcoI (Fermentas) in 1X Buffer Tango as above followed 
by gel purification. The purified vector was eluted in 30µl EB buffer and used 
immediately. 
3.17.4 Dephosphorylation of vector 
This modified protocol was initially provided by Dr. Soren Nielsen, Newcastle 
University. Dephosphorylation removes -3’ and -5’ phosphate group from the digested 
vector preventing self-religation which is crucial for cloning experiments involving a 
single restriction enzyme or sticky end cloning. 
The purified vector was dephosphorylated using 1 unit of calf intestine alkaline 
phosphatase (CIAP), (Cat#EF0341) in 1X reaction buffer supplied (100 mM Tris-HCl 
pH 7.5 at 37 °C, 100mM MgCl2) at 37 °C for 30 mins followed by denaturation at 85 °C 
for 15 minutes in an automated thermal cycler in 100 µl reaction volume. Another 1 unit 
of CIAP was added to the mixture and incubated as above. The CIAP treated vector was 
gel purified and eluted in 30 µl of EB buffer. The purified vector was hold on ice and 
used immediately.  
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3.17.5 Ligation 
The insert and the vector were ligated together with 1 unit of T4 DNA Ligase 
(Invitrogen) (Cat# 15224-017) in 1X ligation buffer supplied (50 mM Tris-HCl (pH 7.6) 
10 mM MgCl2, 1mM ATP 1 mM DTT, 5 % (w/v) polyethylene glycol-8000 overnight 
at 4 °C in a refrigerator. A mock ligation consisting of the vector without insert was 
included as a vector self ligation control or background control. As the amount of DNA 
was not quantitated, the volume of insert can be increased up to 6 µl to when relatively 
low insert DNA concentration was used. 
3.17.6 Insert screening with SmaI 
Restriction digest with SmaI is used with pSC11 and pGEM-T Easy clones. SmaI is a 
neoschizomer of Cfr9I but is more economical for screening purposes. 
Plasmid DNA was digested with 10 units of SmaI (Cat#ER0661) in 1X Buffer Tango 
supplied (33 mM Tris-acetate (pH 7.9), 10 mM Magnesium acetate, 66 mM potassium 
acetate, 0.1 mg/ml BSA) for 2 hours at 30 °C in an automated thermal cycler and 
resolved on a gel. No enzyme denaturation step was done as agarose gel electrophoresis 
effectively removes the function of SmaI.  
3.17.7 Orientation screening with Eco81I 
Chimeric pSC11 containing positive inserts were digested with Eco81I to determine the 
insertional orientation. 
Plasmid DNA was digested with 10 units of Eco81I (Cat#ER0371) in 1X Buffer Tango 
supplied (33 mM Tris-acetate (pH7.9), 10 mM Magnesium acetate, 66 mM potassium 
acetate, 0.1 mg/ml BSA) for 16 hours at 37 °C in an automated thermal cycler and 
resolved on agarose gel as described in section 3.15.9. No enzyme denaturation step 
was done as agarose gel electrophoresis effectively removes Eco81I.  
3.17.8 TA cloning 
TA cloning was carried out for the amplification of the gene of interest which failed to 
be cloned directly into pSC11. 
Purified RT-PCR DNA was cloned into a pGEM-T Easy system (Cat#A1360) (Promega) 
according to the manufacturer’s instructions.  
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3.17.9 Transformation  
The pipette tips used to transfer the ligation mix to the competent cells were prechilled 
to -20 °C for an hour before use. SOC medium and ampicillin agar plates were 
prewarmed to 37 °C before use. 
A tube of competent cells was thawed in an ice bath and added to 1-5 µl of the plasmid 
solution (ligation mix or plasmid). Then the cells were held on ice for 1 hour before heat 
shocked at 42 °C for 45 seconds in a waterbath and transferred to an ice bath. The cells 
were resuspended in 800 µl of prewarmed SOC medium, incubated at 37 °C and shaken 
vigorously for an hour. A volume of 200µl of the culture was plated on ampicillin agar 
plates followed by overnight incubation at 37 °C. Colonies were picked for screening 
either by restriction enzyme digest or colony PCR.  
3.17.10 Miniprep Plasmid Extraction 
Plasmid minipreps were carried out using Qiaprep Spin Miniprep Kit, QIAGEN 
(Cat#27106) according to the manufacturer’s instructions.  
3.17.11 Maxiprep Plasmid Extraction 
Maxipreps were carried out using Endofree Plasmid MaxiKit, QIAGEN (Cat#12362) 
with modifications. All buffers used except growth medium and antibiotic were 
supplied with the kit. 
A single colony was picked using a sterile yellow tip and inoculated into 5 ml of LB 
broth supplemented with 100 µg/ml ampicillin and grown for 8 hours at 37 °C with 
shaking at 260 rpm.  
1 ml of the culture was inoculated into 500 ml of prewarmed LB broth with 100 µg/ml 
ampicillin in a plugged 2 litre glass conical flask and grown overnight as above. The 
following day, the culture was chilled on ice with gentle swirling and pelleted by 
centrifugation at 5000 rpm for 20 minutes at 4 °C in a JA14 rotor in a Beckman J2-21 
centrifuge (Beckman Coultier UK Ltd.). The supernatant was removed by decantation 
and left to drain by leaving the centrifuge pot in the inverted position on a piece of 
paper towel for 5-10 minutes. 
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The pellet was dispersed in 10 ml of Buffer P1 supplemented with 100 µg/ml of 
RNAseA by vigorous pipetting with a 10 ml serological pipette with a bulb attached. 30 
ml of Buffer P1 was added and vortexed vigorously to ensure complete dispersal.  
40 ml of prewarmed Buffer P2 was added and mixed thoroughly by invertion and 
incubated at room temperature for 5 minutes. Lysis was stopped with the addition of 40 
ml of prechilled Buffer P3 and mixed well by inversion. The mixture was centrifuged in 
JLA10.5 rotor at 5000 rpm for 15 minutes at 4 °C without brake to separate the 
precipitate from the solution. 
A QIAGEN-tip 500 was equilibrated with 10 ml of Buffer QBT and allowed to empty 
by gravity flow. The lysate was filtered through the QIAfilter cartridge into QIAGEN-
tip 500. The QIAGEN-tip was washed with 2 x 30 ml of Buffer QC and plasmid was 
eluted with 15 ml of prewarmed (70°C) Buffer QF. 
The plasmid was concentrated by isopropanol precipitation by adding 10.5 ml (0.7 
volumes) of isopropanol to the eluate, mixed well by inversion and spun at 14 500 rpm 
for 30 minutes at 4 °C in a JA20 rotor. The outer side of the centrifuge tube was marked 
to facilitate to location of the precipitate. The isopropanol was removed by aspiration 
and washed with 5 ml of 70% (v/v) ethanol and spun at 14 500 rpm for 10 minutes at 
4 °C in a JA20 rotor. Ethanol was removed by aspiration and the pellet was left to air 
dry for 30 minutes. The plasmid pellet was dissolved in 200 µl of Buffer EB and stored 
at -20 °C. 
3.17.12 Preparation of frozen bacterial stock 
A single colony was picked and grown overnight. 700 µl of bacterial culture was 
dispensed into a 2 ml screw-capped vial and mixed with 300 µl of 50 % (v/v) of 
glycerol stock to make a final concentration of 15 % (v/v) and mix by brief vortexing. 
The mixture was snap-frozen in liquid nitrogen and stored at -20 °C until use.  
3.17.13 Revive bacterial culture from frozen bacterial stock 
The surface of the frozen glycerol stock were scraped using a flame sterilized platinum-
wire bacterial loop and streaked on a prewarmed LB plate (with ampicillin if applicable) 
and incubate overnight at 37 °C. 
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3.18 HRSV  
3.18.1 Source of viruses 
HRSV strain A2 and 8/60 representing prototype strain for subgroup A and subgroup B 
respectively were obtained without passage number from Dr. Sarah E Welsh, Newcastle 
University. The virus was propagated once in one T75 flask of HeLa cell and 
resuspended in 4 ml of fresh MM2 and stored as 500 µl aliquot in screw capped vials, 
snap frozen in liquid nitrogen and stored at -80 °C and used as a virus stock. 
Specimens in the form of nose swabs (NSs) and/or nasopharyngeal secretions (NPSs) 
for Winter 2007/2008 and 2008/2009 which were tested positive by 
immunofluorescence were obtained from the Health Protection Agency, Newcastle 
upon Tyne. 
Volunteers were recruited by research nurse Kerry Pollard. Specimens in the form of 
NSs and/or NPSs for Winter 2009/2010 were obtained from recruited volunteer infants 
hospitalized due to HRSV disease. 
Table 9 HRSV strains selected for the source of G gene. 
HRSV 
strain 
Genotype Source Passage Reference 
2567 SAA1 - P5 (A.  McGill et 
al., 2004b) 
4208 GA2 Isolated during the 07/08 
epidemic 
P2 - 
24702 GA3 - P5 (A.  McGill et 
al., 2004b) 
4908 GA5 Isolated during the 07/08 
epidemic 
P2 - 
25173 GA7 - P5 (A.  McGill et 
al., 2004b) 
5608 BA4 Isolated during the 07/08 
epidemic 
P2 - 
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3.18.2 Virus isolation 
The viscous snort in either NS or NPS was homogenized by pipeting using a sterile 1 ml 
hydrophobic barrier tip before inoculation. When necessary, the volume can be 
increased by the addition of HBSS.  
The growth medium in the cell culture test tube was discarded by aspiration and 100-
500 µl of the unfiltered NPS/NS was inoculated directly onto HeLa monolayer. The 
tubes were placed in a drum and incubated in a rotary incubator for 1 hour at 37 °C. The 
volume was adjusted to 1 ml with MM2. The tubes were incubated as above and the 
media was changed every alternate day until 4+ cytophatic effect (CPE) was observed. 
Concurrently, a mock infection tube was prepared as a negative control which is 
comparable to the above except that the inoculums was substituted with MM2. The 
monolayer was scraped into the medium and a specimen slide was prepared for 
immunofluorescence. The remaining isolate named passage 1 (P1) was snap frozen in 
liquid nitrogen as approximately 500 µl aliquot in 2 ml vial and stored at -80 °C.  
3.18.3 Virus propagation 
Passage 1 (or higher passage number) virus stock was thawed rapidly in a 37 °C water 
bath and then held on ice. 100 µl of the virus stock was transferred into a fresh 2 ml vial 
and diluted to 1 ml with MM2 and used to inoculate HeLa monolayer grown in 4 oz 
glass bottle followed by 1 hour incubation with rocking every 15 minutes to prevent 
desiccation. The volume was adjusted to 10ml with MM2 and incubated for 2 days. The 
progression of the cytopathic effect was observed under the microscope daily and the 
medium was replaced every alternate day until 4+ CPE can be observed. The scoring of 
CPE was based on arbitrary 4 scales scoring with 1+ being the lowest and 4+ being the 
highest. The monolayer was then scraped into the medium and dispensed as 1 ml 
aliquots in 2 ml vial, snap frozen in liquid nitrogen and stored at -80 °C. 
3.19 Modified Vaccinia Ankara 
3.19.1 Viruses 
MVA strain 575, passage 1 was a gift from Dr Simon Bridge, Newcastle University. 
The virus was propagated in QT35 cells and regarded as passage 2 (P2) without prior 
plaquing. The stock titer was 6 × 107 pfu/ml. The same stock was used to generate 
recombinant MVA throughout this thesis. 
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9NS3V5His, passage 1 (Chiam et al., 2009) was a generous gift from Dr Rachael 
Chiam, Cambridge University. 9NS3V5His expressed the NS3 protein of African Horse 
Sickness disease virus with C-terminal V5 epitope and polyhistidine (6xHis) sequence 
as a fusion protein under the control of vaccinia P7.5 promoter and co-expressing beta-
galactosidase (Bgal) under the control of vaccinia P11 promoter was included as a 
positive control for Xgal staining. 9NS3V5His was propagated once in QT35 cell line 
as described in 3.19.3 and the titer for the passage 2 virus was 2	× 107 pfu/ml. 
MVA-T, a recombinant MVA expressing the bacteriophage λ T7 RNA polymerase 
under the control of the vaccinia virus P7.5 promoter (B. Moss et al., 1990) was a gift 
from Prof. Malcolm McCrae, Warwick University. The virus was received without 
passage number, propagated once in QT35 and the stock virus was regarded as passage 
2 virus. 
3.19.2 Cell disruption 
Cell disruption to release virus particles from cells was immersion of virus infected cells 
in liquid nitrogen followed by rapid thawing of virus stock in 37 °C water bath. This 
process was done trice followed by sonication at 3x30 seconds burst in a water bath 
sonicator with 30 seconds interval between each burst.  
3.19.3 Virus propagation 
MVA and other recombinant MVAs stock viruses were prepared in T75 tissue culture 
flasks of confluent QT35. The virus stock was thawed rapidly in 37 °C	waterbath and 
aliquoted into 100µl/vial aliquots in 2ml vial and one aliquot was then disrupted as 
described in section 3.19.2 followed by 1:10 dilution in MM2 and inoculated onto a 
confluent monolayer of QT35 cells followed by incubation for 1 hour with rocking 
every 15 minutes. Unused aliquots were snapped frozen in liquid nitrogen and stored at 
-80 °C. The volume of MM2 was adjusted to 10ml and incubated for 48-72 hours until 
4+ CPE can be observed. Cells were then scraped into the medium, transferred into a 
sterile centrifuge tube (either 15 ml or 50 ml) and pelleted by low speed centrifugation 
at 1000 rpm for 5 minutes. The medium was removed by aspiration and resuspended in 
4 ml of fresh MM2, dispensed as 500 µl aliquots in 2 ml screw-capped vial, snap frozen 
in liquid nitrogen and stored at -80 °C until use.  
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T7-MVA stock used for transient expression was resuspended in SAF due to the 
toxicity of antibiotics to the cell line during transfection. 
3.19.4 Virus titration 
The following method is used to estimate the titer of non-Bgal expressing MVA 
strain 575 and T7-MVA. 
100 µl/vial of virus stock was obtained as described in section 3.19.3 and undergo ten-
fold serial dilution in ice cold MM2. Each dilutions was dispensed in duplicate at 200 
µl/well in 24 well plate (Corning) and two wells were mock infected with the same 
volume of fresh MM2 followed by 1 hour incubation. The inoculum was removed by 
aspiration and the monolayer was washed once with 500 µl/well of PBS and replenished 
with 500 µl/well of MM2 followed by 48 hours incubation. Plaques should be visible at 
at 28 hours post infection (p.i). The medium was removed by aspiration and the 
monolayer was fixed with 500 µl/well of 10 % formal saline for 30 minutes, rinsed once 
with PBS followed by 100 µl/well of crystal violet solution. Plaques were observed and 
manually counted under a microscope.  
The following method is used to estimate the MVA virus titer which co-expresses 
Bgal under the p11 vaccinia virus promoter. 
The inoculation procedure was carried as described above but after the 1 hour 
incubation, the monolayer was washed once with PBS and removed by aspiration. 
Residual PBS was removed by tilting the plate at an angle between 30-45 degrees and 
aspirated using a 200 µl yellow tip attached to P200 Pipetman micropippeter adjusted to 
the maximum volume capacity. The monolayer was overlayed with 500 µl/well of 
agarose overlay, solidified at 4 °C for 15 minutes followed by 48 hours incubation or 
until plaques cn be observed under a microscope. The second overlay was layered with 
500 µl/well of Xgal Agarose overlay, solidified as described above followed by 
overnight incubation. Βgal expressing plaques will be stained blue and can be counted 
without the need of a microscope. 
The dilution with the most significant number of plaques was counted. 
Stock virus titer =5φ	× 10λ pfu/ml; where λ = dilution factor, and φ=number of plaques 
counted   
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3.19.5 Multiplicity of Infection (MOI) 
The MOI can be determined with the following formula. 
MOI= 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3.19.6 Recombination of shuttle vector into MVA 
Lipofectin preparation (Part A) 
30 µl of Lipofectin (Cat#18292-011) (Invitrogen) was diluted into 100µl of OPTIMEM 
and incubated for 45-60 minutes at ambient temperature. 
DNA preparation (Part B) 
5 µg of plasmid DNA was diluted into 100 µl of OPTIMEM and incubated for 30 
minutes at ambient temperature. 
DNA-Lipofectin complexes I 
This formulation is to be used for pSC11 shuttle vector and its derived constructs  
Part A and Part B was combined and incubated for 15 minutes at ambient temperature 
and the volume was adjusted to 2 ml with OPTIMEM and used immediately. 
DNA-Lipofectin complexes II 
This formulation is to be used for pTM3 shuttle vector and its derived constructs  
Part A and Part B was combined and incubated for 15 minutes at ambient temperature 
and used immediately. 
Procedure 
CEF cells were grown without antibiotics in T25 tissue culture flask (Corning) until the 
monolayer reached approximately 70% confluency. The medium was removed by 
aspiration and the monolayer was inoculated with wild type (w/t) MVA at the MOI of 
0.05 in OPTIMEM medium and incubated for 2 hours. The inoculum was removed and 
washed once with 5 ml of OPTIMEM. The monolayer was transfected with the shuttle 
vector by the addition of 2 ml of DNA-lipofectin complex I (see above) and incubated 
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overnight. The following day, 2 ml of antibiotic free GM1 was added to the culture and 
incubated until 4+ CPE can be observed. The monolayer was scraped into the media and 
pelleted by low speed centrifugation at 1000 rpm for 5 min. The pellet was resuspended 
in 500 µl of MM1, labelled as recombination mix and stored as a single aliquot in a 2 ml 
vial, snap frozen in liquid nitrogen and stored at -80 °C until use. 
3.19.7 Plaque assay 
Serial plaquing was carried out to screen and enrich the recombinant MVA generated in 
3.19.6. First round of plaquing was done on confluent QT35 cells grown in 24 well 
plate (Corning). The recombination mix was thawed in 37 °C waterbath and 100 µl was 
transferred into a fresh 2 ml vial and disrupted as described in 3.19.2 and subjected to 
tenfold serial dilution in MM3. Unused recombination mix was snapped frozen in liquid 
nitrogen and stored at -80 °C. Each dilution was dispensed in replicates of two from 10-1 
to 10-6 at the volume of 200 µl/well. A pSC11 recombinant virus 9NS3V5His 
(section.3.19.1), was serially diluted in the identical manner and was included as a 
positive control for Xgal staining. The wells in the last row were mock infected with 
MM3. The plate was incubated for 2 hours, washed once with PBS and overlayed with 
500 µl of Agarose overlay followed by 48-72 hours incubation. Once plaques can be 
observed through the microscope, the X-gal Agarose overlay was layered, solidified and 
incubated overnight. Plaques were picked by stabbing a crystal tip attached to a P20 
Pipetman (Gilson) with the volume adjusted to 10 µl. The agarose plug together with 
blue coloured materials were resuspended in 500 µl of MM3, snap frozen in liquid 
nitrogen, stored at -80 °C or used immediately. 
The subsequent rounds of plaquing were done in 6 wells plates (Corning). The agarose 
plug suspension was disrupted as described in section 3.19.2 and 100 µl was dispensed 
into a fresh 2 ml vial and undergo fourfold serial dilution in MM3. Unused stock was 
snapped frozen in liquid nitrogen and stored at -80 °C. The volume of each dilution was 
adjusted to 500 µl with MM3 and inoculated onto the monolayer in their respective well 
and incubated for 2 hours with rocking every 15 minutes to prevent dessication. The 
monolayer in one of the well was mock infected with 500 µl of fresh MM3 as an 
uninfected cell control. The inoculums were removed by aspiration and the monolayer 
was washed once with PBS and residual PBS was removed as described above. The 
agarose overlay procedure was identical to the first round plaquing except that the 
volume of each agarose overlay was increased to 1500 µl/well to prevent desiccation of 
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the monolayer. Blue plaques were observed under microscope and whenever possible, 
only blue plaques without any adjacent unstained plaque were chosen to be picked for 
the subsequent round of plaquing. The plaquing procedures were repeated 5-7 rounds. 
3.19.8 Transient expression 
HeLa cells were grown in a 24 well plate (Corning) to approximately 90 % confluency 
in antibiotics free MM3. The medium was removed by aspiration and superinfected 
with T7MVA at the MOI of 3 and incubated for 30 minutes. Then, the inoculum was 
removed by aspiration and the monolayer was washed twice with 2×500 µl/well of 
OPTIMEM. The infected monolayer was then transfected with 200 µl of DNA-
lipofectin complex II prepared as described in section 3.19.6 and incubated for 4 hours. 
The monolayer was treated with 200 µl of antibiotics free GM3 and incubated overnight. 
The following day, 4+ CPE should be observed due to superinfection. The cells were 
scraped into the medium using a disposable plastic Pasteur pipette and slides were 
prepared as described in section 3.10.3.  
3.20 Glycosylation inhibition 
3.20.1 Stock Tunicamycin 
One vial of containing 1 mg of Tunicamycin (cat#T7765-1MG) was dissolved in 1 ml 
of sterile DMSO by direct injection using a hypodermic needle through the rubber 
septum of the vial preventing dust formation. The stock solution was stored at -20 ºC 
until use.  
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3.21 Peptide synthesis 
164-177: peptide AcNH-HFEVFNFVPCSIC-CONH2 was synthesized by Eurogentec, 
SePop purified and selectively precipitated to remove salt and organic starting materials 
used in the synthesis process. The average purity was determined by MALDI-TOF 
Mass Spectrum-Instrument Autoflex1 to be ~65 % and the yield was 2 mg. 
172-187: Peptide 172-PCSICSNNPTCWAICK-187 was synthesized by Dr. J Gray, 
Institute for Molecular Biosciences, Newcastle University and stored frozen as 200 µl 
aliquot at -20 °C. 
The lyophilysed peptides were dissolved in 100 µl of DMSO and volume adjusted to 1 
ml in distilled water to make 2 mg/ml stock solution in 5 % DMSO, stored as 100 µl 
aliquot at -20 °C until use. 
3.22 Decay curve 
A non-linear regression line (refered to herein as decay curve) was fitted with the single, 
two parameter exponential decay algorithm using the ‘Fit Curve’ function with 
extrapolation in Sigmaplot version 11. 
3.23 t test 
Paired t test was carried out in SPSS statistics version 17 under the ‘analyze’; ‘compare 
means’ tab and p<0.05 was considered significant. 
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Chapter 4 Molecular Epidemiology of HRSV in Newcastle over 3 
epidemics 
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4.1 Introduction 
The prevalence of the epidemic strains of HRSV over 3 epidemics in Newcastle upon 
Tyne is evaluated in this chapter. Work on the HRSV epidemic seasons 2007/2008 and 
2008/2009, which were mainly studied to establish a method for virus isolation and 
genotyping, involved the isolation of HRSV from nasopharyngeal secretions (NPSs) 
previously positive for HRSV by immunofluorescence staining (IF) carried out by the 
Health Protection Agency (HPA), Newcastle upon Tyne. Virus isolation also provided a 
collection of representative HRSV isolates in circulation for the cloning and expression 
of the G and the F glycoprotein genes described in Chapter 5. Phylogenetic analysis was 
carried out on gene sequences amplified from virus isolates which will be discussed 
later in this chapter. Specimens negative for isolation were not further investigated. In 
2009/2010, specimens from recruited volunteers mainly in the form of nose swabs (NSs) 
rather than NPSs were available due to a major change in the routine diagnostic system 
employed by the HPA which no longer requires the collection of NPSs for IF and virus 
isolation. In this season, both virus isolates and isolation negative specimens were 
subjected to nested or hemi-nested RT-PCR for genotyping. 
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4.2 Isolation and identification of HRSV 
In the 2007/2008 epidemic, 20 NPSs were inoculated into HeLa tubes for virus isolation 
(Section3.18.2). 17 of these produced characteristic CPE as shown in Figure 12. Isolates 
were harvested and specimen slides were prepared (section 3.10.2) and IF testing was 
carried out with HRSV Mab pool as described in section 3.10.4 and the representative 
result is shown in Figure 13. The isolation rate from NPSs was 85%. 
In the following epidemics, a total of 29 NPSs were obtained and inoculated  into Hela 
tubes and 18 of 29 showed characteristics CPE of which 16 were positive with HRSV 
Mab pool by IF giving an HRSV isolation rate of about 60%.  
In the 2009/2010 epidemic, both respiratory and blood samples were obtained from a 
total of 23 patients of which 2 had both NPS and NS taken, 4 and 19 volunteers had 
only NPS and NS taken respectively. 500µl of each dilution of NPSs and NSs in HBSS 
was aliquoted into 2ml screw-cap vial, snap frozen and stored at -80 °C and the 
remainder was put into Hela tubes for isolation. 6 of 6 NPSs yielded CPE and were 
confirmed HRSV positive by IF yielding a 100% isolation rate from NPSs. However, 
only 6 of 21 NSs including two isolated from NPSs showed CPE which were also 
confirmed to be HRSV by IF giving the isolation rate of about 30% from NS. The 
overall isolation rate for this epidemic was about 43%.  
Table 10 Summary of the isolation and identification of HRSV 
 2007/2008 2008/2009 2009/2010 
 NPS NS NPS NS NPS NS 
Total specimens (n) 20 N/A 29 N/A 6 21 
CPE 17 N/A 18 N/A 6 6 
HRSV Mabpool 17 N/A 16 N/A 6 6 
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(A) Infected (B) Uninfected 
 
 
Figure 12 Classical HRSV cytopathic effect  
(A) HRSV isolate 5608 passage 2 infected HeLa cells in Hela tube showing classical 
RSV cytophatic effect compared to (B) uninfected HeLa cells. Cells were fixed and 
stained using Diff-Quik Stain, Dade Behring Ag, Switzerland and visualized under 
100X magnifications  
(A) Infected (B) Uninfected 
 
 
Figure 13 Immunofluorescent staining of HRSV. 
(A) HRSV isolate 5608 at passage 2 and (B) uninfected HeLa cells stained HRSV Mab 
pool; SAM-FITC visualized under 400X magnifications. Apple green staining shows 
positive fluorescence (A) while red background staining shows negative fluorescence 
(B). 
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4.3 Subgrouping of HRSV isolates 
During most epidemics of HRSV both virus subgroups and several genotypes co-
circulate. Genotyping of HRSV virus isolates is probably best achieved by phylogenetic 
analysis of the highly variable 3’-terminus of the G gene. In order to achieve this, it was 
first necessary to establish an RT-PCR system capable of amplifying this fragment.  
The confirmed HRSV isolates were passaged in HeLa cells and the total RNA obtained 
as described in section 3.15.2, and cDNA was synthesized (section 3.15.3) using primer 
G1 which is universal for both subgroups A and B HRSV. Subgrouping was then done 
by PCR (section 3.15.4, programme PCR55) using subgroup A specific primer set GC1-
F164 and subgroup B specific primer set GB1-GB2 
4.3.1 MgCl2 concentration optimization for PCR 
The optimization of MgCl2 concentration for PCR was done on the cDNA generated 
from isolate 4208 passage 2. The PCR mastermix was prepared as described in section 
3.15.4 with primer set GC1-F164 except the concentration of MgCl2 was adjusted 
individually ranging from 4mM to 0.5mM. PCR was carried out with programme 
PCR55 as described in section 3.15.4 and the PCR products were resolved by agarose 
gel electrophoresis as described in section 3.15.9 visualized under UV illumination. The 
results are shown in Figure 14. The expected size of the amplication product was 628bp 
and the band of interest was the most intense at 4mM of MgCl2 followed by 3mM. A 
faint band was observed at 2mM MgCl2 and no amplification was observed below that 
concentration. A non-specific band was observed in between 400-500bp in all 
concentrations except 1.0mM and 0.5mM. The MgCl2 concentration of 4mM 
determined for primer set GC1-F164 was also found to work satisfactorily for primer set 
GB1-GB2. 
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Figure 14 MgCl2 concentration optimization for PCR reaction. 
4.3.2 Amplification of the partial G gene of HRSV isolates 
Representative virus isolates from epidemic 2007/2008 which were confirmed to be 
HRSV by IF were passaged once in HeLa cells grown in 4oz flat bottom glass bottle to 
obtain passage 2 viruses (section 3.18.3) followed by total RNA extraction as described 
in section 3.15.2. The cDNA synthesis was generated as described in section 3.15.3 and 
PCR was carried out as described in section 3.15.4 with primer set GC1-F164 and 
resolved on agarose gel as described in 3.15.9. A representative result is shown in 
Figure 15. 
 
Figure 15 RT-PCR on HRSV isolates using primer GC1-F164  
 
628bp 
628bp 
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In this example, all isolates yielded a band of the expected size of 628bp except isolate 
4508. Non specific bands were not present in the HeLa cell control or water control. 
Neither A2 nor any other known subgroup A HRSV total RNA extract or cDNA was 
included as a positive control for reverse transcription and PCR respectively to 
minimize the possibility of cross-contamination by amplicand from the positive control. 
cDNA not amplifiable by this primer set was subjected to PCR with GB1-GB2 with 
programme PCR55 as described in section 3.15.4. and resolved in an agarose gel as 
described in section 3.15.9. The result obtained with two isolates found to be negative 
with primer GC1-F164 is shown in Figure 16. 
 
Figure 16 Amplification of  the Group B HRSV by using GB1-GB2 
Neither isolate yielded a DNA band with the expected size of 680bp as expected from 
according the genome of HRSV subgroup B prototype strain 9320 but both generated an 
intense band in between 700-800bp which corresponded to the expected size of 740bp 
with the HRSV Buenos Aires strain which contains a 60nt repeats in the G gene (Trento 
et al., 2003). Non-specific band(s) with relatively lower molecular weight than the band 
of interest are present in both isolates and in the HeLa cell control but not in the water 
control.  
The whole procedure described above was repeated for all the isolates described in 
section 4.2 and the summary of the results is displayed in Table 11. All cDNAs not 
amplifiable by GC1-F164 were successfully amplified by GB1-GB2 and yielded band 
of 740bp.  
740bp 
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Table 11 HRSV isolates subgrouping by RT-PCR 
Subgroup Primer set 2007/2008 2008/2009 2009/2010 
A GC1-F164 14 11 3 
B GB1-GB2β 3 5 7 
 Total 17 16 10γ 
β only PCR bands with the size of 740bp was amplified, γ when HRSV was isolated 
from both NPS and NS, only the isolate from NPS was used for RT-PCR. 
4.4 Subgrouping of HRSV from NSs 
The established subgrouping method by RT-PCR from the isolates (section 4.3.2) 
worked for epidemics 2007/2008 and 2008/2009 without any problem due to the 
relatively high isolation rate from NPSs. The isolation rate from NPSs remained high in 
epidemic 2009/2010 but NPSs were only available from 26% (6 of 23) infant volunteers 
recruited for this study. Although the single round RT-PCR system proved sensitive 
enough to amplify the partial G gene from RNA extracted from isolates, its sensitivity 
was insufficient for the RNA extracted directly from the NSs. The genotyping of the 
specimens is crucial for this study as the maternal antibody titer to the G glycoprotein 
from the infant volunteers needs to be measured on the recombinant G glycoprotein of 
the infecting HRSV genotype. Thus hemi-nested and nested PCR strategies  were 
devised for subgroup A and subgroup B HRSV respectively utilizing the available 
primers and depicted in Figure 17.  
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4.4.1 Strategy 
 
Figure 17 Nested and Heminested PCR strategy.  
Diagram not drawn to scale. mRNA is depicted but G1 primer binds to genomic RNA.  
The cDNA synthesis was carried out as described in section 3.15.3. The first round PCR 
(1°PCR) was carried out with primer set G1-F164, which are pan-HRSV primers 
binding to both subgroup A and subgroup B cDNA, as described in section 3.15.4 using 
programme PCR55. The second round PCR (2°PCR) was carried out in an identical 
manner but the PCR product from 1°PCR was diluted 1:1000 in DEPC-H2O and used as 
template. The primer sets GC1-F164 and GB1-GB2 was used for the identification of 
subgroup A and subgroup B respectively. 
 
  
 93 
 
4.4.2 Validation 
To test this strategy, two passage 1 isolates, namely 1610 and 4510, representing HRSV 
group A and B respectively were chosen for the optimization of heminested and nested 
PCR. These two isolates were chosen for 2 reasons; Firstly, HRSV was successfully 
isolated, confirmed by IF and genotyped by phylogenetic analysis (Figure 22 and Figure 
23). Secondly, for both isolates sufficient NS was available to be used to validate the 
nested/heminested PCR and also to be included as a positive control in the subsequent 
assays. The total RNA extracted and cDNA was synthesized as described in section 
3.15.3 and the cDNA was serially diluted from 10-1 to 10-10 in DEPC-H2O and 10µl of 
each dilution was subjected to 1°PCR with primer set GC1-F164 as described in section 
3.15.4 with the programme PCR55. 10µl of each of the 1°PCR products was resolved in 
agarose gel as described in section 3.15.9 and the results are shown in Figure 18. Bands 
of the expected size of 1168bp and 1228bp were observed for 1610 and 4510 
respectively. The 1°PCR is sensitive enough to amplify cDNA template of 1610 and 
4510 diluted to 10-2 and 10-6 respectively but this does not indicate differences in the 
sensitivity of the primer sets as the viral RNAs were not quantitated and standardised 
for this purpose. Both 1°PCR products were diluted 1:1000 in DEPC-H20. Diluted 
templates for 1610 and 4510 were subjected to the 2°PCR with primer set GC1-F164 
and GB1-GB2 respectively as described in section 3.15.4 with programme PCR55 and 
10µl of the template was resolved in an agarose gel as described in section 3.15.9. The 
results are displayed in Figure 19. Hemi-nested PCR [Figure 19(a)] on isolate 1610 
yielded a band with the expected size of 628bp sensitive down to 10-5 which boosted the 
sensitivity of the 2°PCR up to 103 fold compared to 1°PCR. Nested PCR on 4510 did 
not show any increase in sensitivity compared to the 1°PCR but significantly boosted 
the intensity of the band of interest [Figure 19(b)]. These strategies proved to be 
satisfactory in boosting the sensitivity of single round PCR and were used subsequently 
with the total RNA extracted from the NSs. 
  
 94 
 
 
Figure 18 1°PCR amplification.  
(a) 1610 P1 (b) 4510 P1 amplified with G1-F164. The negative number indicates the 
10-fold dilution factor. 
 
 
Figure 19 2°PCR amplification. 
(a) Hemi-nested PCR on isolate 1610 using GC1-F164. (b) Nested PCR on isolate 4510 
using GB1-GB2. The negative number indicates the 10-fold dilution factor. 
  
1168bp 
1228bp 
628bp 
740bp 
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4.4.3 Amplification of the partial G gene from NSs 
The total RNA was extracted from the stored NSs (section 4.2) as described in section 
3.15.2 and subjected to hemi-nested PCR and nested PCR as described in section 4.4.1 
and the results is shown in Figure 20 and Figure 21 respectively.  
With reference to the hemi-nested PCR results in Figure 20, specimens 4310, 5110 and 
the positive control 1610, yielded band with the expected size of 628bp and identified as 
subgroup A HRSV. Numerous bands were present in which a band with the molecular 
weight in between 1000-1500bp relative to the marker was present in 1610, 2910, 3210, 
and 4510 probably represents the product from 1°PCR . Non-specific band with the 
consistent size between 750-1000bp relative to the marker was present in 2110, 4310, 
4610, 4810,5210, 5410. No DNA bands were present in both water controls.  
The results of the nested PCR is shown in Figure 20. Two species of dominant band 
were observed. For subgroup B, or specifically the BA virus, the expected band would 
be 740bp. This was observed in the positive control for subgroup B, specimen 4510 and 
also for 2110, 2910, 3210, 4610, 5110, 5210 and 5410 and clearly identified these 
viruses as subgroup B, BA like. However, a band with the lower molecular weight than 
the expected size of 740bp was observed in the subgroup A postive control, specimen 
1610 and also 4310 and 5010. Without the presence of the subgroup A positive control 
1610, it would be tempting to speculate that the lower band corresponded to the 
molecular weight of 680bp, the expected size of subgroup B prototype strain 9320 non-
BA subgroup B. This phenomenon was not observed in the previous epidemics because 
only non-subgroup A isolates by RT-PCR with GC1-F164 were tested with RT-PCR 
with GB1-GB2 and the subgroup specificity of primer pair GB1-GB2 was not 
evaluated. Subsequent sequencing and phylogenetic analysis confirmed that the lower 
band observed derived from subgroup A HRSV (see Figure 22). 
Isolate 2110 yielded a faint band of 628bp with hemi-nested PCR and 740bp with 
nested PCR. There is a posibility that 2110 is a mixed infection of both subgroups A 
and B with subgroup B being dominant. However if this is true, nested PCR should 
amplify 2 bands of 680bp and 740bp corresponding to subgroup A and B respectively 
but only a single band of 740 was observed in nested PCR thus 2110 is regarded as 
subgroup B. 
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Figure 20 Hemi-nested PCR on total RNA extracted from nose swabs.  
The numbers above the bands indicates the specimen number. 1610 and 4510 are 
considered positive control for Group A and Group B HRSV respectively. 
 97 
 
 
Figure 21 Nested PCR on total RNA extracted from nose swabs.  
The numbers above the bands indicates the specimen number. 1610 and 4510 are 
considered positive control for Group A and Group B HRSV respectively. 
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4.5 Genotyping by phylogenetic analysis 
Sequences from Edinburgh (R), Netherlands (NL) and Bangkok (BK) (Gaunt et al., 
2011) were provided by Dr. Eleanor Gaunt, Edinburgh University with sequences from 
NL and BK initially obtained from Dr. Rogier Jansen, Leiden University Medical 
Center (LUMC), and Dr. Yong Poovorawan, University of Bangkok.  
The PCR products which were positive by RT-PCR described in sections 4.3.2 and 
4.4.3 were resolved in agarose gel as described in section 3.15.9 and the appropriate 
DNA band was excised and gel purified as described in section 3.15.10, quantitated and 
sequenced as described in section 3.15.13. 
The alignment of subgroup A sequences obtained as described above was carried out 
together with archived isolates from Newcastle upon Tyne (A. McGill et al., 2004a) and 
representative isolates from Edinburgh (R), Netherlands (NL) and Bangkok (BK) as 
described in section 3.16. The resulted phylogenetic tree is shown in Figure 22.  
The isolation of the BA genotype of HRSV in Newcastle upon Tyne had never been 
reported until epidemic 2007/2008 due to the absence of continuous epidemiological 
surveillance thus no archived sequences can be compared with the sequences obtained 
from the recent epidemics described throughout this chapter. The BA genotypes were 
the only subgroup B HRSV detected over the three epidemics. To solve this problem, 
published sequences (Trento et al., 2003; Trento et al., 2010) were included in the 
alignment and the construction of the phylogenetic tree. No other genotypes other than 
the prototype CH18537 was included in the analysis and the resulting phylogenetic tree 
is shown in Figure 23. DNA sequences correspond to nucleotide 526-782 of the G gene 
of the prototype HRSVstrain CH18537 or nucleotide 526-842 of strain BA/802/99 
(Trento et al., 2010). 
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With reference to Figure 22, the recent isolates from Newcastle, Edinburgh and 
Netherlands can be grouped into a clade identified by the name GA2 according to Peret 
et al., (2000) and identified with the previously characterized GA2 anchor isolate, 
NCL/8923/97 (A. McGill et al., 2004a) supported with the bootstrap value of 91. It was 
interesting to note the following similarity between isolates from different countries: (i) 
Isolate NCL/27/10, NCL/41/10 and NCL/51/10 sub-clustered together with Edinburgh 
isolate R14414/08-09 with the bootstrap value of 69. (ii) Isolate NCL/7/09 clustered 
together with the Dutch isolates NL20752112/07-08 and NL20850001/07-08 with the 
bootstrap value of 68. (iii) Isolate NCL/14/09 and NCl/16/10 clustered together with 
R25857/09-10, R25827/09-10 and R25993/09-10 with the bootstrap value of 85. 
However, all of them were grouped together under a major subclade with the bootstrap 
value of 94, differing from the ancestral anchor isolate NCL/8923/97 and two recent 
Edinburgh isolates R9070/07-08 and R9088/07-08. One isolate each from Netherlands; 
NL20752144/07-08 and Edinburgh; R3506/06-07 subclustered together as an ancestral 
group to NCL8923/97 which are highly similar with the bootstrap value of 98. No 
Bangkok isolates was clustered in genotype GA2 clade. 
Meanwhile, the other group A Newcastle isolates together with the the rest of the 
isolates from Netherlands and Bangkok were grouped into a clade named GA5 
identified with anchor isolates obtained in 1996,1997 and 1989 shown with the legend ◊ 
(A. McGill et al., 2004a) supported with the bootstrap value of 97. It was interesting to 
note that all of the current isolates clustered together as a subclade with the bootstrap 
value of 89 while the anchor isolates forms a distinct subclade with the bootstrap value 
of 81 except RS89-6190 (isolated by Patricia Cane in Birmingham) which is considered 
the veteran genotype for genotype GA5 showing significant evolution of the past from 
current GA5 genotype. 
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 R9100/07-08
 BK8/06-07
 MAD/5097/05-06
 MAD/4938/05-06
 MAD/4557/04-05
 MAD/5058/05-06
 BK7/06-07
 BA/100/04
 MAD/4577/04-05
 R14940/08-09
 MAD/4540/04-05
 MAD/4953/05-06
 MAD/5144/05-06
subclade 1
 NCL/06/09
 NCL/30/09
 R3314/06-07
 R9122/07-08
 R9131/07-08
 NCL/52/10
 NCL/03/09
 R9123/07-08
 NCL/49/10
 NCL/45/10
subclade 2
 NCL/45/08
 R14405/08-09
 MAD/4957/05-06
 MAD/4993/05-06
 NL20752084/07-08
 R3316/06-07
 NL20850191/07-08
 R3526/06-07
 MAD/4950/05-06
 NCL/46/10
 NCL/11/09
 NCL/25/09
 R25828/09-10
subclade 3
 R25837/09-10
 MAD/5015/05-06
 NL20752223/07-08
subclade 4
 MAD/4055/03-04
 MAD/4515/04-05
 MAD/6194/07-08
 BA/354/04
BA4b
 R25977/09-10
 R25900/09-10
 R25970/09-10
 R25810/09-10
 NCL/21/10
subclade 5
 MAD/4668/04-05
 NCL/54/08
 BK5/06-07
 BK1/06-07
 R9124/07-08
 NCL/30/10
 NCL/44/10
 NCL/56/08
 NL20752400/07-08
 MAD/6214/07-08
 MAD/6222/07-08
 MAD/6312/07-08
 MAD/5688/06-07
 MAD/5732/06-07
 MAD/5751/06-07
 MAD/5745/06-07
 MAD/5755/06-07
 MAD/6212/07-08
 NCL/54/10
 NCL/50/10
 NCL/32/10
 NCL/29/10
 NCL/23/10
 NCL/53/10
 NCL/47/10
 NCL/35/10
subclade 6.1
subclade 6
BA4
 BA/6564/03
 BA/5021/03
BA3
 MAD/3553/01-02
 BA2
 BA3
 BA3
 BA1
 CH18537
74
84
84
84
84
84
66
69
90
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86
91
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49
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59
59
39
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63
83
84
56
65
67
32
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69
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71
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As Figure 23 shows the Newcastle sub-group B isolates from this study all mapped 
within the BA4 clade of the phylogenetic tree The BA viruses were novel to Newcastle 
and were only described in Buenos Aires in 2003. Thus, the anchor sequences for the 
BA viruses were obtained from published sequences in the genbank (Trento et al., 2006; 
Trento et al., 2010). 
The BA4 viruses were subdivided into 6 subclades. As the interpretation of the 
bootstrap value, particularly those of less than 70, must be made with care, attribution to 
sub-clades is uncertain. Subclade1 contains two of each virus from Neatherlands and 
Bangkok and this clade is supported by a bootstrap value of 87. Subclade 1 viruses 
cluster together with the MAD-III clade as reported by Trento et al., (2010). Meanwhile 
subclade 2 contains four members from Newcastle (NCL03/09, 45/10, 49/10, 52/10) 
and 3 members from Edinburgh (R9122/07-08, R9131/07-08, R9123/07-08) with the 
bootstrap value of 86. Subclade 3 and 4 correspond to MAD-IV clade which was 
supported by the bootstrap value of 74 and 78 respectively. Within subclade 3, 
NCL/11/09, NCL25/09 and NCL46/10 and R2582809-10 were clustered together with a 
lower bootstrap value of 68 showing their relatedness. Subclade 5 consists of 
NCL/21/10 and 4 other members from Edinburgh and supported with a stong bootstrap 
of 83. Subclade 6 contains the highest number of members with the bootstrap value of 
80 which includes members from MAD-IV. Within this subgroup, 8 of the Newcastle 
viruses from epidemic 2009/2010 clustered together with members from the MAD-III 
clade. The differences in clade assignment between this study and those of Trento et al., 
(Trento et al., 2003; Trento et al., 2006; 2010) may be due to the different algorithm 
used in the construction of the phylogenetic tree. The trees in Figure 22 and Figure 23 
were constructed using the neighbour joining method but Trento et al., (Trento et al., 
2003; Trento et al., 2006; 2010) uses the maximum-likelihood method. 
The prevalence of each genotype detected over the three consecutive epidemics in 
Newcastle upon Tyne is summarized in Table 12. The table shows the gradual decrease 
in both genotype of subgroup A while the sole representative of subgroup B rose 
steadily over the study period.  
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Table 12 Breakdown of prevalent HRSV genotypes in Newcastle upon Tyne over 
the three epidemics. 
Epidemic 
Year 
SubgroupA Subgroup B 
GA2 GA5 BA4 
2007/2008 12 2 3 
2008/2009 9 1 5 
2009/2010 4 0 13 
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Chapter 5 Recombinant glycoprotein expression 
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5.1 Poxvirus expression system 
5.1.1 Vaccinia virus 
Vaccinia virus belongs to the family of Poxviridae, subfamily Chordopoxvirinae and 
genus orthopoxvirus. Other members include camelpox, cowpox, ectromelia, 
monkeypox, raccoonpox, skunkpox, Uasin Gishu, volepox and the notorious variola 
which causes smallpox (B Moss, 1996).  
The origin of vaccinia virus is rather speculative. Edward Jenner himself thought that 
his cowpox formulation used for the vaccination originated from horses in which the 
parent virus is now extinct but there is no clear documentation on where or when the 
modern vaccinia virus emerged. Other hypotheses of the origin of vaccinia virus had 
been put forward including the hybridization of cowpox and smallpox virus in the early 
years of vaccination carried out in the Woodville's Smallpox Hospital (Baxby, 1996). 
However, genomic sequence analysis has revealed distinct differences between the three 
viruses (M. Mackett and Archard, 1979). 
5.1.2 Modified Vaccinia Ankara (MVA) 
MVA virus was derived by Anton Mayr by the serial passage of a vaccinia virus derived 
from a horse through chick embryo fibroblasts more than 570 times, after which it could 
no longer replicate, or replicated very inefficiently, in a variety of mammalian cell lines. 
The attenuation of MVA virus has greatly reduced the genome of the virus to 175 kb in 
length compared to the Copenhagen strain which is 192 kb (Antoine et al., 1998). 
5.1.3 Biological safety 
Although vaccinia virus is categorised as a class II pathogen (MacNeil et al., 2009), the 
safety issue of the use of vaccinia virus in research has always been of great concern in 
the post smallpox era. Vaccinia virus is highly contagious with the need for minimal 
contact for secondary transmission from vaccinees (Sepkowitz, 2003) or laboratory 
acquired vaccinia infection (MacNeil et al., 2009). 
MVA has a similar host range as its parental vaccinia virus but the host range can be 
divided into permissive and non-permissive. MVA multiples in permissive hosts such as 
avian cells, chick embryo fibroblasts (CEF) and the quail cell line (QT35) and the baby 
hamster kidney cell line (BHK-21). The life cycle of MVA in non-permissive cell lines 
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is identical to its life cycle in permissive cell lines but the final virion packaging is 
inhibited (Sutter and Moss, 1992; Sancho et al., 2002). 
MVA has consistently passed phase I clinical trial as a vaccine vector (Rochlitz et al., 
2003; Richard Harrop et al., 2006; Hawkridge et al., 2008; Amato et al., 2009; Currier 
et al., 2009; Kaufman et al., 2009; Ramanathan et al., 2009; Sander et al., 2009; 
Whelan et al., 2009; Amato, 2010; Amato et al., 2010; Currier et al., 2010; R. Harrop et 
al., 2010; Vasan et al., 2010). Furthermore, IMVAMUNE® a third generation smallpox 
vaccine candidate formulated using MVA-BN®, a strain of MVA which is now under 
preparation for phase III clinical trial, was found to be well tolerated without any 
unexpected side effects by 2800 vaccinees including those with HIV, eczema and atopic 
dermatitis (Jones, 2008; Kennedy and Greenberg, 2009). 
The use of MVA over vaccinia virus in expression systems for foreign proteins 
eliminates the risk of laboratory acquired infection and and time consuming 
deactivation of vaccinia virus after recombinant protein expression. 
5.1.4 Expression under the control of the vaccinial P7.5 promoter 
The early and late phases of vaccinia virus life cycle refered to the time before and after 
DNA replication. The P7.5 promoter is an early and late promoter as the 7.5kDa 
polypeptide promoter is synthesized throughout the life cycle of the virus. This 
promoter is driven by the specific vaccinia virus RNA polymerase and is not affected by 
the host’s RNA polymerase II. P7.5 has a yield 10-20 fold lower than P11 vaccinia virus 
promoter but nonetheless, remained the most widely used promoter (Michael Mackett 
and Smith, 1986).  
5.1.5 pSC11 shuttle vector 
The pSC11 vector is a co-expression vector which allows the cloning of foreign genes 
adjacent to E. coli β-galactosidase gene (βgal) within the thymidine kinase (TK) gene of 
vaccinia virus. The βgal gene is driven by a P11 late vaccinia virus promoter. MVA 
virus infected tissue culture cells can be co-transfected with a recombinant pSC11 
plasmid allowing recombination to occur between wild type MVA virus and the 
plasmid in the thymidine kinase gene introducing the recombinant and beta 
galactosidase genes into the virus. Recombination into the TK locus destroys the 
capability of the recombinant virus to produce enzyme TK, thus resulting in TK minus 
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(TK-) phenotype recombinants which are selectable in the presence of 5-
bromodeoxyuridine (BudR) and/or visually distinguishable from spontaneous TK 
mutants by the addition of βgal indicator to detect βgal gene expression (Chakrabarti et 
al., 1985). The pSC11 vector contains no ATG start codon downstream of the vaccinia 
virus promoter which is ideal for cloning and expression of complete open reading 
frames which contains their own translational initiation codon. The topographical map 
of pSC11 is shown in Figure 24. 
 
 
Figure 24 A topographical map of pSC11.  
P11, P7.5 are vaccinial promoters; TKR: vaccinial thymidine kinase sequence, right 
hand; TKL: vaccinial thymidine kinase sequence, left hand; ampR: ampicillin resistance 
gene; EcoRI, BamHI, Bsu36I, SmaI: restriction sites; SmaI: cloning site for foreign 
open reading frames. 
The cloning of foreign genes into the pSC11 vector is restricted to the SmaI restriction 
site downstream of the vaccinial P7.5 promoter. The foreign gene does not have to be 
inserted in frame with the promoter but must carry ATG start codon to initiate 
transcription and translation. Any non-specific ATG upstream of the actual start codon 
must be silenced. Kozak consensus sequence (Kozak, 1987) is not required for efficient 
translation of vaccinia virus mRNA (Michael Mackett and Smith, 1986).  
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5.2 Preparation of pSC11 for cloning. 
The insertion of recombinant genes into MVA is facilitated by a shuttle vector such as 
pSC11 which contains flanking sequence of the thymidine kinase (TK) gene of vaccinia 
virus where the recombinant gene is inserted. Thus, the very first step was to prepare 
pSC11 plasmid for the cloning procedures. 
pSC11 plasmid prepared from a 1.5ml overnight culture of pSC11/TG1 (section 3.17.10) 
was digested with Cfr9I (an isoschizomer of XmaI and neoschizomer of SmaI)(section 
3.17.3) to produce a sticky end 5’-C/CCGGG-3’ and dephosphorylated using CIAP 
(section 3.17.4). An undigested pSC11 vector was resolved together as an undigested 
plasmid control as shown in Figure 25. Digested pSC11 migrates as a band between 6k-
8kbp corresponding to the expected size of 7.6kbp. 
 
Figure 25 Cfr9I digested pSC11 vector resolved together with native pSC11. 
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5.3 Preparation of the glycoprotein genes for cloning 
As the purpose of this project was to measure maternal antibody titer to the G 
glycoprotein of the virus genotype infecting infants, the prevalent genotype during the 
epidemic 2009/2010 could not be predicted and a library of G genes from different 
genotypes was prepared. A collection of HRSV isolates representing genotype SAA1, 
GA2, GA3, GA5, GA7 and BA were selected from archived materials and HRSV 
strains isolated during the 2007/2008 epidemic.  
5.3.1 Cloning primer design 
All cloning primers are shown in Table 5 
The forward cloning primer for the G gene was designed based on strain A2 with a 
restriction enzyme site Cfr91 added and an ATG codon upstream of the actual start 
codon silenced to TTG. The mutated adenosine residue is at position -8 from the actual 
start codon. The primer is named gpGA_For. 
The reverse cloning primer for the G gene of subgroup A was designed based on the 
untrimmed sequence alignment obtained from isolates shown in Table 11 which also 
provided sequence date used in the construction of the phylogenetic tree as described in 
section 4.5. This provided sequence data for the end of the G gene, the G/F intergenic 
region and into the beginning of the fusion gene. Eco86I and Cfr9I sites were included 
which was named gpGA_Rev. gpGA_Rev binds at the natural stop codon and into the 
G/F intergenic region which is conserved compared to the -3’ end of the G gene. This 
will allow the use of a single primer to amplify all members of subgroup A and allows 
each individual strain to use its natural stop codon. 
This sequence data was also used for the design of the forward cloning primer for the 
fusion gene. A Cfr9I restriction enzyme site was added and the primer was named 
gpFA_For.  
The reverse cloning primer for the fusion gene was designed based on the HRSV strain 
A2 with Eco81I and Cfr9I restriction enzyme restriction enzyme sites added. The 
primer is named gpFA_Rev. 
The forward cloning primer for the BA genotype was similar with gpGA_For but the 
5’- end was lengthened to ensure efficient digestion by Cfr9I. To obtain the sequence 
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data for the design of the reverse primer, PCR was carried out on the cDNA generated 
from the total RNA of isolate 5608 from section 4.3.2 with primer set G1-F164 as 
described in section 3.15.4 using programme PCR55. The amplicant was resolved in an 
agarose gel (section 3.15.9). The DNA band of the expected size of 1228bp was excised 
and gel purified as described in section 3.15.10 followed by sequencing with primers 
G1, GB1 and F164 as described in section 3.15.13. The sequence was assembled as 
described in section 3.16.3. The reverse primer was designed with Eco81I and Cfr9I 
sites added and named gpGB_Rev.  
5.3.2 Amplification of the G gene. 
The total RNA of subgroup A isolates in Table 9 was extracted as described in section 
3.15.2. and the cDNA synthesis was carried out using primer gpGA_For as described in 
section 3.15.3 followed by PCR using primer set gpGA_For-gpGA-Rev as described in 
section 3.15.4 using programme PCR50. The DNA was resolved in an agarose gel as 
described in section 3.15.9 and shown in Figure 26. All five isolates yielded a product 
with the expected size of 956bp with no significant non-specific band although some 
faint smear of approximately 500bp was observed in 24702 and to lesser extent in 2567. 
No non-specific bands were present in either HeLa cell or water control. The primer set 
was not tested on the A2 strain. 
 
Figure 26 Amplification of the G gene of subgroup A HRSV by RT-PCR 
The total RNA of isolates 4508, 5408 and 5608 representing all subgroup B HRSV 
isolated during the 2007/2008 epidemic was extracted as described in section 3.15.2 and 
subjected to reverse transcription with primer gpGB-For as described in section 3.15.3 
followed by PCR with primer set gpGB_For-gpGB_Rev with programme PCR50 as 
G gene 
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described in section 3.15.4. The PCR products were resolved in an agarose gel as 
described in section 3.15.9 and the results is as shown in Figure 27. All three isolates 
tested yielded band with the correct size of 1017bp according to strain BA/802/99. Two 
intense bands of size between 500-750bp and below 250bp were observed in all strains. 
A faint band with the size in between 750-1000bp was observed but these bands were 
isolate specific and not due to non-specific binding of primers to the cellular nucleic 
acids based on the absence of corresponding band in the HeLa cell control. A faint 
smear was observed in the HeLa cell control but the water control was clean. No further 
optimization of the annealing temperature was carried out as the amount of DNA in the 
band of interest was sufficient for the cloning procedure. Only the G gene from isolate 
5608 was selected for cloning. 
 
Figure 27 Amplification of the G gene of representative BA4 genotype by RT-PCR.  
5.3.3 Amplification of the F gene  
The RNA extracts from subgroup A isolates used in section 5.3.2 were subjected to 
reverse transcription with primer gpFA_For as described in section 3.15.3 followed by 
PCR with primer set gpFA_For-gpFA_Rev using programme PCR50 as described in 
section 3.15.4. The PCR products were resolved in an agarose gel as described in 
section 3.15.9 and the result is shown in Figure 28. All isolates tested yielded bands 
with the expected size of 1796bp based on A2. The water control was clean but two 
non-specific bands can be observed in the HeLa cell control, both of size in between 
750-1000bp.The higher non-specific band was observed in three strains namely 4208, 
24702 and 2567 but is most prominent in strain 24702 as is associated with lower 
intensity of the band of interest. The lower non-specific band was present in all 
subgroup A strains tested. 
G gene 
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Figure 28 RT-PCR amplifying the HRSV fusion gene of various genotypes. 
5.4 Cloning of the inserts into pSC11 vector. 
The G genes of subgroup A strain 25173 (GA7), 4208 (GA5) of subgroup A and 5608 
of subgroup B, genotype BA4 from section 5.3.2 and the F gene of strain 4208 from 
section 5.3.3 were digested with Cfr9I as described in section 3.17.3 and ligated into 
pSC11 as prepared in section 5.1 using the procedures described in section 3.17.5. 
Isolates 4208 and 5608 were chosen as a representatives for the contemporary 
genotypes while 25173, a GA7 genotype was chosen as a full length G glycoprotein 
control in section 7.5.7. The ligated products were transformed as described in section 
3.17.9 into chemically competent E.coli TG1 as prepared in section 3.17.2. To identify 
the strain and the gene of each PCR, the strain number will be followed by a suffix G or 
F representing the G gene and F gene respectively. 
All transformations yielded bacterial colonies except for strain 25173G. The procedures 
above (from RT-PCR on) were repeated thrice without any success probably due to 
inefficient digestion by Cfr9I. Thus, the PCR product of 25173G was cloned into the 
pGEM-T Easy vector as described in section 3.17.8 and six colonies was picked and 
grown in 2ml LB and the plasmids extracted as described in section 3.17.10 followed by 
insert screening by SmaI as described in section 3.17.6. The result is shown in Figure 29. 
Three clones were found you harbour the G gene and resolved as a band with the size 
similar to the PCR product (956bp) namely clone 2, 3 and 5. Clones without the correct 
insert yielded 2 bands with the size in between 1500-2000bp and 4000-5000bp. pSC11 
plasmid was digested with SmaI as a control. Clone 2 of 25173G/pGEM-T, designated 
as 25173G2 was chosen to be subcloned into pSC11. 
F gene 
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Figure 29 Insert screening of 25173G/pGEM-T Easy by SmaI digestion.  
Lane 1-6 represents 6 clones screened, Lane 7: SmaI digested pSC11; M: GeneRuler™ 
1kb DNA ladder. 
5.4.1 Insert screening by restriction digest. 
4208G/pSC11 colonies resulting from section 5.4 were picked, grown overnight in LB 
culture, and plasmid minipreps prepared as described in section 3.17.10. Plasmids were 
screened by SmaI digestion as described in section 3.17.6 and the result is shown in 
Figure 30.  
 
Figure 30 Insert screening of 4208G/pSC11 by SmaI digestion.  
Lane 1-18 represents different clones from individual colony. Lane 19:digested pSC11 
as a positive control; Lane20; undigested pSC11; M: GeneRuler 1kb DNA ladder 
From the 18 colonies picked and screened, 6 colonies were harbouring an insert with the 
size of about 950bp corresponding to the size of the amplified G gene. They are clone 4, 
5, 6, 12, 14, 16. Clones 10 and 11 yielded insert size which did not correspond to the 
size of the amplified G gene. Clones 17 and 18 contained no plasmid. Glycerol stocks of 
bacterial clones with insert including those with incorrect size were prepared for storage 
as described in section 3.17.12. Comparison between the digested pSC11 (lane19) with 
undigested pSC11 (lane20) shows the complete cleavage of pSC11 by SmaI.  
G gene 
G gene 
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Five resulting colonies of 4208F/pSC11 from section 5.4 were treated as above and the 
results are shown in Figure 31. Only 1 of 5 colonies screened harbour an insert with a 
size of about 1790bp corresponding to the amplified fusion glycoprotein gene. Frozen 
bacterial stock for clone 4208F/pSC11_4 was prepared as described in section 3.17.12. 
 
Figure 31 4208F/pSC11 insert screening by SmaI digestion.  
Lane number represents actual clone number. 
5.5 Colony screening 
Colonies was initially screened for inserts by restriction enzyme digest as above. This 
strategy itself is laborious and lengthy involving overnight growth of bacterial culture, 
plasmid miniprep, restriction enzyme digestion and agarose gel electrophoresis. 
Carrying out a large number of plasmid miniprep at any one time can be limited by the 
capacity of the available centrifuge. Thus, colony PCR was later developed to make 
colony screening more efficient. 
5.5.1 Colony PCR primer set design 
In order to design primers for colony PCR, vector sequences flanking the gene insert are 
required. There is currently no published vector sequence for pSC11. Thus a 
characterised pSC11/SH2.1 clone containing the SH gene of HMPV was obtained as a 
frozen bacterial stock from Dr Alison B. Tedcastle, Newcastle University. The original 
cloning primers used to generate this clone SH Forward and SH Reverse as shown in 
Table 8. 
Both SH Forward and SH Reverse had their sequence upstream of Cfr9I restriction site 
omitted, reversed complement and the primers were named MCS_upstream and 
MCS_downstream as shown in Table 7 
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Miniprep plasmid was prepared from pSC11/SH2.1 as described in 3.17.10, quantitated 
and sequenced using MCA_upstream and MCS_downstream as described in section 
3.15.13. The sequence determined is shown in Figure 32. The sequences were 
assembled using CAP3 programme as described in section 3.16 and the colony PCR 
primer set was designed manually and named pSC_For and pSC_Rev. 
ACTCAAGACTACGAAACTGATACAATCTCTTATCATGTGGGTAATGTTCTCG
ATGTCGATAGCCATATGCCCGGTAGTTGCGATATACATAAACTGATCACTAA
TTCCAAACCCACCCGCTTTTTATAGTAAGTTTTTCACCCATAAATAATAAAT
ACAATAATTAATTTCTCGTAAAAGTAGAAAATATATTCTAATTTATTGCACG
GTAAGGAAGTAGAATCATAAAGAACA//TCTGTGAGCGTATGGCAACGAAGG
AAAATAGTTATAGTAGCCGCACTCGATGGGACATTTCAACGTAAACCGTTT
AATAATATTTTGAATCTTATTCCATTATCTGAAATGGTGGTAAAACTAACTG
CTGTGTGTATGAAATGCTTTAAGGAGGCTTCCTTTTCTAAACGATTGGGTGA
GGAAACCGAGATAGAGATAATAGGAGGTAATGATATGTATCAATCGGTGTG
TAGAAAGTGTTACATCGACTCATAATATTA  
Figure 32 Partial pSC11 vector sequence flanking the MCS derived from 
pSC11/SH2.1 for colony PCR primer design.  
Underlined: binding site for pSC_For and pSC_Rev respectively; // gene sequence not 
determined. 
5.5.2 Validation of colony PCR primer set 
In order to validate the newly designed colony PCR primer, a panel of characterised 
pSC11 clones are required. Thus, 4208G/pSC11 clones 4, 5, 6 (with correct insert size) 
and clones 10 and 11 (with incorrect insert size) from Section 5.4.1 were chosen to be 
used in the colony PCR experiment and carried out as described in section 3.15.6. A 
pSC11/TG1 clone was included as an empty vector control and water for a template free 
negative control. Results of the colony PCR is shown in Figure 34. The amplification 
profile of the clones was comparable to the profile of the SmaI restriction digest profile 
except the corresponding bands were more than 200bp larger than the insert size 
obtained by restriction digest due to the incorporation of the vector sequence flanking 
the cloning site. As expected clones 4, 5 and 6 yielded band of similar size above 1000 
kb corresponding to the theoretical size of 1191bp and clone 10 and 11 yielded smaller 
incorrect size bands of approximately 500bp and 600bp respectively. 
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The colony PCR product generated from empty pSC11 vector was cloned into pGEM-T 
Easy as decribed in section 3.17.8 and a positive clone was sequenced using the M13 
primers set as decribed in section 3.15.13. The sequences were assembled using the 
CAP3 sequence assembly programme (section 3.16). The sequence is shown in Figure 
33 and the length was determined to be 235bp. However, the electromobility size if this 
fragment on an agarose gel was consistently migrating above 250bp with reference to 
the GeneRuler 1kb DNA ladder. Sequencing of pSC11 plasmid using pSC_For and 
pSC_R as described in section 3.15.13 followed by sequence assembly reconfirmed the 
sequence length to be 235bp. 
TTGAAATGTCCCATCGAGTGCGGCTACTATAACTATTTTTCCTTCGTTTGCCA
TACGCTCACAGAATTCCCGGGGATCCGTCACTGTTCTTTATGATTCTACTTC
CTTACCGTGCAATAAATTAGAATATATTTTCTACTTTTACGAGAAATTAATT
ATTGTATTTATTATTTATGGGTGAAAAACTTACTATAAAAAGCGGGTGGGTT
TGGAATTAGTGATCAGTTTATGTATA 
Figure 33 Sequence of the amplification product generated from native pSC11 
vector using the colony PCR primers.  
The colony PCR primers pSC_For and pSC_Rev are underlined respectively; The Cfr9I 
restriction enzyme site is in bold. 
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Figure 34 Validation of colony PCR primer for pSC11 using 4208G/pSC11 clones.  
Lane number correspond to the actual clone number; pSC11: empty vector control; 
Water: control without template; M1: GeneRuler™ 1kb DNA ladder; M2: GeneRuler™ 
100bp DNA ladder. 
5.5.3 Insert screening by Colony PCR 
 
Figure 35 Colony PCR for 25173G2/pSC11.  
M: GeneRuler™ 1kb DNA ladder; pSC11 empty cassette template control; Water: 
template free control. 
Ten colonies of 25173G2/pSC11 were picked and subjected to colony PCR as described 
in section 3.15.6 and the results are displayed in Figure 35. Two pSC11/TG1 colonies 
were included as an empty cassette control and also as a positive control for the PCR. A 
water control was included as a template free control or negative control. Clones 1 to 9 
yielded a single band of just above 1000bp relative to the marker corresponding to the 
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expected size of 1191bp and were regarded as positive clones. Clone 10 did not yield 
any band was probably a satellite colony as negative clones will always give a band at 
least with the smallest size equivalent to the pSC11 control. Frozen bacterial stocks 
were prepared for all positive clones as described in section 3.17.12. 
Sixteen colonies of 5608G/pSC11 resulting from section 5.4 were picked and treated as 
described above and the results are displayed in Figure 36. 10/16 5608G/pSC11 clones 
contain insert of the correct size with the electrophoretic mobility in between 1000-
1500bp corresponding to the theoretical size of 1252bp. They are clones 2, 4, 5, 7, 8, 9, 
10, 11, 12, and 14. Clone 13 contains no insert but yielded a band with the size 
equivalent to the band generated by pSC11 vector control. Clones 15 and 16 failed to 
generate any band probably represent plasmid free satellite colonies. Frozen bacterial 
stocks were prepared for all positive clones as described in section 3.17.12. 
 
Figure 36 Colony PCR for 5608G/pSC11.  
Lane number represents the clone number. Water control and pSC11 plasmid included 
as controls. 
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5.6 Orientation screening 
As the insertion of gene into pSC11 occurs via a non-directional manner through a 
single restriction site, it can be inserted in either direction. To screen for genes inserted 
in the correct orientation for translation and transcription, the presence of a unique a 
second restriction site, Eco81I an isoschizomer of BSu36I site in the P11 promoter of 
pSC11 was exploited. A second restriction site, Eco81I was engineered into the 
downstream primer (Table 5) and upon digestion with Eco81I, the enzyme cleaved the 
two Eco81I sites; one as engineered into the downstream primer and the other located in 
the p11 vaccinia virus promoter, approximately 600bp upsteam away from cloning site. 
Thus, plasmid clones with the insert in the correct orientation will yield a band with the 
size of the insert plus another 600bp from the vector and clones with the wrong 
orientation will yield a band of approximately 600bp as estimated from Figure 11. 
Frozen bacterial stock containing the G gene and F gene prepared in sections 5.5.1 and 
5.5.3 were revived as described in section 3.17.13.  
The plasmid minipreps of 4208G/pSC11 clones 4, 5, 6, 12, 14 and 16 were digested 
with Eco81I together with pSC11 plasmid as described in section 3.17.7 and the results 
are shown in Figure 37. All clones tested yielded a band with the size slightly above 
1500bp which corresponded to the size of the G gene insert plus an extra 600bp of 
vector sequence. Thus all 4208G/pSC11 clones screened here contain the G gene in the 
correct orientation. 4208G/pSC11_4 was chosen to be recombined into MVA.  
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Figure 37 Insert orientation check for 4208G/pSC11 clones by Eco81I digestion.  
Numbers on lane correspond to the actual clone number; digested and undigested 
pSC11 vector for restriction enzyme digestion control. 
Plasmid minipreps of 25173G2/pSC11 were treated as above and the result is shown in 
Figure 38. Clone 1, 4, 6, 7, 8 and 9 yielded a band above 1500bp as described above and 
are confirmed to contain G gene inserts in the correct orientation. Clones 2, 3 and 5 
yielded a band of about 600bp corresponding to the size when an insert in the wrong 
orientation is present. Thus, clone 25173G2/pSC11_1 was chosen to be recombined into 
MVA. 
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Figure 38 Orientation check for 25173G2/pSC11 by Eco81I restriction enzyme 
digest.  
Lane 1-9 represents individual clones with insert of the correct size; Lane 10: digested 
pSC11; Lane 11: undigested pSC11. 
 
Figure 39 Orientation check for 5608G/pSC11 by restriction digest with Eco81I.  
Numbers on lane represents the actual clone number used; digested and undigested 
pSC11 was included as a control for the restriction enzyme. M: GeneRuler™ 1kb DNA 
ladder.  
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Plasmid minipreps from ten positive clones of 5608G/pSC11  were treated as above and 
the result is displayed in Figure 39. The digestion of these clones with Eco81I shown 
that clones 5, 7, 9 and 10 contain inserts with the correct orientation yielding a band 
with the size above 1500bp, which is visually larger than positive sense clones observed 
in Figure 37 and Figure 38 due to the extra 60 nucleotides insert in the G gene of this 
BA strain. Clones 5, 8, 11, 12, and 14 contain inserts in the wrong orientation which can 
be deduced from the lower sized band. The bands from the clones with inserts in the 
wrong orientation migrate around 750bp relative to the marker, about 150bp higher than 
the expected size of 600bp. Clone 4 yielded no visible band other than the vector band 
probably due to the low concentration of the plasmid. Nevertheless, clone 4 was 
deduced to have the insert in the wrong orientation judging by the larger vector band 
which is similar to other wrong orientation clones. 5608G/pSC11 clone 2 was chosen to 
be recombined into MVA. 
The orientation screening for pSC11 clones with the fusion gene insert is the same as 
described above. Clone with the insert in the correct orientation produces a 2.4kbp band 
while clone with insert in the wrong orientation yielded a 600bp band.  
Plasmid minipreps from the sole clone of 4208F/pSC11_4 was digested with Eco81I 
and the result is shown in Figure 40. The digestion of the clone yielded a band of 2.4kbp 
showing that this clone contains the F glycoprotein gene inserted in the correct 
orientation. This clone was chosen to be recombined into MVA. 
 
Figure 40 Orientation check for 4208F/pSC11 by Eco81I digestion 
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5.7 Plasmid preparation 
High concentration plasmid DNA from selected clones in section 5.6 was prepared by 
Maxiprep as described in section 3.17.11 and the concentration was determined as 
described in section 3.15.12 and the results are shown in Table 13. Plasmid 9NS3V5His 
was used as a positive control for the recombination (section 5.8.3) and recombinant 
virus enrichment (section 5.8.4) experiments. This provides stocks of plasmid DNA to 
be used in the recombination experiment described in section 5.8.3. 
Table 13 Concentration of recombinant plasmid DNA generated by Maxiprep 
Clone Plasmid Concentration(ng/µl) 
N/A pSC11 1609.2 
9NS3V5His/pSC11 9NS3V5Hisγ 4707.3 
4208G/pSC11_4 GA2G 5111.0 
25173G2/pSC11_1 GA7G 3204.5 
5608G/pSC11_2 BAG 192.8 φ 
4208F/pSC11_4 GA2F 3801 
φ Clone was not able to grow to high density in large volume, γ (Chiam et al., 2009) 
The clone was a gift and used as a positive control for the recombination experiment. 
Bacterial clone 5608G/pSC11_2 grew normally in 2ml LB but when scaled up to 500ml 
LB, the bacterium failed to achieve high density and started to lyse judged by the 
gradual clearing of the culture due to unknown reason.  
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5.8 The generation of recombinant MVA virus 
5.8.1 Cell line selection 
A robust cell and sensitive cell line for the replication of MVA was sought. Three 
permissive cell lines for MVA were evaluated namely BHK21 (section 3.6), CEF 
(section 3.3) and QT35 (section 3.5). The three cells lines were grown in T75 tissue 
culture flasks to confluency in their appropriate growth medium as described in section 
3.7. The growth medium was removed and the monolayer was infected with 
9NS3V5His (section 3.19.1) at the MOI of 0.1 as described in sections 3.19.3 and 
3.19.5. Mock infections were carried out in parallel using the appropriate maintenance 
medium as inoculum. Cultures were incubated and observed daily for CPE and medium 
replenished every alternate day until 4+CPE can be observed. The cytophatic effect of 
MVA and its recombinant is identical to the CPE of vaccinia virus which involves the 
rounding up of cells followed by detachment from the flask. 
The virus stocks grown in different cell lines were titered on the parental cell line used 
to propagate the virus as described in section 3.19.3 The virus titer for 9NS3V5His 
propagated in both avian cell lines were quite similar with those propagated in CEF, 
regarded as a gold standard in the propagation of MVA, being the highest. Thus, QT35 
and BHK21 produced 0.67 and 2×103 times less virus respectively when compared with 
CEF. Thus, CEF was the most sensitive cell line tested for the propagation of MVA 
followed by QT35 with lastly BHK21.  
Although CEF is the best cell type to be used in the routine MVA procedures such as 
propagation, plaquing and titering, QT35 was chosen for routine work as it is an 
immortalized cell line which is more homogenous compared to CEF and can be 
passaged indefinitely in the laboratory. CEF had been successfully passaged for more 
than 10 passages but CEF at passage 8, 9 or later tend not to reach full confluency thus 
restricting its use in the study.  
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Table 14 Cell line efficiency in cultivating MVA demonstrated using 9NS3V5His, 
P2 
 Number of days for 
4+CPE  
Virus titer (pfu/ml) 
BHK21 3 3.25 x 104 
CEF 5 1.50 x 107 
QT35 3 1.00 x 107 
 
5.8.2 MVA stock preparation 
MVA-575 P2 (section 3.19.1), hitherto referred to as MVA, was titrated on QT35 
monolayer and plaques were stained with crystal violet as described in section 3.19.4 
and the titer was 6× 107pfu/ml. An example of the stained plaques under 100X 
magnification is shown in Figure 41. 
 
Figure 41 A vaccinia virus plaque and uninfected QT35 cells stained with crystal 
violet under 100X magnification 
5.8.3 Homologous recombination 
Homologous recombination involves the low frequency recombination of the gene of 
interest and βgal gene into MVA via cross-overs between the  thymidine kinase gene 
sequences flanking these inserts in the  pSC11 vector and the thymidine kinase loci in 
the virus genome.. The recombinant genome will then be replicated  and packaged into 
progeny virions identified by its TK- phenotype and the ability to express β-
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galactosidase due to the presence of the βgal gene driven by the p11 vaccinia virus 
promoter. Plasmids were diluted to 5µg and recombined into MVA (sections 3.19.1 and 
5.8.2) as described in section 3.19.6. The recombination of plasmid 9NS3V5His with 
MVA was regarded as a positive control as the construct was successfully used in other 
homologous recombination experiments (Chiam et al., 2009). 
5.8.4 Recombinant virus enrichment 
The recombinant MVA viruses can be selected by bromodeoxyuridine (BudR) selection 
in a thymidine kinase negative (TK-) cell line  but this was not available for this study. 
Instead, the resulting recombinant MVAs expressing the βgal gene were subjected to 5-
7 rounds of plaque purification as described in section 3.19.7 with the help of Xgal 
staining. Recombinant MVA plaques were stained blue by Xgal and could be visualized 
under the microscope as shown in Figure 42(A) or easily observed by the naked eye, but 
wild type MVA plaques were colourless and could only be observed through a 
microscope as shown in Figure 42(B). The choice of blue plaques picked was very 
selective opting for lone blue plaques without any adjacent wild type or with wild type 
at a significant distance from the blue plaque to reduce amount of wild type picked 
together with the recombinant thus producing maximum enrichment of the recombinant 
virus. Blue foci were confirmed by microscopy to ensure they showed typical poxvirus 
plaque formation and were not clumps of cells. For unknown reasons, cell clumps 
exhibited a certain degree of βgal activity and appeared as false positives yielding no 
viable virus. The plaques from the positive control were not enriched but was solely 
used as a control for Xgal staining.  
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Table 15 Recombinant MVAs 
Plasmid∆ Clone 
number 
Name of 
recombinant 
virus 
P4 titer 
GA2G 1221222 vvGA2G 8.00x107 
GA7G 1111313 vvGA7G 5.25x107 
BAG 1353632B vvBAG 1.75x107 
GA2F 61393γ vvGA2F 5.25x107 
GA2F 6139311φ vvGA2F 1.45x107 
pSC11 611114 vvBgal 4.25x107 
γ clone which produces rapid syncytia in Hela (section5.9), φ clone used in antigen 
production, ∆ nomenclature as defined in  
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A. Recombinant MVA  
 
B. Wild type MVA 
 
C. Uninfected QT35 
 
Figure 42 Recombinant and wild type MVA plaques stained with Xgal visualized 
under 100X magnifications.  
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5.9 Expression of G glycoproteins in QT35 and HeLa cells. 
The enriched recombinant MVA expressing the G glycoprotein in section 5.8.4 were 
propagated on QT35 cells as described in 3.19.3 and fixed specimen slides were 
prepared as described in section 3.10.3 and stained with the anti-G Mab133 by 
immunofluorescent as described in section 3.10.4. vvBgal and mock infected QT35 
cells were included as controls. The immunofluorescent staining result is displayed in 
section Figure 43. The G glycoprotein expressed by vvGA2G, vvGA7G and vvBAG 
were stained apple green as shown in Figure 43 showing the presence of the G 
glycoprotein in the vvGA2G, vvGA7G and vvBAG infected cells. vvBgal and mock 
infected QT35 cells were only stained red by Evan’s blue counterstain showing the 
absence of G glycoprotein and the specificity of Mab133 on the G glycoprotein without 
any observable cross-reactivity on MVA viral proteins, beta-galactosidase nor the 
cellular proteins. 
Recombinant MVAs expressing the recombinant G glycoproteins were titered and 
inoculated onto HeLa monolayers grown in T75 at the MOI of 3. vvBgal was inoculated 
in parallel at the MOI of 3 and mock infected HeLa cells were included as controls. The 
inoculums were incubated for 30 minutes and the volume of each tissue culture flask 
was adjusted to 10 ml with fresh MM2 and incubated overnight and 4+ CPE was 
observed the following day. The cells were scraped into the medium and fixed onto 
slides as described in section 3.10.3 and stained with Mab133 by IF as described in 
section 3.10.4 and the results are shown in Figure 44. Cells inoculated with vvGA2G, 
vvGA7G and vvBAG were stained apple green by 133 by IF but not vvBgal and mock 
infected HeLa showing the expression of G glycoprotein in vvGA2G, vvGA7G and 
vvBAG infected cells.  
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vvGA2G vvGA7G 
 
 
vvBAG  
 
 
vvBgal Mock infected 
  
Figure 43 Expression of the recombinant HRSV G gene by recombinant MVAs in 
QT35 cell line stained with Mab133 by IF and visualized under 400X 
magnifications. 
Apple green staining showed positive IF while red background staining showed 
negative IF. 
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vvGA2G vvGA7G 
  
vvBAG  
 
 
vvBgal Mock infected 
  
Figure 44 Expression of the recombinant HRSV G gene by recombinant MVAs in 
HeLa stained with Mab133 by IF and visualized under 400X magnifications. 
Apple green staining showed positive IF while red background staining showed 
negative IF. 
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5.10 Expression of F glycoproteins in QT35 and HeLa cells. 
Enriched vvGA2F clone 61393 P4 was inoculated onto QT35 monolayer in T75 as 
described in section 3.7, absorped for 30 minutes and the volume adjusted to 10ml with 
fresh MM3. vvBgal and mock infected QT35 was include as controls. The cultures were 
incubated until 4+ CPE was observed about 48-72 hours post inoculation. No giant cell 
was observed. The monolayers were scraped into the medium and specimen slides were 
prepared and fixed onto slides as described in section 3.10.3 and stained with the anti-F 
Mab 1A12 by IF and the results are shown in Figure 45. vvGA2F infected QT35 cells 
were stained apple green showing the presence of the fusion glycoprotein. vvBgal and 
mock infected QT35 were only stained red by Evan’s blue counterstain. This showed 
that the fusion glycoprotein was successfully expressed in by vvGA2F in QT35 and 
Mab1A12 was specific to the fusion glycoprotein and does not cross react with MVA 
viral proteins, beta-galactosidase nor the cellular proteins. 
vvGA2F vvBgal Mock infected 
   
Figure 45 Expression of recombinant fusion glycoprotein in QT35 stained with 
1A12. 
Apple green staining showed positive IF while red background staining showed 
negative IF. Slides were visualized under 400X magnifications. 
HeLa monolayers were inoculated with vvGA2F clone 61393 P4 at the MOI of 10 and 
this experiment was repeated with vvBgal. A mock infected HeLa was included as 
control. The cultures were incubated for 30 minutes and the volume was adjusted to 
10ml with fresh MM2 followed by incubation. Upon inspection at 2.5 hours post 
infection, massive giant cells were observed on vvGA2F infected HeLa monolayer as 
shown in Figure 46 (Figure 46 was obtained by repeating the experiment and the 
monolayer was fixed and stained with Diff-quik as described in section 3.8). No 
formation of giant cells was observed in vvBgal infected HeLa monolayer suggesting 
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the formation of giant cells were caused by the expression of the recombinant F 
glycoprotein. 4+CPE was observed the following day with the cells rounding up. The 
monolayer was scraped into the medium and fixed onto slides as described in section 
3.10.3 and stained with Mab1A12 by IF as described in section 3.10.4 and the results 
are shown in Figure 47. vvGA2F infected HeLa was stained apple green showing the 
presence of F glycoprotein while vvBgal and mock infected HeLa were stained red with 
Evan’s blue.  
vvGA2F vvBgal Mock infected 
   
Figure 46 Formation of rapid giant cells by vvGA2F clone 61393 passage 4 
Visualized under 100X magnifications 
vvGA2F vvBgal Mock infected 
   
Figure 47 Expression of recombinant fusion glycoprotein in HeLa stained with 
1A12. 
Apple green staining showed positive IF while red background staining showed 
negative IF. Slides were visualized under 400X magnifications. 
To explore whether synthesis of recombinant F glycoprotein occurred early enough in 
infected cultures to cause the formation of syncytia at 2.5 hours post-infection vvGA2F 
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was inoculated onto 6 wells of HeLa monolayer grown in a 24 well plate at the MOI of 
10 with vvBgal inoculated in parallel as a control. After 30 minutes of virus absorption, 
the monolayers were washed trice with 1ml/well of PBS and replenished with 1ml/well 
of MM2. The monolayers from one set of wells consisting of vvGA2F, vvBgal and 
mock infected HeLa cells were scraped into the medium and fixed onto individual slides 
as described in section 3.10.3. These procedures were repeated every 30 minutes until 3 
hours post inoculation and fixed specimens were stained with 1A12 by IF as described 
in section 3.10.4 and the results are shown in Figure 48. The IF staining at t=0.5 hour p.i. 
showed no visible apple green staining. Apple green staining can be clearly visualized at 
1 hour p.i. and the intensity increases over time showing rapid expression of 
recombinant F glycoprotein in HeLa.  
The gradual increase in the fluorescent intensity over 3 hours post inoculation showed 
rapid synthesis of recombinant F glycoprotein by MVA which is consistant with the 
rapid formation of syncytia. This suggests that newly synthesized F glycoprotein could 
be responsible for the rapid formation of syncytia but the possible involvement of F 
glycoprotein from the inoculums in producing the effect cannot be ruled out. When 
vvGA2F clone 61393 was serially passaged in QT35, the virus stocks retained the 
ability to form rapid syncytia when assayed on HeLa monolayers up to passage 7 with 
later passages losing the ability to form rapid syncytia. Virus titration on higher passage 
virus stock done as described in section 3.19.4 with Xgal overlay showed the presence 
of unstained plaques suggesting the presence of wild type MVA. A cloning experiment 
carried out on the original passage 1 stock as described in section 3.19.7 yielded clone 
6139311. Reselection of 6139311 resulted in a wild type free but non-fusogenic virus. 
The role of the wild type virus in the formation of giant cells is unresolved. It is also 
possible that 61393 contain a rapid fusion mutant of the recombinant of the recombinant 
virus but this hypothesis remains to be tested. 
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Figure 48 Timeline for the expression of recombinant F glycoprotein at MOI of 10 
in HeLa cell line. 
vvGA2F clone 61393 P4 vvBgal was used. Cells were stained with Mab1A12 in IF. 
Apple green staining showed positive IF while red background staining showed 
negative IF. Slides were visualized under 400X magnifications. 
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Chapter 6 Development of assays for the measurement of maternal 
antibodies in infants 
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6.1 Introduction  
This chapter describes the development of a lectin capture ELISA utilizing the 
recombinant glyproteins described in Chapter 5. These lectin captured recombinant 
glycoproteins will be used to measure the titer of maternal antibodies to the G 
glycoprotein of the infecting genotype of HRSV and also to the F glycoprotein of 
genotype GA2. This chapter will provide a test of the hypothesis that maternal antibody 
to the genotype specific G glycoprotein is protective.  
6.2 Development of concanavalin A capture ELISA 
HRSV is known to bind to a series of plant lectins but Concanavalin A (ConA) is 
probably the most widely used lectin in HRSV research. ConA was previously used in 
sepharose bead-conjugated forms for the affinity purification of fusion glycoproteins 
from HRSV infected cell culture lysate (Prince et al., 2000) and recombinant fusion 
glycoproteins expressed in vaccinia virus and baculovirus expression systems (Wathen 
et al., 1989a). The same ConA format was also used in the affinity purification of Gs 
from HRSV infected cell culture supernatant (Teresa R. Johnson et al., 1998; Ray et al., 
2001).  
ConA capture ELISA was previously developed to capture gp120 of human 
immunodeficiency virus (HIV) (James E. Robinson et al., 1990) and simian 
immunodeficiency virus (SIV) (Clements et al., 1995) for the measurement of serum 
antibodies to the gp120 of the respective viruses. Both authors coated Maxisorp ELISA 
plates with 2.5µg of ConA in 50µl volume and this amount of ConA was adopted here. 
ConA was also successfully used to capture recombinant F and G glycoprotein antigens 
of HRSV expressed from recombinant vaccinia viruses in ELISA (M. J. Robinson, 
2007). 
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6.2.1 Cell line comparison 
A permissive cell line (QT35) and a non-permissive cell line (HeLa) were chosen to 
establish the best cell line for the expression of recombinant proteins by recombinant 
MVA.  
Confluent T75 monolayers of QT35 and HeLa cells were inoculated with vvGA2G at a 
MOI of 0.1 and 3 respectively. Parallel cultures were similarly inoculated with vvBgal. 
These cultures were treated as described in section 3.19.3 and the antigens processed as 
described in section 3.11.5 except that, after pelleting, the infected cells were 
resuspended in 500µl of ice cold SAF. 
The concentration of each  antigen was determined as described in section 3.14.1 and 
adjusted to 4mg/ml in SAF. Each was titrated twofold in bicarbonate coating buffer and 
direct ELISA was carried out in duplicate as described for HRSV antigens in section 
3.11.6 with Mab133 (1/100 dilution) and GAMPx as the primary and secondary 
antibody respectively. Mab133 was diluted 1/100 in PTF, a dilution previously shown 
to give a corrected optical density of 3.0 with HRSV subgroup B strain 8/60 infected 
HeLa cell lysate (M. J. Robinson, 2007). Optical densities obtained for antibody binding 
to the GA2G antigen were corrected by subtraction of binding at equivalent dilutions to 
Bgal antigen and the results are shown in Figure 49.  
The results showed that the GA2G antigen prepared in HeLa cells at high MOI gave 
higher optical densities compared to that prepared in QT35 cells at a lower MOI. The 
HeLa cell line was chosen for the expression of all recombinant proteins in MVA for 
ELISA as use of antigen prepared in human cells may reduce background binding in 
ELISA of antibodies in human serum. 
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Figure 49 Expression of GA2G in HeLa and QT35 compared in a direct ELISA. 
6.2.2 ConA capture ELISA vs Direct ELISA 
To test if ConA capture ELISA is better than direct ELISA, A comparison was made 
and is described in this section. Confluent T75 monolayers of HeLa cells were 
inoculated with vvGA2G at MOI of 3. Parallel cultures were similarly inoculated with 
vvBgal. These cultures were treated as described in section 3.19.3 and antigens 
processed as described in section 3.11.5 and the antigens were resuspended in 500µl of 
ice cold PBSTx.  
Half of a Maxisorp plate was coated with ConA diluted in bicarbonate coating buffer 
and the other half was left blank, incubated overnight and washed as described 3.11.7.  
The concentration of recombinant GA2G and Bgal was determined as described in 
section 3.14.1, adjusted to 4mg/ml in SAF, subjected to twofold serial dilution in 
PBSTx and dispensed onto the ConA coated wells. In parallel, the antigens were serially 
diluted in bicarbonate coating buffer and coated on the second half of the plate for direct 
ELISA as described in section 3.11.6. The plate was incubated for 2 hours and the rest 
of the procedures were carried out as described in section 3.11.6 with 133 (Table 2) as 
the primary antibody and GAMPx (Table 3) as the secondary antibody. Optical 
densities obtained for antibody binding to GA2G antigen were corrected by subtraction 
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of binding at equivalent dilutions to Bgal antigens and the results are shown in Figure 
50. 
 
Figure 50 Comparison between direct ELISA and ConA capture ELISA 
demonstrated using GA2G.  
The optical density of direct ELISA started off at about 0.7 and in increases slowly until 
an antigen dilution of 1/16 and decreasing thereafter probably suggesting the end of a 
plateau where the plate is saturated with antigen. The reason for the lower OD at the 
starting dilutions is unclear. The binding of antibody to ConA captured antigen was 
increased above the maximum OD that direct ELISA achieved suggesting a higher 
density of bound antigen at low antigen dilution.  
The results showed GA2G can be captured using ConA and the antigen capture format 
is superior to direct ELISA in selecting for the protein of interest and boosting the signal 
at high antigen concentration.  
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6.2.3 Coating buffer (BCB vs PBS) 
Different authors cited in section 6.2 have described the use of two different buffers for 
the coating of ConA namely bicarbonate coating buffer, pH9.6 (BCB) (James E. 
Robinson et al., 1990; M. J. Robinson, 2007) and phosphate buffered saline, pH7.4. 
(PBS) (Clements et al., 1995). This section describes the comparison between the 
effects of these two dissimilar coating buffers on ConA with GA2G and GA2F antigens. 
GA2G, GA2F and Bgal antigens were prepared as described in section 6.2.5 and Bgal 
antigen was adjusted to the neat antigen concentration of GA2G and GA2F respectively.  
ConA stock was diluted separately to the working concentration in either BCB or PBS. 
Half of the Maxisorp plate was coated with ConA diluted in BCB and the other half 
with ConA diluted in PBS and incubated overnight at 4°C washed as described in 
section 3.11.7. GA2G was diluted twofold in PBSTx and captured onto the ConA plate 
coated in BCB and PBS respectively in duplicate. In parallel, Bgal was coated at the 
equivalent concentration to GA2G. ConA capture ELISA was carried out as described 
in section 3.11.7 with Mab133 and GAMPx as primary antibody and secondary 
antibody respectively. The optical densities obtained for antibody binding to GA2G 
antigen were corrected by subtraction of binding at equivalent dilutions to Bgal antigen 
and the results are shown in Figure 51.  
This experiment above was repeated with GA2F as antigen except that Mab1A12 was 
used as the primary antibody and the results are shown in Figure 52. 
The results in Figure 51 showed that the optical densities obtained from ConA coated in 
PBS is higher than the optical densities obtained from ConA coated in BCB at any 
GA2G dilutions. This shows that PBS is a better coating buffer compared to BCB for 
ConA. 
The results in Figure 52 supported the results obtained in Figure 51. The optical 
densities of ConA coated in PBS is higher than the optical densities obtained from 
ConA coated at BCB at any GA2F dilutions supporting that PBS is a better coating 
buffer compared to BCB. The results also shows that the recombinant fusion 
glycoprotein expressed in MVA can also be captured by ConA. 
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Figure 51 Comparison of coating buffer for ConA with GA2G as antigen 
 
Figure 52 Comparison of coating buffer for ConA with GA2F as antigen. 
ConA coating efficiency was higher in PBS than in bicarbonate coating buffer with the 
boost of at least 0.5 units in corrected optical density at any dilution compared as shown 
in Figure 52. Thus, PBS was chosen for the coating of ConA on Maxisorp plate.  
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6.2.4 Serum dilutions 
Serum collected from infant volunteers is of small volume and insufficient is usually 
available for testing at low dilution. This section explores whether the ConA capture 
ELISA is of sufficient sensitivity to measure maternal antibodies to the recombinant G 
glycoprotein in achievable dilutions of infant sera. Two infants’ sera (3810 and 1510) 
were chosen based on two criteria. Firstly, the infants were hospitalised due to severe 
HRSV disease but no NPS or NS was collected rendering them unsuitable for enrolment 
into the main study (see Chapter 9) and secondly, the volume of sera collected was 100 
µl or more.  
Both sera were obtained from infants with mean age of 140.5 days (both born in August 
2009 and admitted in December 2009) but since NPSs or NS failed to be obtained, the 
infecting HRSV genotype could not be determined.  
BAG and Bgal antigens were captured on a ConA plate as described in section 3.11.7. 
Individual sera were diluted 1/10, 1/20, 1/30 and 1/40 and assayed in duplicate on the 
captured antigens described above. Results are displayed as two individual bar charts in 
Figure 53. 
Serum 3810 yielded extremely high background where the level of optical density 
generated from BAG and Bgal control are similar yielding a corrected optical density of 
approximately zero.  
With reference to serum 1510, the ideal dilution used would be 1/10 but this dilution is 
not generally feasible due to the limited volume of serum collected from most infants. 
Thus, a compromised serum dilution of 1:40 was fixed for all assays. This dilution was 
used by Murphy et al.,(1986) for a comparable purpose.  
 144 
 
A 
 
B 
 
Figure 53 Reactivity of maternal antibody to the recombinant BAG and the virus 
Bgal virus control. 
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6.2.5 Antigen preparation 
To provide a sensitive assay for the measurement of the total maternal antibody titer to 
the respective glycoproteins. Antigens were prepared giving a  corrected optical density 
of 3.0 or above with either Mab133 or Mab1A12 for the G and F glycoproteins 
respectively.  
Enriched recombinant viruses (Table 16) were propagated to passage 5 in four flasks of 
QT35 cells grown in T225 as described section 3.19.3 and the virus was resuspended in 
3ml/flask of MM2, titered as described in section 3.19.4 and the results were shown in . 
Table 16 Recombinant virus stock used to prepare recombinant proteins in HeLa 
cells. 
Recombinant virus Titer (pfu/ml) 
vvGA2G, P5 2.00x108 
vvGA2F, P5 1.50x108 
vvBAG, P5 1.25 x108 
vvBgal, P5 1.40x108 
 
The GA2G, BAG and Bgal were prepared separately in four T225 of confluent HeLa 
cells as described in section 3.11.5 at the MOI of 3 and the concentration determined as 
described in section 3.13.2.  
GA2G and BAG antigens were titrated in duplicate by ConA capture ELISA on ConA 
plates coated in PBS with Mab133 and GAMPx as the primary and secondary antibody. 
The concentration of Bgal was adjusted to the neat concentration of GA2G and BAG 
and titrated in parallel. The optical densities obtained from the binding of antibody to 
GA2G and BAG was corrected by subtracting with the binding to Bgal at the equivalent 
concentrations and the results are shown in Figure 54. 
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Both antigens produced corrected optical densties of >3.0 at the lowest dilutions which 
are sufficiently sensitive to detect maternal antibodies in infant sera. 
GA2F and Bgal antigens were prepared separately in four T225 of confluent HeLa cells 
as described in section 3.11.5 at the MOI of 3 and the cell debries were clarified by 
centrifugation at 10000g for 10 minutes at 4°C and the supernatant was recovered by 
aspiration. The protein concentrations were determined as described in section 3.13.2 
and Bgal concentration was adjusted to the concentration of GA2F and titrated in 
duplicate by ConA capture ELISA on plates coated with ConA in PBS and carried out 
as described in section 3.11.7 with Mab1A12 as the primary antibody. The optical 
densities obtained from the binding of antibody to GA2F were corrected by subtracting 
with the binding to Bgal at the equivalent concentrations and the results are shown in 
Figure 55.  
GA2F produced optical density of >3.0 at the lowest dilutions which is equivalent to the 
optical densities achieved with Mab1A12 with HRSV strain A2 infected HeLa cell 
lysate (section 8.2). 
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Figure 54 Antigen titration for the recombinant G glycoproteins. 
 
Figure 55 Antigen titration for recombinant fusion glycoprotein 
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Chapter 7 Development of a tool for the measurement of cross-
reactive antibody 
 149 
 
7.1 Introduction 
This chapter explores the possibility of designing a tool for the measurement of 
antibodies to the conserved region of the G glycoprotein (Aim III) so that the antibody 
directed to the conserved region and hypervariable regions of the G glycoproteins can 
be measured separately. The subtraction of antibodies to the conserved region from total 
antibodies to the G glycoprotein would provide indirect measurement of antibodies 
directed against the hypervariable regions. 
Two monoclonal antibodies were available to aid in this task.  Mab133 and Mab21 were 
developed by Dr Mark Robinson and shown to be reactive with the G glycoprotein of 
both sub-groups A and B and all genotypes of both available for testing (Robinson 
2007).  It was reasoned that these MAbs might be used to identify the conserved 
epitopes on the G glycoprotein, which might then be reproduced in the form of a 
peptide or recombinant protein to produce suitable antigens for the detection of 
antibodies of similar specificity in human sera.  
7.2 Peptide binding ELISA 
The peptide binding ELISA experiments were carried out with Christopher Chambers, a 
final year undergraduate student in Microbiology at Newcastle University who 
submitted the results for assessment as part of his degree course. 
The first approach was to test if Mabs133 and 21 recognised the highly conserved 
sequence in the G glycoprotein as this is the only extensive region which is fully 
conserved between subgroups A and B HRSV. For screening purposes, a peptide 
corresponding to the highly conserved amino acid sequence 164-177 was synthesized as 
described in section 3.21. Peptide 172-184, a mapped epitope for Mab1C2, was used as 
a positive control.  
Peptide 164-177 was diluted to 67, 17, 4 and 1µg/ml respectively in BCB and coated 
onto a Maxisorp plate overnight at 4°C. Peptide 172-184 was coated onto a separate 
Maxisorp plate in parallel. Monoclonal antibodies 1C2, 21 and 133 were titrated four-
fold in PTF and assayed on both Maxisorp plates and ELISA was carried out as 
described in section 3.11.6 with GAMPx as the secondary antibody. The optical 
densities generated due to the binding of antibodies to the respective peptides were 
plotted against antibody dilutions and results are shown in Figure 56. 
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1C2 binds to 172-187 coated at 67, 17 and 4µg/ml respectively yielding optical 
densities >3.0 from the lowest dilution of 1/16. Binding of 1C2 to 172-187 at 1µg/ml 
was lower than at the higher peptide concentrations suggesting that antibody binding is 
dependent on dose for concentrations of peptide below 4µg/ml.1C2 does not bind to 
peptide 164-177 at any peptide concentration or antibody dilution. However a slightly 
higher optical density was observed at the lowest antibody dilution probably due to non-
specific binding of antibody to the Maxisorp plate. 
Binding of 133 and 21 to 164-177 and 172-187 yielded low optical densities 
comparable to the binding of 1C2 to 172-187. The optical densities due to the binding 
of antibodies to 164-177 coated at 67µg/ml were corrected by subtracting with the 
binding to 172-187 coated at the same concentration. Positive values indicate binding to 
164-177 while negative values indicate binding to 172-187 and the results are shown in 
Figure 57. The corrected optical densities for 1C2, 133 and 21 ranged between -0.093 to 
-3.170, 0.010 to 0.176 and -0.016 to 0.177 respectively showing that 133 and 21 did not 
bind to 164-177. 
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Figure 56 ELISA of 1C2, 133 and 21 on peptide 172-187 and 164-177 
●: 1µg/ml; ○: 4µg/ml; ▼: 17µg/ml;∆: 67µg/ml 
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Figure 57 Corrected peptide binding ELISA 
7.3 N-glycosylation inhibition 
The previous results indicate that Mab133 and Mab21 failed to recognize a peptide 
corresponding to the highly conserved region of the G glycoprotein. However, the 
possibility remains that the antibody epitopes are in the conserved region but are 
dependent upon glycosylation, not present in synthetic peptides. The next step therefore 
was to determine whether binding of these two monoclonal antibodies is independent of 
glycosylation of the protein. 
For this an unglycosylated form of the G glycoprotein is required which can be obtained 
either by the expression of the G gene in a prokaryotic expression system, by growing 
HRSV or recombinant virus expressing G glycoprotein in the presence of glycosylation 
inhibitors or by deglycosylation of mature G glycoprotein by enzyme digestion such as 
with endoglycosidases and PNGase F. The use of glycosylation inhibitors was  adopted 
as being more straightforward. 
The HRSV prototype strain 8/60 was selected for this purpose (and will be refered to 
herein as 8/60).  HRSV was inoculated onto a confluent HeLa monolayer grown in a 
T25 tissue culture flask at the MOI of 5 and treated as described in section 3.18.3 in the 
presence of 1 µg/ml of Tunicamycin (MM-Tu) and harvested 48 hours post inoculation. 
A mock infection and untreated 8/60 cultures were conducted in parallel. 
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Cells were pelleted and resuspended in 100µl of 1X reducing sample buffer. All 
samples were heated to 95 °C in a thermal cycler and 20 µl was resolved by SDS-PAGE 
(section 3.12.3) and transferred to a PVDF membrane (section 3.12.4) and stained with 
either Mab133 or Mab21 at 1/100 and GAMPx (1/1000) as primary and secondary 
antibody respectively and western blotting was carried out as described in section 3.12.5 
The results are shown in Figure 58. Mab1C2 was not included as it is subgroup A and 
does not recognise the 8/60 G glycoprotein.  
 
133 21 
 
 
Figure 58 Tunicamycin treatment of HRSV strain 8/60. 
Patterns of staining were similar for both 133 and 21. The Mabs did not recognize HeLa 
cell control. Untreated 8/60 shows two dominant smears of 60-90kDa and 45kDa. For 
Mab133 in 8/60-Tu, the 60-90kDa smear was separated into two distinct bands of 
approximately 80-90kDa and 60kDa. For both Mabs the 45kDa band which is present in 
untreated 8/60 was also present but at a much reduced intensity. Three extra bands were 
observed in 8/60-Tu which were not present in untreated HRSV with the molecular 
weight of approximately 36, 33 and 32 kDa respectively with the 36kDa band being the 
most intensely stained. The 36 kDa band corresponds to the electrophoretic mobility of 
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the unglycosylated full-sized G gene product in SDS PAGE. The fainter, smaller bands 
may represent truncated forms of the polypeptide (Gail W. Wertz et al., 1985; Roberts 
et al., 1994). These results suggest that tunicamycin is capable of inhibiting N-
glycosylation of the G glycoprotein and reducing the efficiency in O-glycosylation and 
that, as Mab133 and Mab21 recognises the 36kDa precursor, they bind to the peptide 
backbone of the G glycoprotein rather than the carbohydrates. 
7.4 Epitope mapping 
Their apparent ability to recognize deglycosylated G glycoprotein in western blots 
under reducing condition suggests that these antibodies recognize linear epitopes. As 
they are cross-reactive between virus sub-groups, these linear epitopes must be at least 
partially conserved. The inability of either Mab to bind to a peptide corresponding to the 
conserved central region of G suggests that there is an alternative region of the 
polypeptide sufficiently conserved to act as a cross-reactive antibody epitope. Discovery 
of these regions will require epitope mapping of the Mabs. Two approaches were 
adopted to this end. Firstly the two cross reactive Mabs were tested together with other 
Mabs to G in additive binding assays in order to assess how many epitopes are involved. 
Secondly, the Mabs were reacted with truncated forms of the G glycoprotein, transiently 
expressed under the control of T7 RNA polymerase promoter to locate the epitopes on 
the polypeptide chain. 
7.4.1 Additive ELISA 
In the additive ELISA for epitope mapping, Mabs are tested in pairs to determine 
whether they compete for the same epitope or bind additively to two separate epitopes. 
The concentration of target antigen is adjusted so that the optical density produced by 
antibody binding in the presence of excess antibody is approximately 1.0. In antibody 
excess, doubling the concentration of either Mab or mixing the two Mabs which bind to 
the same epitope does not increase the amount of antibody bound. Mixing two Mabs 
which bind to different epitopes increases the amount of antibody bound by a maximum 
of 2-fold. MAbs 21 and 133 were tested together with MAb 1C2, known to bind to a 
defined sub-group specific epitope, and MAbs 4G4 and 3F43 which bind an undefined 
epitope present on only some sub-group A strains but which have previously been 
shown to bind additively (Routledge et al., 1986) and are thus regarded as positive 
controls. 
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Additive binding ELISA was carried out in triplicate with anti-G monoclonal antibodies 
133, 21, 1C2, 4G4 and 3F43 as described in section 3.11.8 and the results are shown in 
Figure 59. The effective dilutions used for 133, 3F43, 4G4, 21 and 1C2 was 1/256, 
1/2048, 1/8, 1/128 and 1/256 respectively. The concentration of HRSV strain A2 
antigen prepared as described in section 3.11.4 were coated in BCB at 1/1000 dilution, a 
dilution previously determined to give an OD of approximately 1.0 with the mentioned 
dilution of Mabs. Mixtures comprise of equal volumes a double concentration of each 
Mab.  
 
Figure 59 Additive binding ELISA. 
 
Figure 60 Epitope relationship between monoclonal antibodies 
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The relationship of the monoclonal antibodies tested is summarized in Figure 60. 
Mab133 and Mab 21 were competing for the same or overlapping epitopes. Part of this 
epitope is shared by Mab1C2 and Mab4G4 independently. Mab1C2 and Mab4G4 were 
found to bind to two distinct epitopes judged by the additive binding effect (p=0.002) 
whereas Mab3F43 binds to a distinct epitope from Mab133 (p=0.014), Mab21 
(p=0.011), Mab1C2 (p=0.011) and Mab4G4 (p=0.013) (statistical analysis was carried 
out using paired t test as described in section 3.23). 
7.5 Truncation of G 
To facilitate the further definition of epitopes on the G glycoprotein, the full gene and 
truncated forms of it were cloned into plasmid pTM3 downstream of a T7 promoter and 
expressed transiently in HeLa cells  under the control of T7 RNA polymerase supplied 
by superinfection with a recombinant MVA expressing that enzyme.  
All full length and truncated G gene products were amplified from plasmid clone 
25173G2/pSC11_1. A miniprep plasmid of 25173G2/pSC11_1 was diluted 1/1000 in 
DEPC-H20 and PCR was carried out using the primer pairs in Table 17 as described in 
section 3.15.4 using programme PCR55 and resolved in an agarose gel as described in 
section 3.15.9. The truncated forms of the polypeptide generated are presented 
schematically in Figure 61. The results are shown in Figure 62 and Figure 63. 
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Table 17 Truncation primer sets 
Construct Forward primer Reverse Primer Length (bp) 
A G-N151F G284R 423 
B G-N155F G284R 411 
C G-N158F G284R 402 
D G-NcoIF G177R 558 
E G-NcoIF G172R 543 
F G-NcoIF G284R 876 
G G-NcoIF G190R 597 
H G-NcoIF G163R 516 
The number in the forward primer indicated the start of the amino acid corresponding to 
strain 25173 of genotype GA7 (A.  McGill et al., 2004b) and the complete G gene 
sequence is shown in section 12.6. The number in the forward primer and reverse 
primer indicated the starting and last amino acid position in the G gene. 
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Figure 61 Schmatic diagram showing the representation of truncated products 
compared to the full length G glycoprotein of GA7G (construct F). 
Note: Truncate G and H were purposely not displayed in increasing length with the 
truncate D, E and F for ease of comparison with Figure 62 and Figure 63. 
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Figure 62 Truncation PCR I 
Lane alphabets corresponds to the primer pair used in Table 17  
 
Figure 63 Truncation PCR II 
Lane alphabets corresponds to the primer pair used in Table 17 
Constructs  A, B and C yielded a dominant band in between 250-500 bp corresponding 
to the expected size of 423bp, 411bp and 402bp respectively with non specific bands 
observed in between 750-1000bp. Constructs  D and E yielded bands corresponding to 
the expected size of 558bp and 543bp respectively with non-specific bands observed 
above the band of interest.  
Figure 63 shows the amplification of the full length G gene, construct F, with the 
expected size of 876bp. Constructs G and H yielded bands corresponding to the 
expected size of 597bp and 516bp respectively. All yielded single bands without any 
visible non-specific bands.  
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7.5.1 Preparation of pTM3 for cloning 
A maxiprep plasmid of pTM3 was prepared as described in section 3.17.11 and digested 
with NcoI and BamHI separately as described in section 3.17.3. 
7.5.2 Cloning into pTM3  
All bands of interest from section 7.5 were excised and gel purified as described in 
section 3.15.10, digested with NcoI and BamHI as described in section 3.17.3 and 
ligated into pTM3 prepared in section 7.5.1 as described in section 3.17.5 followed by 
transformation into chemically competent TG1 (section 3.17.9). 
7.5.3 Insert screening 
Insert screening by colony PCR requires the use of colony PCR primer sets which bind 
to the vector sequence. As for pSC11, there is no published sequence for pTM3 or 
pTM1 in the public domain. Thus, a sequencing primer pair was designed 
complementary to the multi cloning site (MCS) (B. Moss et al., 1990) and named 
pTMvec_F and pTMvec_R (Table 8). pTM3 was sequenced using pTMvec_F and 
pTMvec_R as described in section 3.15.13 and the colony PCR primers binding 
sequences were manually designed based on the sequences obtained and were named 
pTM-coF and pTM-coR. pTM3 was sequenced with pTM-coF and pTM-coR and the 
sequences were assembled together with sequences obtained with primers pTMvec_F 
and pTMvec_R and are shown in Figure 64.  
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AAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTAT
GGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAG
GTTAAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTG
AAAAACACGATAATACCATGGGAATTCCCCGGGGAGCTCACTAGTGGATCC
CTGCAGCTCGAGAGGCCTAATTAATTAAGTCGACGATCCGGCTGCTAACAA
AGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGC
ATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGG
AGGAACTATATCCGGGTCCGGAGTTAACTCGACATCTATATACTATATAGTA
ATAC 
Figure 64 Partial pTM3 sequence. 
Bold: pTM-coF and pTM-coR binding site respectively; underlined: multicloning site 
(B. Moss et al., 1990); italiced start codon.  
In order to identify colonies with and without inserts on which to validate the colony 
PCR primer set, plasmid minipreps of the resulting colonies from experiment F, G and 
H (alphabets according to Table 17, PCR product according to Figure 63, cloned into 
plasmid pTM3 and transformed into TG1 as described in section 7.5.2) were prepared 
as described in section 3.17.10 and digested with NcoI and BamHI separately as 
described in section 3.17.3 and the resolved bands are shown in Figure 65.  
Colonies 1-4 from experiment F contain insert of the correct size of approximately 
876bp, colony 5 did not harbour any visible plasmid on gel and colony 6 contains no 
insert. All of the eight colonies picked for experiment G (aa1-190) yielded positive 
insert with the expected size of about 597bp. All 7 clones from experiment H (aa1-163) 
harbours insert with the expected size of 516bp except colony 6 which contains no 
plasmid.  
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Figure 65 Colony screening by NcoI and BamHI digestion.  
M: 1kb DNA ladder, Numbers representing clone/colony number; + RE digested pTM3, 
- undigested pTM3. Alphabets corresponding to the primer set used in Table 17 
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Colony 1 from experiment F, G and H were streaked on LBA plates followed by 
overnight incubation at 37°C to obtain single colonies. A single colony was picked for 
the plate and colony PCR was performed with pTM-coF and pTM-coR with programme 
PCR50 as described in section 3.15.6. All amplicands showed the expected profiles on 
agarose gel (Figure 66) with the insert PCR product (as shown in Figure 63) plus an 
additional 251bp corresponding to the vector sequence flanking the insert. pTM3 vector 
control yielded a band corresponding to the expected size of 251bp in relation to the 
marker. The water control was clean. 
These results showed that the colony PCR primers set can be used for the screening of 
inserts in recombinant pTM3 clones.  
 
Figure 66 Validation of the primer set for colony PCR on pTM3 and its constructs. 
F, G, H: colony 1 from clones derived from Figure 65; pTM3: vector control, Water : 
template free control. * expected size. 
Subsequently, nine bacterial clones each resulting from section 7.5.2 corresponding to 
experiment A, B, C, D and E (Table 17) were picked and colony PCR was carried out 
using the validated primer set as described in section 3.15.6, resolved in agarose gel as 
described in section 3.15.9 and the results are shown in Figure 67. A bacterial clone 
containing pTM3 plasmid was picked and included in the colony PCR as a control. 
All nine colonies from truncation experiments A, B and C screened for inserts by 
colony PCR yielded a single band of the expected size of about 674, 662 and 674bp 
respectively. Seven of nine clones of experiment D yielded a single band of the 
expected size of 809bp with clones 5 and 9 yielding a band lower than the expected size. 
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Seven of nine clones from experiment E showed a band corresponding to the 
approximate expected size of 794bp with clones 1 and 9 yielding a band smaller than 
the expected size. The pTM3 control showed a band corresponding to the expected size 
of 251bp.  
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Figure 67 Insert screening for the truncated G gene in pTM3. 
φAlphabets representing experiments in Table 17, M: 1kb ladder; C: pTM3 control.  
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7.5.4 Plasmid preparation 
The first positive clones from each experiment from section 7.5.3 including the bacterial 
clone containing pTM3 plasmid were selected. Plasmid maxipreps were carried out as 
described in section 3.17.11 and the concentration of each plasmid was determined as 
described in section 3.15.12 and the results are shown in Table 18 
Table 18 Concentration of plasmid DNA of pTM3 clones 
Clone name Concentration (ng/µl) 
1-284 1900 
1-190 4000 
1-163 308 
1-172 665 
1-177 1000 
151-284 1700 
155-284 1600 
158-284 1200 
pTM3 2800 
 
7.5.5 Transient expression 
The recombinant G glycoprotein gene and its truncated products in pTM3 plasmid listed 
in Table 17 were transiently expressed in HeLa cells superinfected with MVAT7 as 
described in section 3.19.8. pTM3 transfected cells, MVAT7 infected cells and 
uninfected HeLa cells were included as controls. The monolayer was scraped into the 
medium 24 hours p.i. and slides were prepared as described in section 3.10.3. 
A nearly confluent monolayer of HeLa in T75 was infected with HRSV strain 25173 
(refered to herein as HRSV GA7 as described in section 3.18.3. A mock infection was 
carried out in parallel. When 4+ CPE was observed, the monolayer was scraped into the 
medium and was fixed onto slides as described in section 3.10.3. These slides were 
included in immunofluorescence tests as controls.  
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7.5.6 Antibody optimization for Immunoflourescence 
Prior to testing anti-G Mabs on truncated G antigens it was necessary to determine the 
dilution of each  MAb preparation by immunofluorescence staining of HRSV positive 
control antigen. 
A confluent HeLa monolayer in a T75 flask was infected with HRSV strain A2 as 
described in section 3.18.3 and cultivated until 4+ CPE was observed. A mock infected 
HeLa monolayer was prepared in parallel. The monolayer was scraped into the medium 
and smears prepared on microscope slides and fixed (section 3.10.2) as described in 
sections 3.10.3. Anti-G monoclonal antibodies (Mabs 1C2, 21, 133, 4G4)  
were titrated on the fixed antigen in PBS and immunostaining was carried out as 
described in section 3.10.4 and the results are shown in Table 19 
Table 19 Antibody dilutions against HRSV strain A2 by IF. 
 Antibody dilutions 
Mabs 1/2 1/4 1/8 1/16 1/32 
21 4+ 4+ 4+ 4+ 4+ 
1C2 4+ 4+ 4+ 4+ 3+ 
133 4+ 4+ 4+ 3+ 2+ 
4G4 4+ 4+ 4+ 2+ 1+ 
Mabs 1C2, 133, 21 and 4G4 were used at 1/16, 1/8, 1/32 and 1/8 respectively for 
subsequent immunofluorescent detection of recombinant G glycoproteins and its 
truncates in section 7.5.7. 
7.5.7 Immunofluorescence staining of anti-G Mabs on truncated G antigens 
Specimen slides prepared from section 7.5.5 were stained with Mabs 133, 21, 1C2 and 
4G4 and immunofluorescent procedures were carried out as described in section 3.10.4 
and the results are shown in Figure 68. An example of immunoflourescent staining with 
Mab133 on transiently expressed G glycoproteins is shown in Figure 68. 
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Figure 68 Immunofluorescent staining on transiently expressed G glycoprotein. 
Truncated fragment 1-284 (full length G) transiently expressed in HeLa cell and stained 
with Mab133 followed by SAM-FITC counterstain and visualized under 400X 
magnifications.. Apple green staining represents positive IF while red background 
represents negative IF.   
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Table 20 Monoclonal antibodies profile to the truncated G protein fragments by 
immunofluorescence. 
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Figure 69 Schematic diagram showing the binding of the monoclonal antibodies to 
the G glycoprotein and its truncated fragments. 
Solid lines and hatched lines represent binding and no binding respectively. 
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To analyse the binding of each monoclonal antibody to the G glycoprotein and its 
truncated products, the G glycoprotein was divided into five regions represented with 
the alphabets A to E as shown in Figure 69. 
Both Mab133 and Mab21 displayed a similar binding profile to the truncated fragments 
and will be analysed together. The epitope of both Mabs were mapped within residues 
155-190 spanning 45 amino acids in length while further truncation of the 3 residues 
from the C-terminus end within region A (Figure 69) fully ablated the binding of 
Mab133 and weakened the binding of Mab21 suggesting that at least one of the three 
amino acids is  important for the binding of these two cross-reactive Mabs which may 
bind to different overlaping epitopes within the same region.  At the N terminus end, 
region E is important for the binding of both Mabs. Lack of  binding to fragments 1-177 
and 185-284 which contains the complete 13 amino acids conserved sequence (164-177) 
reinforced the results of the peptide binding ELISA which suggested that residue 164-
177 is not sufficient for the binding of these two cross-reactive Mabs. 
The truncation experiment narrowed down the epitope of subgroup A specific 
monoclonal Mab1C2 to 155-190 which contains the known epitope of residues 172-184. 
Removal of region E completely ablated the binding of Mab1C2 to the truncated 
fragment. 
The epitope for the strain-specific monoclonal antibody Mab4G4 was narrowed to 
residue 155-172 which requires region A and C at the C terminus and N terminus end 
respectively for efficient binding. Similar to Mab21, the deletion of region A causes 
Mab4G4 to bind weakly judging by the 1+ IF to fragment 158-284. 
Within region A, residue 155 and 156 consist of two proline residues which are 
conserved in both subgroups A and B HRSV. Residue 157 is variable being serine or 
asparagine residue in subgroup A or a conserved lysine residue in subgroup B. Thus, 
residue 157 is the only variable residue in the Mab4G4 epitope it is likely to be involved 
in binding of that antibody conferring strain specificity. At least one of the two 
conserved prolines are likely to be involved in binding of the cross-reactive Mab133 
and Mab21. 
Region E, essential for binding of cross-reactive Mab133 and Mab21, and also of sub-
group A specific Mab1C2,  contains conserved residues 178, 179, 182, 185-187, 189, 
190 while residues 177, 180, 181, 183, 184 and 188 vary between but are conserved 
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within subgroups (Table 21)). It is surmised that one or more of the conserved residues 
contribute to the binding of Mab21 and Mab133 whilst at least one variable residue is 
important in the binding of Mab1C2. 
Table 21 Differences between amino acid residues within region E in the G 
glycoprotein. 
  Amino acid residues 
Subgroup 177 180 181 183 184 188 
A Ser Pro Thr Trp Ala Arg 
B Gly Gln Leu Lys Ser Thr 
Subgroup specific Mab4G4 and subgroup A specific Mab1C2 binds to distinct epitopes 
in the G glycoprotein while the cross-reactive monoclonal antibodies Mab133 and 
Mab21 binds to overlapping epitope shared by Mab4G4 at the C terminus end and 
Mab1C2 in the N-terminus end missing the 13 amino acids conserved sequence in the 
middle. 
 
Figure 70 Epitopes for cross-reactive, subgroup specific and strain specific 
monoclonal antibodies in the G glycoprotein. 
The overall relationship between these cross-reactive, subgroup specific and strain 
specific monoclonal antibodies are summaried in *including Mab21. 
Thus, the design of a straight forward antigen tool for the measument of maternal 
antibodies directed to the cross-reactive epitopes is not feasible without measuring the 
subgroup specific and strain specific antibodies. 
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Chapter 8 Screening for Immunoglobulin A (IgA) in infants 
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8.1 Introduction 
As maternal IgG is indistinguishable from an infants’ own IgG, the screening of IgA in 
infants’ sera collected from epidemic 2009/2010 was crucial. The presence of IgA 
antibody in the serum indicates that the infant has already mounted its own humoral 
response against HRSV and that there is a possibility that IgM and/or IgG against 
HRSV glycoprotein might have been produced to the current or previous infection. 
Thus, all IgA positive infants were excluded from the study. 
8.2 Mab1A12 
Development of an ELISA for anti-HRSV IgA requires prior  optimization of an HRSV 
antigen, testing of known HRSV IgA positive sera and demonstration of the specificity 
of the assay for IgA immunoglobulins. Optimization of the ELISA antigen was carried 
out using anti-RSV Mab1A12, which was first titrated on an arbitrary dilution of 
antigen. 
HRSV strain A2 (section 3.18.1) (refered to hereafter as HRSV antigen) was inoculated 
into 4 confluent T75 of HeLa cells and antigens were prepared as described in section 
3.11.4. A mock infected cell control was prepared in parallel as a control (refered to 
hereafter as cell control). The protein concentration of each antigen was determined as 
described in section 3.14.1.  
Half of a Maxisorp plate was coated with HRSV infected HeLa cell lysate and the other 
half with uninfected HeLa cell lysate at the concentration of 20 µg/ml in BCB and 
incubated overnight at 4 °C. Mab1A12 was serially diluted twofold on each antigen and 
direct ELISA was carried out as described in section 3.11.6 with GAMPx as the 
secondary antibody. The assay was carried out in duplicate. The optical densities from 
the binding of antibody to HRSV antigen was corrected by subtraction of binding to the 
uninfected cell control and the results are shown in Figure 71. 
The corrected optical densities plateaued from dilution 1/4000. Thus, a 1/2000 dilution 
within the plateau region was fixed as the optimal concentration for Mab1A12 in 
ELISA.  
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Figure 71 Optimization of Mab1A12 on a direct A2 ELISA. 
8.3 A2 antigen concentration optimization 
HRSV antigen and uninfected cell lysate (section 8.2) were titrated in parallel in 
duplicate in 50µl/well of BCB and uninfected cell lysate was titrated in parallel in a 
Maxisorp plate followed by overnight incubation at 4°C. Direct ELISA was carried out 
as described in section 3.11.6 with 1A12 and GAMPx as the primary and secondary 
antibody respectively. 1A12 was diluted 1/2000 in PTF as optimized in section 8.2. The 
optical densities resulting  from the binding of antibody to HRSV antigen were 
corrected by subtracting the binding to the uninfected HeLa cell lysate at the equivalent 
concentration and the results are shown in Figure 72. The corrected optical density 
plateaued from 1/256 dilution and dropped thereafter. The optimal antigen coating 
concentration should fall within the plateau and was fixed at 1/200 corresponding to a 
coating concentration of 50 µg/ml total protein. 
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Figure 72 Optimization of A2/HeLa coating concentration. 
8.4 IgA Controls 
In order to screen for IgA in infants’ sera, a known anti-HRSV IgA is required as 
control. Anti-HRSV IgA can be found in colostrum and expressed breast milk, serum 
and nasal secretions (Mark Fishaut et al., 1981; Nandapalan et al., 1987; Yamazaki et 
al., 1994; de Alarcon et al., 2001) but in this section, NPS collected for virus isolation 
during the 2008/2009 epidemic was chosen due to its availability. 
Half of a Maxisorp plate was coated with 50 µg/ml of HRSV infected HeLa antigen 
prepared in section 8.2 and the other half with the equivalent concentration of 
uninfected HeLa cell antigen as described in. section 3.11.6.  
Due to the unknown quantity of nasal secretions and the dilution factor (in Hank’s 
balanced salt solution) in the NPS, a 2-fold dilution in PTF was chosen for the test. 50 
µl of the diluted NPS was overlayed onto antigen coated plate as the primary antibody 
and direct ELISA was carried out as described in section 3.11.6 with RAHAPx as the 
secondary antibody. The optical densities obtained for antibody binding to HRSV 
antigen were corrected by subtraction of binding at equivalent dilutions to uninfected 
HeLa antigen and the results are shown in Figure 73. Mab1A12 was used together with 
GAMPx as a positive control and PTF was used in place of the primary antibody as a 
background control. 
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Figure 73 Immunoglobulin A in selected NPSs collected from 2008/2009 HRSV 
epidemic.  
Among 8 selected NPSs screened for IgA, only one NPS (1309) yielded IgA titer 
comparable to Mab1A12. Two NPSs namely 2609 and 3609 yielded moderate IgA titer 
about half compared to Mab1A12. The rest of the NPSs only yielded mild IgA response 
with the corrected OD less than 0.5 with three of them (1509, 2309 and 2509) less than 
0.1. 
Thus NPS 1309 was selected as high IgA positive control, 2609 as medium IgA control 
and 2309 and 1509 as negative IgA control.  
8.5 Specificity of RAHAPx 
As IgA does not cross the placenta, the specificity of the anti-HRSV IgA assay in the 
presence of anti-HRSV IgG can be tested by assaying cord bloods simultaneously for 
IgA and IgG anti-HRSV antibodies. As IgA specific assay should prove negative 
despite the presence of high titer IgG maternal antibody in the cord blood. 
Two Maxisorp plates were coated with HRSV and uninfected HeLa cell antigens as 
described in section 8.4. Sixteen cord bloods (see section 3.9.1) were diluted 1/40 in 
PTF, assayed in duplicate and used as the primary antibody. Direct ELISA was carried 
out with peroxidase conjugated anti-human IgG (RAHGPx) on one and peroxidase  
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conjugated anti-human IgA (RAHAPx) on the second plate as the secondary antibody. 
NPS1309 (1/2) (section 8.4), PTF and Mab1A12 was included as controls and treated 
the same as the cord blood except that the secondary antibody for Mab1A12 was 
replaced with GAMPx. 
The optical densities obtained as a result of binding of antibodies to HRSV were 
corrected by subtracting the binding to the uninfected cell control and the results for 
both assays are summarised in Figure 74. 
 
Figure 74 Direct ELISA on cord blood with RAHGPx and RAHAPx 
All cord blood exhibited IgG reactivity with the mean corrected optical density between 
0.5935 to 3.134 while IgA reactivity was indistinguishable from the background 
generated with PTF. NPS1309 gave a corrected optical density of about 3 with both 
RAHPx and PAHAPx showing the presence of both IgA and IgG at equivalent levels. 
These results indicate that the RAHAPx based assay does not cross-react with IgG but 
is specific to IgA. 
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8.6 Screening for IgA 
Maxisorp plates were coated, half with 50 µg/ml HRSV antigen and the other half with 
the equivalent concentration of uninfected HeLa antigen. Infants’ sera were diluted 1/40 
in PTF and assayed in triplicate and direct IgA ELISA was carried out as described in 
section 3.11.6 with RAHAPx as the secondary antibody. The IgA controls identified in 
section 8.4 were included at 2-fold dilutions in PTF and treated the same as the test sera. 
Primary antibody free PTF was included as a control for background activity of the 
peroxidase. 1A12 together with GAMPx as described in section 8.3 was included as a 
quality control for the HRSV antigen. The optical densities obtained for antibody 
binding to HRSV antigen were corrected by subtraction of binding at equivalent 
dilutions to uninfected HeLa antigen and the results are shown in Figure 75.  
 
Figure 75 IgA titer against HRSV.  
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The corrected optical density for the IgA titer of the sera was plotted against the age 
when the specimen was taken as shown in Figure 75. Serum from infant volunteers 
infected with genotype GA2 and BA4 HRSV are depicted as blue dots and red dots 
respectively. Sera obtained from non-HRSV infected infant volunteers are depicted as 
black square boxes. The mean corrected optical densities ranged from -0.069 to 1.510. 
Negative values are due to higher optical densities to the uninfected HeLa cell control 
and regarded as zero. In a similar assay reported by Weaver et al.,(1991), a cut off value 
of >0.1 was chosen as indicative of prior HRSV infection and was adopted in this study. 
30% (6 of 20) of the controls, 25% (1 of 4) of GA2 infected and 14% (2 of 14) of BA4 
infected infants were concluded to have mounted an immune response to HRSV and 
were excluded from the study.  
 
 
 181 
 
Chapter 9 Measurement of maternal antibody  
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9.1 Introduction 
The measurement of maternal antibody to the G and F glycoproteins in infants’ sera is 
described in this chapter. This is to test the hypothesis that genotype specific anti-G 
antibodies are protective and that infants hospitalised with severe HRSV infection lack 
genotype specific antibodies to the G glycoprotein of the infecting genotype. 
HRSV infected infants under six months of age and admitted onto the children’s wards 
of the Newcastle upon Tyne Royal Victoria Infirmary and Newcastle General Hospital 
were recruited between December 2009  and April 2010. Within 24 hours of recruitment 
a nasopharyngeal secretion and blood sample were collected from each infant. In order 
to allow a paired analysis of serum antibody levels, for each recruited HRSV infected, 
index child, it was initially proposed to recruit and collect serum from an aged-matched 
uninfected comparison infant, sampled in the same week. Recruitment of uninfected 
hospitalised infants within the target age group, however, proved more difficult than 
anticipated and matched pairs were not  achieved. Only infants negative for serum anti-
HRSV IgA antibodies as described in section 8.6 were entered into the study.   
9.2 Measurement of antibody to GA2F 
Sera were diluted 1/40 in PTF (section 6.2.4) for all ELISA assays. ConA was coated 
onto Maxisorp plates except for 18 wells reserved for controls. Half of each plate was 
loaded with GA2F antigen and the other half with an equal concentration of Bgal 
antigen. ELISA procedures were carried out in triplicate as described in section 3.11.7 
with IgA free sera from infant volunteers (section 8.6) as the primary antibody and 
RAHGPx as the secondary antibody. To monitor the binding of ConA and antigens to 
Maxisorp plates, three ConA coated wells each were loaded with HRSV antigen, 
uninfected Hela control antigen, GA2F and Bgal control. These were stained with anti-
HRSV Mab 1A12 followed by GAMPx as the primary and secondary antibody. These 
controls should give the corrected optical densities of >3.0. Six antigen free wells were 
loaded with PTF as the surrogate for the primary antibody and stained with RAHGPx 
and GAMPx to test the non-specific binding of the peroxidise conjugates to ConA. 
The optical densities resulting from the binding of antibodies to GA2F (antibody ODs) 
were corrected by subtraction of the optical densities resulting from the binding to Bgal 
antigen at an equivalent concentration and the results are shown in Figure 76. 
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The coating of ConA on the Maxisorp plate and the capture of GA2F and HRSV 
antigens were optimal judging by the corrected optical densities of >3.0 as shown in 
Figure 77. There was no evidence suggesting non-specific binding of either of the 
peroxidase conjugates to ConA as both gave no measurable optical densities. 
Due to the the absence of age matched comparison infants for the HRSV infected 
infants, a decay curve of the mean corrected antibody ODs of the comparison infant sera 
was fitted as described in section 3.22 using a non-linear regression model to predict the 
theoretical corrected antibody ODs of age matched comparison infants by extrapolation. 
The antibody ODs to the GA2F antigen showed an estimated half life of 40 days (Figure 
76). For each HRSV infected infant the actual OD was compared with the predicted OD 
from the comparison infants decay curve for the child of that age and tested for 
significance by paired t test. All but three of the antibody ODs for the infected infants 
exceeded the predicted antibody ODs for an uninfected infant of their age . Overall the 
actual HRSV infected infant antibody ODs exceeded the predicted uninfected infant 
ODs by a mean of about 1.8 fold. This difference was statistically significant (p<0.006). 
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Figure 76 Maternal IgG to GA2F in infants plotted against their age.  
 
Figure 77 Corrected optical densities for the controls for the measurement of 
antibodies against GA2F 
  
Age (day)
0 20 40 60 80 100 120 140
Co
rr
ec
te
d 
O
D
49
2n
m
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Control
GA2 infected
BA4 infected
Controls
PTF
/RA
HGP
x
PTF
/GA
MP
x
HRS
V/1A
12/G
AM
Px
GA2
F/1A
12/G
AM
Px
Co
rr
e
ct
e
d 
OD
49
2n
m
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
 185 
 
Two comparison infant outliers were present in Figure 76. To study the effect of outliers 
(see arrows in Figure 76) to the halflife of antibody ODs, a separate decay curve was 
generated with outlier day 48, 127 or both deleted (Figure 78). The deletion of outlier 
day 48, 127 and both altered the predicted antibody ODs at birth to 2.43, 2.44 and 2.50 
respectively by extrapolation. Based on the antibody OD at birth, the deletion of outlier 
day 48, 127 and both reduce the halflife of the antibody ODs to 33, 34 and 28 days 
respectively. The latter is similar to the estimated halflife of the antibody ODs to the G 
glycoproteins estimated in sections 9.3 and 9.4 (below). A paired t test comparing the 
ODs every 20 days of age from birth to 120 days of age showed that the deletion of any 
one or both of the outliers did not produce a decay curve which is significantly different 
(p>0.01) from the decay curve without the omission of outliers. Thus, these outliers 
were not excluded from the analysis. 
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Figure 78 Effect of the deletion of outlier age day 48, 127 and both on the decay 
curve in the control sera.   
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9.3 Measurement of antibodies to GA2G 
GA2G and Bgal antigens were captured onto ConA coated plate and ELISA was carried 
out as described in section 3.11.7 with infants sera (sections 8.6 and 9.2) and RAHGPx 
as the primary and secondary antibodies. Controls were similar to those used in section 
9.2 but HRSV and GA2G and their corresponding control antigens were stained with 
Mab anti-HRSV G 133 and GAMPx as the primary antibody and secondary antibody 
respectively. 
The optical densities resulting from binding of antibodies to GA2G (antibody ODs) 
were corrected by subtraction of the optical densities to Bgal antigen and the results are 
shown in Figure 79. The decay curve for the comparison group of infants was fitted as 
for GA2F in section 9.2 and is displayed in the same figure. 
Neither conjugates showed any evidence of non-specific binding to ConA while HRSV 
and GA2G antigen showed optimal binding of ConA and antigens judging by the mean 
corrected ODs of 3.0 and 2.8 respectively (Figure 80). 
The half-life of the antibody OD to GA2G in the comparison group was estimated to be 
28.8 days from the decay curve. All three GA2 infected infants showed an antibody OD 
higher than the decay curve while 11/12 BAG infected infants showed antibody ODs 
higher than the decay curve despite not having been infected with a subgroup A virus. 
The mean antibody ODs of GA2G and BAG infected infants taken together were 1.4 
fold higher than the mean predicted OD from the decay curve for children of the same 
age. Due to the low degrees of freedom from GA2 infected infants, the antibody ODs 
from both GA2 and BA4 infected infants were taken together and compared to the 
predicted antibody ODs for uninfected infants of the same age  and the difference was 
statistically significant (p=0.001). 
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Figure 79 Maternal IgG to GA2G in infants plotted against their age. 
 
Figure 80 Corrected optical densities for the controls for the measurement of 
antibodies against GA2G 
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9.4 Measurement of antibodies to BAG 
BAG and Bgal antigen was captured onto ConA coated plates and ELISA was carried 
out as described in section 9.3. The decay curve for the comparison group infants was 
fitted as described in section 3.22. 
When the infant’s sera were assayed on captured BAG as shown in Figure 81, very 
similar results were obtained as when assayed on captured GA2G as described above 
(Figure 79). 
The conjugates did not show any evidence of non-specific binding while the antigen 
capture with HRSV and BAG yielded corrected optical densities of 3.1 and 3.0 showing 
optimal coating of ConA and efficient capture of antigens for the assay. 
From the decay curve for the control sera the antibody OD to BAG decayed with a 
halflife of 33 days. All GA2 and 11/12 BA4 infected infants have serum antibodies to 
BAG higher than those predicted for uninfected infants of the same age by the decay 
curve. The mean antibody ODs for GA2 and BA4 infected infants taken together was on 
1.5 fold higher than the predicted antibody ODs from the decay curve and these 
differences were statistically significant (p=0.0001). 
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Figure 81 Maternal IgG to BAG in infants plotted againt their age. 
 
Figure 82 Corrected optical densities for the controls for the measurement of 
antibodies against BAG 
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9.5 GA2G against BAG 
From Figure 79 and Figure 81 antibodies to the G glycoprotein of  the homologous and 
heterologous subgroup seem similar. This was confirmed by plotting binding of 
antibodies to GA2G against binding to BAG for both index and comparison group and 
the results is shown in Figure 83. There was a highly significant linear correlation 
between the antibody ODs of GA2G and that of BAG (R2 = 0.9725).  
  
Figure 83 Antibody ODs of GA2G against BAG 
The good correlation shows that the optical densities of anti-G maternal antibodies to 
both contemporary subgroups/genotypes were similar and there is no evidence here of a 
selective deficiency in antibody to either G lineage tested as initially hypothesised. 
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9.6  Age vs date  of serum collection 
It is not clear why antibody titres in the index group should be uniformly higher than the 
predicted antibody titres in uninfected infants of similar age. One possibility is that 
index and comparison groups are mis-matched. As HRSV circulates in the community 
predominantly in the winter months it is conceivable that antibody levels to a winter 
exposure may fall over the summer and autumn. This may affect the level of maternal 
antibody passed to an infant with babies born late in the year receiving lower levels of 
antibody than those born earlier. If this were the case, mismatch in the time of collection 
of index and control samples might introduce errors into the above analysis.  
To test how the age distribution of volunteers varies with the date of collection, the age 
of both control and infected infants were individually plotted against the date of 
collection and displayed in Figure 84 and the R2 values were calculated in Microsoft 
Excel 2007. 
The age of control and infected infants recruited throughout the epidemic did not 
correlate with the date of collection, (R2 values of <0.1) showing no significant  bias of 
age with date of recruitment in either group. Never-the-less, early in the epidemic the 
index cases were mainly young infants. This would tend to bias the index cases to 
higher antibody levels than the decay curve for the controls. Further, 9 of 16 controls 
were collected after the last index case was collected (Figure 84). This would probably 
give a low estimate for the antibody levels in the control babies as they were collected 
further in time from the previous winter epidemic when the mother may have been 
infected. This mismatching of the comparison group may, at least in part, contribute to 
an underestimate of predicted antibody levels. 
  
 193 
 
 
Co
m
pa
ris
o
n
 
gr
o
u
p 
in
fa
n
ts
 
 
In
de
x
 
in
fa
n
ts
 
 
Figure 84 Age of infant against date of collection. 
The red line in the control infants’ scatterplot indicates the date where the last index 
infant was recruited.  
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9.7 F/G ratio 
As antibody levels in infant sera may vary not only as a result of differences in maternal 
immunity but with both age at collection and time of post-maternal exposure it is 
important to seek an assessment of anti-G antibody independent of the two latter 
variables. If it is assumed that antibody to the F glycoprotein will vary with regard to 
these two variables in parallel with anti-G antibody, the ratio of anti-F to anti-G should 
provide  such a measure. As the F glycoprotein is largely conserved and antibody to the 
F glycoprotein, at least following primary infection,  does not vary with the infecting 
strain (McGill et al, 2004b), a high anti-F:anti-G ratio  measured on the infecting virus 
genotype will indicate a relative deficiency of genotype specific antibody to the 
infecting virus. 
As demonstrated above, the half-lives of anti-F and anti-G antibodies in these infants 
were similar. To test if the the anti F/G ratio was independent of the age of the infant , 
the ratio of antibody ODs resulting from binding to the F glycoprotein to  antibody ODs 
resulting from binding to the GA2G were plotted against the respective age of the 
infants. Only IgA free comparison group infants and infected infants were included and 
both groups were taken together for the analysis. This analysis was repeated for F/BAG 
and the representative scatterplots are shown in Figure 85. 
As expected the F/G ratio did not correlate with the age of the infants (R2 =0.005). 
Similar analysis was carried out by plotting the F/G ratios to the date of collection 
(Figure 86) it was found that the F/G ratio for both F/GA2G and F/BAG did not 
correlate with the time of specimen collection across the epidemic (R2 < 0.02). 
To test if the F/G ratio of the control group differs from the infected group, paired t test 
was performed on the F/BAG ratios. The results suggested that there were no 
significance difference between the F/G ratio of the control group and the infected 
group with the (p<0.05, 2-tailed). This does not support the hypothesis under test which 
predicts that the F/G ratio would be higher in the uninfected comparison group than in 
the infected group. Nevertheless, the sample size is small (n=15 for the infected group, 
n=13 for the comparison group).  
 
 
 195 
 
 
 
Figure 85 The antibody ODs of F/G ratio against the age of the infant volunteers. 
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Figure 86 The antibody ODs of F/G ratio against the date of collection of the infant 
volunteers. 
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Chapter 10 Discussion 
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10.1 Molecular epidemiology 
10.1.1 Virus isolation 
The first aim of this project (Aim I) was to establish the molecular epidemiology of 
HRSV over the three consecutive epidemics studied, and to accurately define the 
contemporary genotypes. The first step was to obtain respiratory specimens in the form 
of NPSs and NSs for virus isolation in HeLa tubes. 
The isolation rate for HRSV shows a reduction over the three seasons as shown in 
Figure 87. The interpretation of the rate of isolation must start with the specimen history. 
In the 2007/2008 and 2008/2009 epidemics, only NPSs positive by immunofluorescence 
to HRSV by the HPA, Newcastle were used for isolation. NPS are preferred over NS in 
the isolation of HRSV offering significantly increased sensitivity (Ahluwalia et al., 
1987; Masters et al., 1987; T. Heikkinen et al., 2002). This would explain the higher 
isolation rate for the first two epidemics compared to the third where mainly NS were 
collected (see Figure 87). The drop from first to second year remains unexplained. 
Although the isolation rate was high, at least in the first year, it did not achieve 100% 
probably for several reasons. Firstly, isolation was attempted only after the results of IF 
were made available by the HPA. This meant, in some cases, a delay of several days 
before inoculation of cell cultures during which time the specimen was held at 4°C. 
Secondly, specimens were stored at ambient temperature in the ward before being sent 
to the HPA for diagnosis bearing in mind that wards are well heated during winter. Thus 
the specimens spent a significant amount of time at a temperature range which is not 
conducive to the viability of HRSV. This does not take into consideration the amount of 
time the specimens were left at ambient temperature in the HPA before and after the 
diagnostic protocol was carried out before storage at 4°C. Finally, the specimens were 
diluted without any standard dilution factor. Low volume NPSs were often resuspended 
in HBSS to make up the volume for isolation. 
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Figure 87 Isolation rate of HRSV over 3 epidemics  
In the 2009/2010 epidemic, there was a major policy change in the HPA in dealing with 
specimens and in many cases, NPS were not readily available and freshly collected NS 
were used for virus isolation. The sensitivity of virus isolation is lesser with NS 
compared to NPS. However, the utilization of a more sensitive diagnostic assay can 
make up for the use of a less sensitive specimen (Meerhoff et al., 2010)  and 
approximately 60% of NS negative for HRSV isolation were positive by nested or 
heminested RT-PCR.  
10.1.2 Prevalence 
The RT-PCR amplification and sequencing of the C-terminal end of HRSV G gene and 
subsequent phylogenetic analysis has been widely used to determine the circulating 
virus genotypes (Patricia A. Cane et al., 1992). Although the use of complete G 
sequence for the construction of phylogenetic trees can improve the bootstrap value  the 
nodes and  allow  the definition of HRSV variants with different G gene length, analysis 
of partial gene sequences was chosen here for reasons of economy and speed. . 
In this study revealed a predominance of subgroup A in the 2007/2008 and 2008/2009 
epidemics while the subsequent epidemic was dominated by subgroup B HRSV. It was 
not surprising that subgroup A predominated for two of three epidemics in Newcastle as 
previous reports have shown the tendency of subgroup A to predominate more 
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frequently than subgroup B HRSV. For example, relatively recently subgroup A viruses 
predominated in 7 of 9 epidemics in Germany (Reiche and Schweiger, 2009), 5 of 8 
epidemics in Belgium (Zlateva et al., 2007) and 4 of 6 epidemics in Argentina (Viegas 
and Mistchenko, 2005). 
The subsequent phylogenetic analysis revealed the appearance of three co-circulating 
genotypes namely GA2, GA5 and BA4. In the first two epidemics GA2 was the 
predominant genotype with GA5 and BA4 as the minor genotypes. The epidemic 
2009/2010 showed a shift of the predominant group to BA4. In this epidemic, only GA2 
co-circulates as the minor genotype while GA5 was not detected at all. 
Neither GA2 nor GA5 are new in Newcastle upon Tyne having been previously 
reported in 1995-1997 by our group (A. McGill et al., 2004a) although the number of 
representatives for genotype GA2 was low. A stable co-circulation of these two 
genotypes in the western European continent over many epidemics has previously been 
described. Co-circulation of GA2 and GA5 was reported in Germany from 1998-2007 
with GA5 predominating in every epidemic (Reiche and Schweiger, 2009) and in 
Belgium from 1998-2006 where GA5 predominated in 7 of 10 epidemics (Zlateva et al., 
2007). Nevertheless, the prevalence of both GA2 and GA5 in Newcastle upon Tyne 
during the study period showed gradual decrease over time with the possible extinction 
of GA5 in 2009/2010. A similar phenomenon was reported in Ireland (Salter et al., 
2011), Edinburgh (Gaunt et al., 2011) and Japan (Nakamura et al., 2009; Goto-Sugai et 
al., 2010; Fujitsuka et al., 2011). 
Previously identified genotypes of subgroup A in Newcastle upon Tyne (A. McGill et 
al., 2004a) namely the GA1, GA3, GA7 and SAA1 were not detected over these three 
epidemics suggesting the absence from this continent although GA7 appeared in 
1999/2000 and 2002/2003 in Germany (Reiche and Schweiger, 2009). 
There was no other circulating subgroup B genotype detected over the three epidemics 
other than genotype BA which carries a distinctive 60 nucleotide insertion at the C 
terminus of the G gene (Trento et al., 2003). This observation is similar to those 
reported in Argentina, India, South Afrika and Japan whereby all other prevailing 
genotype from subgroup B HRSV was completely replaced by BA viruses (Parveen et 
al., 2006; Trento et al., 2006; Nakamura et al., 2009; Dapat et al., 2010; Goto-Sugai et 
al., 2010; Fujitsuka et al., 2011; van Niekerk and Venter, 2011) suggesting an 
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undefined selective advantage of genotype BA over other subgroup B genotypes. 
However, genotype GB2 and GB3 were still detected in China during the 2008/2009 
epidemic (Rong-Fang Zhang et al., 2010a; Zhi-yong Zhang et al., 2010b). 
BA viruses were initially found to form four distinct clades namely BA1 to BA4 
(Trento et al., 2006) but 6 new clades namely BA5 to BA10 have recently been 
described (Dapat et al., 2010). Genotype BA from Newcastle upon Tyne over the three 
consecutive epidemics was made up from a single clade BA4 which has been reported 
in Ireland, Edinburgh, Thailand, Argentina and Madrid where other earlier BA clades 
had been replaced by clade BA4 (Boonyasuppayakorn et al., 2010; Trento et al., 2010; 
Salter et al., 2011).  
10.2 Recombinant protein expression 
Sera for assessing anti-G antibody levels were collected from infants only in the 
2009/2010 epidemic when the prevalent genotypes  were GA2 and BA4. In order to 
develop an ELISA assay to measure the maternal antibodies to the G glycoproteins in 
these sera (refer to Aim II), the G glycoproteins of representative strains of both 
genotypes GA2 and BA4 were cloned and expressed in MVA under the control of the 
vaccinia virus p7.5 promoter.  In order to measure antibodies to the F glycoprotein, as 
the F glycoprotein is largely antigenically conserved, the F gene of only the GA2 strain 
was expressed likewise.  
Recombinant F and/or G glycoproteins of HRSV have been successfully expressed in 
the vaccinia virus expression system to high level and the expressed glycoproteins were 
shown to be highly immunogenic and antigenic in rodents (Elango et al., 1986; R A  
Olmsted et al., 1986; Stott et al., 1986; G W Wertz et al., 1987), monkeys (Robert A. 
Olmsted et al., 1988)  and chimpanzees (Crowe et al., 1993). The immunization of mice 
with recombinant G glycoprotein induces virus specific CD4+ T cell responses which 
involve both Th1 and Th2 (Teresa R. Johnson et al., 1998; Varga et al., 2000) and 
confers protection in the lungs shown by a significant reduction in the virus titers 
following subsequent intranasal challenge with the homologous HRSV strain (Wayne 
M. Sullender et al., 1990), a phenomenon which was also demonstrated in chimpanzees 
(Peter L. Collins et al., 1990). Immunization of cotton rats with recombinant F 
glycoproteins also induced high levels of serum neutralizing antibodies which was 2-3 
fold higher compared to those induced by HRSV infection (R A  Olmsted et al., 1986). 
Recombinant F and G glycoproteins expressed in MVA was shown to be highly 
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immunogenic in mice (Wyatt et al., 2000) and protected mice from HRSV challenge 
post immunization (Olszewska et al., 2004) but experimental work in macaques failed 
to show any protection upon challenge with HRSV four months after vaccination (de 
Waal et al., 2004). 
The recombinant F and G glycoproteins expressed from recombinant vaccinia virus 
were shown to be indistinguishable from the authentic HRSV glycoproteins in terms of 
glycosylation, disulphide linkage, electrophoretic mobility, cell surface expression and 
antigenic specificity (Ball et al., 1986; Elango et al., 1986; R A  Olmsted et al., 1986). 
Further characterization of the expressed G and F via western blotting would definitely 
be helpful in providing valuable information regarding the molecular weight and the 
glycosylation of the respective glycoproteins.  
Interestingly, in the current study the expression of the recombinant fusion glycoprotein 
of HRSV genotype GA2 in MVA showed rapid syncytia formation in HeLa cells, a 
phenomenon not seen during expression in CV-1 and Hep-2 cells of fusion glycoprotein 
of prototype strain A2 in WR vaccinia virus although in both cases expression was 
controlled under the p7.5 vaccinia virus promoter (R A  Olmsted et al., 1986). This 
apparent discrepancy may be attributed to the masking effect of the vigorous CPE on 
the cells of vaccinia virus infection compared to the more attenuated MVA. The 
formation of syncytia by recombinant HRSV fusion glycoprotein was observed in 
recombinant vesicular somatitis virus propagated in BHK cells (Kahn et al., 1999) and 
Simian virus 40 (SV40)/monkey cells (R A  Olmsted et al., 1986). However, none have 
reported the observation of syncytia as rapid as 1 hour p.i. Furthermore, other authors 
expressing recombinant F glycoproteins in MVA did not report the occurrence of 
syncytia in cell culture (Wyatt et al., 2000; Olszewska et al., 2004).  
F glycoprotein expression was regulated by the p7.5 promoter, which is active 
throughout the life cycle of MVA. The early stage genes of vaccinia virus in HeLa cells 
can be detected 20 min p.i. and peak around 100 min p.i. before declining with the half 
life of 30 min (Baldick and Moss, 1993). Commensurate with this F glycoprotein, 
although undetectable immediately after inoculation, was demonstrable in cells infected 
with recombinant MVA one hour post infection supporting the observation that the 
formation of syncytia at approximately 1 hour p.i. is attributable to the newly 
synthesised recombinant F. 
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10.3 Concanavalin A captured ELISA 
The ConA capture ELISA was adopted to capture the expressed fusion and attachment 
glycoproteins without prior purification (Aim III). The capture of the F and G 
glycoproteins of HRSV strain A2 expressed in vaccinia virus under the control of 
bacteriophage T7 RNA polymerase promoter has previously been reported (M. J. 
Robinson, 2007). Coating of ConA onto Maxisorp plates at high pH in BCB in the latter 
study was found to be suboptimal (section 6.2.3) and this problem was solved by 
coating ConA at physiological pH. 
Each subunit of ConA binds one molecule of saccharide with the greatest affinity to the 
non-reducing ends of α-linked mannose residues and their glycosides in α-anomeric 
form (Goldstein et al., 1965). ConA exists in three forms namely monomeric, dimeric 
and tetrameric. The monomeric form is approximately 26-27kDa and forms a dimer at 
pH5 (Abe et al., 1971), a tetramer at physiological pH and undergoes irreversible 
denaturation at pH above 8 at room temperature (Pflumm et al., 1971). The ability to 
bind saccharides reduces from tetrameric>dimeric> monomeric form (Wang and 
Edelman, 1978; Ishii et al., 1984). Thus, the coating of ConA at pH 9.6 would be 
expected to have a detrimental effect on ConA binding while coating at pH7.4 allows 
the formation of the most potent tetrameric form.       
10.4 Epitope mapping 
Having established a method suitable for the assay of antibodies to the individual 
glycoproteins of the infecting virus strains it remained to attempt differentiation of 
antibody to the conserved G epitopes from variable epitopes (Aim III). To facilitate the 
design of a serologic tool for the measurement of maternal antibodies directed against 
conserved epitopes it was decided to map the epitopes recognised by the cross-reactive 
monoclonal antibodies 133 and 21 in the hope that an immunogen capable of 
recognising exclusively cross-reactive antibodies could be constructed. . 
The antigenic map of the G glycoprotein has been previously mapped, by competitive 
ELISA with 19 Mabs raised against the Long strain, into 9 antigenic areas namely 
antigenic areas I to IX with area VI, VII, VIII and IX showing the greatest degree of 
overlap (B Garcia-Barreno et al., 1989). Further work using another set of Mabs raised 
against HRSV strain Mon/3/88 tested on subgroup A and B HRSV by western blot 
revealed three distinct patterns. Two Mabs, which reacted with both subgroups A and B, 
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identified conserved epitopes of the G glycoprotein. Seven Mabs reacted with only 
subgroup A but not subgroup B viruses and identified subgroup A specific epitopes. 
The remaining ten Mabs reacted with some viruses from subgroup A but not other 
strains from a different genotype and identified strain specific epitopes (I. Martinez et 
al., 1997). Walsh and co-workers (1989) were also able to differentiate 5 subgroup A 
specific epitopes, 11 subgroup B specific epitopes and 3 conserved epitopes. Two of 
their three Mabs to the conserved epitope namely K6 and L9 have been further mapped 
within residue aa162-172 and 151-172 respectively (Murata et al., 2010). These 
observations suggest that the epitopes of specific antigenicity clusters within certain 
defined regions which can be defined and that the conserved epitopes overlap the 
conserved 13 amino acid sequence between residues 164 and 177. 
The initial assumption that the Mabs to the conserved epitope (Mab133 and Mab21) 
would bind the highly conserved 13aa sequence was not supported when tested by 
peptide ELISA. It appears that these antibodies either bind to shorter runs of conserved 
amino acids embedded within the variable regions of the molecule or that binding to the 
conserved central region is dependent upon interaction of that region with other  regions 
of the polypeptide chain or the sugar molecules, which make up the bulk of the mass of 
the mature glucoprotein. Palomo et al., (1991) have shown that epitope binding of most 
G specific Mabs are glycosylation dependent binding strongly to the mature G 
glycoprotein but to a lesser extend the O-glycosylated species and the unglycosylated 
precursor. One of their Mabs bound to N-glycosylated intermediates but not an O-
glycosylated intermediates suggesting an unique glycosylation requirement for each 
epitope. In addition to this (Rawling and Melero, 2007) have shown that anti-lectin and 
carbohydrate Mabs are common and have been used extensively to study the 
glycosylation of proteins.  
To study the effect of glycosylation on the binding of the Mabs to the conserved epitope, 
a glycosylation inhibitor, tunicamycin was used to inhibit N-glycosylation of HRSV 
propagated in HeLa cells. Tunicamycin enters the HRSV infected cells via a putative 
plasma membrane transporter known as MFSD2A (Reiling et al., 2011) and inhibits the 
first step in the lipid linked oligosaccharide pathway which produces GlcNAc-
pyrophosphoryldolichol (Heifetz et al., 1979) essential in the addition of N-linked sugar 
side chains. The effect of tunicamycin is not efficient as its effect is dose dependent and 
it also induces endoplasmic reticulum (ER) stress which leads to cell toxicity and death 
(Reiling et al., 2011) which can be observed as the rounding up of cells under a 
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microscope. Tunicamycin treated HRSV infected cells yielded three extra bands not 
found in tunicamycin free virus culture The size of the bands was approximately 36, 33 
and 32 kDa. The 36 kDa band corresponded to the electrophoretic mobility of 
unglycosylated Gm in SDS PAGE (Gail W. Wertz et al., 1985; Roberts et al., 1994). 
Although the predicted length of unglycosylated Gm is 32kDa.  the high proline content 
is thought to contribute to the slower electrophoretic mobility in SDS-PAGE (G. W. 
Wertz et al., 1989). This suggests that tunicamycin induced ER stress also affects O-
glycosylation in the Golgi apparatus. The 32kDa band corresponded to the 
electrophoretic mobility of Gs (Roberts et al., 1994). The 33kDa band probably 
corresponded to the translational product from the second AUG start codon at Met48. 
Visualization of these bands by MAbs 133 and 21 in Western blots suggests that the 
binding of Mab133 and Mab21 is not dependent on either O-glycosylation nor N-
glycosylation and that the antibodies bind the peptide backbone of the G glycoprotein.  
Further mapping of the binding sites of two cross-reactive (Mab133 and 21) together 
with two A2 strain specific (Mab4G4 and 3F43) and one subgroup A specific 
monoclonal antibodies (Mab1C2) was attempted. The first method of mapping 
attempted involved additive binding ELISA to study the relationship of the epitopes of 
each monoclonal antibody. Previously the mapping of epitopes on the G glycoprotein 
was conducted by a similar method using competitive ELISA (Palomo et al., 1991) 
which requires the labelling of the monoclonal with a large reporter protein such as 
biotin which can potentially alter the binding of some Mabs (Edward E. Walsh et al., 
1989). Palomo et al, (1991) have shown that sera from covalescent human failed to 
block the binding of the majority of the murine monoclonal antibodies in competive 
ELISA suggesting that the immunodominant epitopes involved in the murine system 
might be irrelevant in the natural infection in humans. Walsh et al., (1989) on the other 
hand carried out competitive ELISA with murine Mabs with and without conjugation 
with biotin as a reporter molecule and found out that biotinylation changed the binding 
of some of the Mabs while three Mabs failed to be biotinylated. Similar inactivation of 
antibodies by peroxidase labelling has also been reported (B Garcia-Barreno et al., 
1989).  In additive binding ELISA the antibodies are unlabeled retaining their native 
specificity and avidity for the corresponding epitope. The results of the additive binding 
ELISA presented here suggest that the conserved epitopes recognised by Mab133 and 
Mab21 cluster closely to both subgroup specific and strain specific epitope recognised 
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by Mab1C2 and Mab4G4 respectively but are distinct from the strain specific epitope of 
Mab3F43.  
In the second method of epitope mapping the G gene of HSRV GA7 was progressively 
truncated from both -3’ and -5’ end and the truncated fragments were transiently 
expressed in HeLa cells and screened by immunofluorescence assay to refine the 
location of the epitopes.  
Using this approach the epitope of Mab1C2 (subgroup A specific) was mapped within 
residue aa158-190. This agrees with the previous observation of Mekseepralard et al., 
(2006a) who demonstrated that this Mab bound to a BSA conjugated peptide 
corresponding to aa172-187, a subgroup A conserved epitope which overlaps the N-
terminus of the wholley conserved region of the G polypeptide. The vaccination of 
peptide corresponding to aa174-187, a subgroup A conserved epitope, induced 
protective immunity in rodents when challenged with HRSV from the same subgroup 
but the antibody to this epitope is non-neutralizing in vitro (Trudel et al., 1991; Simard 
et al., 1997). In addition to this, Mab1C2 also confers passive immunity when 
administered prophylactically (Mekseepralard et al., 2006b). 
MAb 4G4 has previously been reported as strain specific for the sub-group A2 strain of 
HRSV (Morgan et al., (1987). However, the reactivity of Mab4G4 to GA7G in this 
study contradicts that finding. The authors screened Mab4G4 on untyped HRSV strains 
isolated from 1965-1986 by western blot which may not have included the GA7 
genotype. The results presented here also contradict McGill et al., (2005) who showed 
no binding of Mab4G4 to HRSV genotype GA7 in a Biacore assay. The authors used 
strain 17063 compared to 25173 (refer to Figure 22) used in my experiment but these 
two strains clustered together within the GA7 clade supported with a bootstrap value of 
99%. However, the 99% identity refers to the C-terminus end distal to the binding site 
of Mab4G4 which is within the central unglycosylated region. It appears, therefore, that 
4G4 binds to only a restricted number of sub-group A strains. The epitope for Mab4G4 
is currently unknown but here mapped within aa155-173. Within this sequence, N-
terminal residues 164 to 173 resides are the 13 aa conserved sequence and their removal 
ablated binding. The only variable residue in the 4G4 epitope capable of conferring 
strain specificity is residue 157 which is either a serine or asparagines. The alignment of 
aa155-177 (Table 22) of strain A2 and GA7 revealed that amino acid at position 157 is 
a serine and asparagine respectively. Both serine and asparagines are amino acids with 
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polar uncharged side chains and probably the differences in experimental setting have 
contributed to these observations.    
Table 22 Amino acid sequence alignment between nucleotide 155-177 of strain A2 
and GA7 
Genotype (Strain) Amino acid sequence (155-177) 
GA1 (A2) PPSKPNNDFHFEVFNFVPCSIC 
GA7 (25173) PPNKPNNDFHFEVFNFVPCSIC 
Amino acid 157 is in bold and underlined.  
The truncation experiments suggest that the epitopes of Mab133 and Mab21 map to 
aa155-190 within the unglycosylated central core. The deletion of residues 155-158 
ablated binding of Mab133 and severely reduced binding of Mab21 suggesting that at 
least one of these residues contribute to an epitope. The observation that 21 but not 133 
showed low level binding to the 158-284 truncate suggested that there may be some 
differences between the epitopes of the two Mabs. Residue 155 and 156 but not 157 are 
likely to the part of the epitope for 133 because both residue 155 and 156 are both 
prolines which are conserved between subgroups but 157 can be either serine or 
asparagine in subgroup A and is lysine in subgroup B. Deletion of residues 1-177 from 
the C-terminal also ablated the binding of both Mabs showing that residue 177-190 is 
also required for binding. This indicates that these Mabs recognise a complex epitope in 
which these two disparate parts of the polypeptide chain are brought together.  
Thus conserved epitopes overlap with the both strain and subgroup specific epitopes 
suggesting that the distribution of the conserved, subgroup specific and strain specific 
epitopes within the central unglycosylated region are not distinct entities within the 
polypeptide chain as initially suggested by Martinez et al., (1997). This observation 
precludes the manufacture of a synthetic antigen corresponding specifically to the 
conserved epitopes of G and failing to react with either subgroup cross-reactive or strain 
specific antibodies which was the aim of this project (Aim III).  
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10.5 Volunteers recruitment 
The study of the protective role of maternal antibodies in infants against HRSV has 
previously been investigated by the comparison of an infected index group against an 
uninfected comparison group. Researchers have used different criteria for recruitment 
into the comparison group. For example, Brandenburg et al., (1997) have compared 38 
children hospitalized with HRSV disease as the index group with a control group 
consisting of 45 children participating in a Hepatitis B virus vaccination trial which was 
recruited off epidemic to minimize the possibility of HRSV infection. Gimenez et al., 
(1996) compared infants hospitalized with HRSV disease against age and sex matched 
infants either without HRSV infection or protected against severe disease. In the current 
study, two groups of volunteers were recruited (Aim IV). The index group comprising 
infants of less than six months of age with severe HRSV infection requiring 
hospitalization and a comparison  group attending outpatient clinics or hospitalized due 
to reasons other than respiratory disease and with no evidence of prior infection with 
HRSV. Ideally, each index case would be matched for at least one aged and sex 
matched comparison group infant sampled on the same day. Reality fell far short of this 
ideal. Insufficient comparison group infants were identified and pair wise analysis was 
not possible. 
10.6 IgA screening  
All sera were screened for IgA as an indicator for host’s humoral response as maternal 
IgG is indistinguishable from infant’s IgG other than avidity (Meurman et al., 1992). 
Thus in order to eliminate the probability of measuring infant’s IgG from a prior HRSV 
infection, volunteers must be screened for anti-HRSV IgA which does not cross the 
placenta. The presence of serum IgA can result from a genuine humoral response to an 
HRSV infection or from passive uptake of IgA from colostrums (Weaver et al., 1991). 
Although colostral IgA is largely dimeric and serum IgA is largely but not entirely 
monomeric, no literature to date had described methods to differentiate colostral IgA 
from serum IgA. However, Weaver et al., (Weaver et al., 1991) report detection of peak 
titers of anti-HRSV antibody in colostrum fed infants of only 1/16 whilst IgA screening 
in the present study was carried out on sera diluted 1/40. 
The measurement of total IgA to whole HRSV antigen is likely to be sensitive as anti-
HRSV serum IgA (maternal) has been shown to recognise at least the conserved fusion 
glycoprotein and only to a lesser extend the variable G glycoprotein (Yamazaki et al., 
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1994). Whilst Brandenburg et al., (1997) have reported a lower IgA and IgM positive 
percentage of 41%.  Roca et al., (2003) found that 78% of infants infected with RSV 
made a detectable IgA antibody response 1 month after infection. The latter authors 
similarly excluded anti-HRSV IgA positive infants as determined by a membrane 
fluorescence test, from a study of maternal antibody levels. The incidence of prior 
infection in control infants was 12% lower than that in the current study (30%), 
therefore, there is still a possibility that monitoring anti-viral IgA will miss some prior 
infections.  This may account for the infants with exceptionally high IgG antibodies 
which fall as outliers on the decay curve for the comparison group (refer figure 76, 79 
and 81). 
10.7 Analysis 
The infants from both groups should ideally be of the same age at the time of 
recruitment. However, the lack of volunteers did not permit for this ideal to be achieved. 
Thus, two approaches to data analysis were adopted. Firstly, the decay curves for anti-F 
and anti-G antibody in the comparison  group were plotted.  
10.8 Antibody decay 
To study the antibody decay, scatterplots of the antibody ODs against the age of the 
control group were plotted and it was observed that younger infants have higher 
antibody compared to the older infants and the scatterplots mimic the exponential 
decrease shape. A non-linear regression curve was then fitted using the exponential 
decay algorithm as previously applied by Allansmith et al., (1968) and Cloonan et al., 
(1970). The non-linear regression model described here is comparable with the linear 
regression model on a logarithmic scale used by other authors (Cox et al., 1998; Ochola 
et al., 2009). 
The maternal antibodies to the F and G glycoproteins of HRSV in IgA response 
negative comparison infants measured as the antibody ODs show half lives of about 40 
days and 28.8-33 days respectively. The omission of outliers reduces the half life of 
antibody to the fusion glycoprotein to a  mean of 28 days. The half life reported here is 
closer to 21 to 26 days as reported by Brandenburg et al., (1997) and reviewed in 
Collins and Crowe (2001) which suggested that the half life of antibodies to the 
individual glycoproteins are similar to the half life of total antibodies to the whole 
HRSV. However, a much longer mean maternal antibody half life of 79 to 99 days have 
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been reported (Ward et al., 1983; Cox et al., 1998; Ochola et al., 2009). The mean half 
life of the passively acquired maternal antibodies to other viruses ranges from 21 to 80 
days (refer to Table 23) and high variation of half life within (Cloonan et al., 1970) and 
between studies has been reported (Caceres et al., 2000; Shilpi et al., 2009). The titers 
of measles specific maternal antibodies present in German newborns were reported to 
be two-fold higher than in Nigerian newborns (Hartter et al., 2000) suggesting that the 
transfer of maternal antibodies from mother to foetus might be ethnic, demographic or 
continent dependant so that the half life of maternal antibodies of studies conducted 
from countries to countries or among different ethnic groups within countries should be 
interpreted with care.  
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Table 23 The half-life of passively acquired maternal antibodies to various viruses 
in infants. 
N Country Virus Method MatAb 
half-life 
References 
100 
 
Thailand Dengue HI and 
PRNT50 
41 (Watanaveeradej et 
al., 2003) 
69 Itali Influenza  
H1N1 
HI 84.4  (Zuccotti et al., 2010) 
120 Australia Rubella HI 43 
(14-259) 
(Cloonan et al., 1970) 
88 UK Polio PRNT50 21 (Perkins et al., 1958) 
66 USA Polio PRNT50 25 (Gelfand et al., 1960) 
34 USA Measles PRNT50/HI 46.1-60.8 Reviewed in (Caceres 
et al., 2000) 
47 Bangladesh Measles ELISA 35-45 (Shilpi et al., 2009) 
27 Netherlands Varicella
-Zoster  
ELISA 25.5 
(14.6-
76.0) 
(van der Zwet et al., 
2002) 
66 USA hPIV3 HI 51 
(42-60) 
(Min-Shi Lee et al., 
2001) 
HI=Heamagglutination Assay, PRNT50=Plaque reduction neutralization assay 50 
The antibody ODs to the F and G glycoproteins of HRSV were found to be significantly 
higher than the predicted antibody ODs obtained from the corresponding decay curve 
for the control group. This might mean that these HRSV infected infants might have 
mounted their own humoral response against the infecting virus strain by the time of 
testing. Against this, however, it has previously been observed that primary infections 
engender genotype specific anti-G antibody responses (A.  McGill et al., 2004b). If the 
excess of anti-G antibodies were due to responses to the primary infection of the infant 
they would be expected to be type specific for the infecting genotype. This however was 
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not the case here as the anti-BA antibodies to both BAG and GA2G were higher than 
predicted in infants infected with the BA virus.  
The higher antibody ODs of infected infants to the predicted age matched control might 
be taken to indicate that deficiency in strain specific anti-G glycoprotein is not a risk 
factor for the pathogenesis of severe HRSV disease in infants which contradicts the 
findings of other researchers who have found positive correlation of high HRSV 
specific maternal antibodies to protection  in infants (Glezen et al., 1981a; Ogilvie et al., 
1981; Kasel et al., 1987). 
The higher levels of antibody in the index group are, thus, a surprise and may indicate 
that the comparison and index group were not truly comparable. There is some evidence 
that anti-HRSV maternal antibody may fall across the epidemic (Nandapalan et al., 
1986). A lower mean antibody titer in the control group might be produced, therefore, if 
comparison  infants were recruited later in the epidemic than the index group. This 
proved to be the case and it was further noted that the younger index cases tended to be 
recruited earlier in the epidemic. As antibody titers decay exponentially this would tend 
to raise the mean antibody titers of the index group. 
It is noteworthy that Brandenburg et al., (1997) have used a comparison  group recruited 
during off epidemic period about 2-3 years before the recruitment of index group while 
Gimenez et al., (1996) measured HRSV specific antibody from the cord blood while 
assuming that the decay of maternal antibody was a constant as determined by Cloonan 
et al., (1970). As the level of antibody in infant sera is likely to vary with the level of 
immunity of the mother, which may vary with the time of birth post-exposure of the 
mother, and the age of the infant, direct comparisons of mean anti-G glycoprotein 
antibody levels in index and comparison groups are unreliable as a test of the hypothesis 
that the index group are anti-G antibody deficient. However, essentially all mothers 
transfer high levels of strain cross-reactive anti-F glycoprotein antibodies to the infants 
(A.  McGill et al., 2004b). The hypothesis predicts that index infants will be deficient in 
anti-G antibodies specific to the infecting strain. Such a deficiency would be apparent as 
a reduced ratio of anti-G to anti-F antibodies in the index group. This approach depends 
on the assumption that both anti-G and anti-F antibodies decline in infants and in their 
mothers at a similar rate. It has only been possible here to demonstrate approximately 
equal decay rates of anti-F and anti-G antibodies in infants (see above). Thus the ratio of 
anti-G and anti-F antibodies were compared. Anti-F/anti-G ratios were shown to be 
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independent of the age of the infant allowing direct comparison of their means in index 
and comparison groups. No significant differences were observed between anti-F/anti-G 
ratios in index and comparison groups suggesting that hospitalized children are not 
selectively difficient in anti-G antibodies to the infecting virus strain as the hypothesis 
postulates. 
This failure to find any evidence of a deficiency in anti-G antibodies in infected infants 
supports the findings of Vieira et al. (2007). These authors measured the subtype 
specific antibodies, presumably of maternal origin, to the subtype specific antigens of 
GA2, GA5 and GB3,  using the Luminex Multiplex system, in volunteers with 
respiratory disease separated into infected and uninfected groups solely by virus 
isolation.  A similar level of subgroup specific and genotype specific antibodies was 
found in both infected and uninfected groups. In this study the distribution of cases and 
ages of infants across the epidemic was not taken into consideration. 
The presence of comparable levels of antibodies to GA2G and BAG regardless of the 
infecting genotype was probably due to the prevalence of genotypes GA2 and BA4 over 
many epidemics. Epidemiological studies in Newcastle upon Tyne have shown that the 
two HRSV genotypes tested have been circulating for at least 3 epidemics and probably 
many epidemics before that (refer to section 10.1.2) and these genotypes were also 
found in other parts of the world during the similar period. Thus, mothers would have 
been constantly exposed to these two genotypes in each epidemic and might be 
expected to have raised sufficient anti-G antibodies against all three genotypes which 
may explain the apparently good correlation of antibody ODs between GA2G and BAG 
(section 9.5) and by Vieira et al., (2007). Alternatively, these antibodies could be truely 
cross-reactive as reinfection by an identical genotype as the initial infection in infants 
has been reported to mediate production of cross-reactive antibodies at least to the same 
subgroup (Scott et al., 2007).   
It is clear that both anti-F and anti-G antibodies capable of recognising both A and B 
virus sub-groups and multiple lineages within them and are transferred from mothers to 
their infants. Most infants are spared from severe HRSV disease in the first month of 
life corresponding to the higher maternal antibody level. None-the-less most infants 
admitted to hospital with severe HRSV have detectable serum titers of both anti-F and 
anti-G antibodies. It appears that there is a threshold antibody level for protection and 
maternal antibodies must, inevitably drop below this for all infants as maternal anti 
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bodies decay. When this happens, given the ubiquity of the virus, HRSV infection is 
almost inevitable. There is evidence that infants hospitalised with HRSV bronchiolitis 
correlates with low levels of antibodies to the membrane glycoproteins (Ogilvie et al., 
1981) although (Kasel et al., 1987) have reported that low anti-F antibody levels also 
correlate with hospitalisation, in the current study, where antibodies to the G 
glycoprotein were measured against relevant virus strains,  no differences in the ratio of 
anti-F to anti-G antibodies between index and comparison groups was observed.  Thus 
it appears likely that susceptibility correlates with a general lack of anti-glycoprotein 
antibodies and the target specificity of the protective antibody species remains un-
defined. Whilst the successful deployment of Palivizumab confirms the protective 
efficacy of anti-F antibodies, more work is justified  to understand the function of anti-
G antibodies in vivo in which protection by anti-G antibodies might be governed by 
mechanisms yet to be understood.   
  
 215 
 
Chapter 11 Conclusion 
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Human respiratory syncytial virus infection induces incomplete immunity and results in 
repeated infections throughout life without many developing severe lower respiratory 
tract infection. However, a small percentage of HRSV infected infants, progressed on 
from upper respiratory tract infection to acute lower respiratory tract infection ranging 
from bronchiolitis to pneumonia. Studies have shown that infants with high level of 
HRSV specific maternal antibodies tend to be spared from severe lower respiratory tract 
infection. High titered antibodies are made against two major glycoprotein namely the 
fusion (F) and G glycoproteins. Nevertheless, the use of anti-fusion glycoprotein 
prophylaxis only provides average benefit. Thus the question arises whether anti-G 
antibodies or more specifically anti-G antibodies against the infecting genotype is 
protective. Thus, it was necessary to develop a system for measuring antibodies against 
the infecting HRSV genotype in infants admitted to hospital with HRSV infection and a 
comparison group of similar age but without HRSV infection. The purpose of this study 
was to assess the efficacy of anti-G antibodies in conferring protection to infants against 
severe HRSV diseases. 
The first aim (Aim I) of this thesis which was to establish the molecular epidemiology 
of HRSV in Newcastle throughout the three epidemics was straightforward. Two 
primers sets were used to amplify the C-terminal sequences of the RSV G glycoprotein 
gene; GC1-F164 for subgroup A and GB1-GB2 for subgroup B. However, GB1-GB2 
primer set were found to amplify subgroup A HRSV in nested PCR. As this positive 
amplification is not specific to subgroup B HRSV. Amplicands were sequenced and 
genotypes were identified by phylogenetic analysis of the resulting sequences. Over the 
span of three epidemics, these studies revealed the circulation of three genotypes 
namely GA2, GA5 and BA4. GA5 was shown to fade into extinction while GA2 was 
the predominant strain over the first two epidemics, succeeded by BA4 during the third 
epidemic.  
The G glycoprotein genes of the most prevalent genotypes of HRSV, GA2 and BA4, 
and the F glycoprotein gene of genotype GA2 were isolated and cloned for expression 
in MVA.  While preparing recombinant fusion glycoprotein in MVA under the control 
of the vaccinia virus p7.5 promoter in HeLa, a rapid formation of giant cells was 
observed. This phenomenon was not observed while growing the recombinant MVA 
expressing the F glycoprotein in QT35. This rapid formation of syncytia has not been 
reported elsewhere. In this study, the mechanism of the formation syncytia was not 
further explored. Nevertheless, immunofluorescent assay from the time of inoculation 
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has shown a relatively rapid synthesis of the recombinant F glycoprotein suggesting this 
phenomenon was caused by newly synthesized recombinant F but the effect of high 
titered inoculums could not be completely ruled out.  Both recombinant G and F 
glycoproteins were found to bind to ConA and ConA capture ELISA was successfully 
devised for the measurement of antibodies to both glycoproteins. Thus, Aim II was 
fulfilled. 
As for the third aim (Aim III), an attempt to design a serologic tool for the measurement 
of antibodies specific to the conserved epitopes of the G glycoprotein was halted as 
there were overlaps in some conserved and strain specific epitopes. This discovery 
indicates the difficulty or even impossibilities of devising comprehensive and unique 
measurements of antibodies to conserved epitopes by direct means via the peptides or 
recombinant fragments of the G glycoprotein as antigen.  
As for the fulfillement of the fourth aim (Aim IV), the measurement of maternal 
antibodies to the G glycoprotein showed that hospitalized infants were not deficient in 
HRSV-specific maternal antibodies relative to the comparison group but instead 
showing a significantly higher antibody level to the G and F glycoproteins of the 
contemporary strains in the index group compared to the controls. The results indicated 
that the infants with severe HRSV disease were not specifically deficient in anti-G 
maternal antibodies.  
These findings rejected the hypothesis of this study as a significantly higher level of 
maternal antibodies to the genotype specific G glycoprotein does not correlate with 
protection in infants. In addition to this, a significantly higher level of anti-F maternal 
antibodies were also detected in the index infants which contradicted to the widely 
accepted idea that anti-F antibodies correlated with immunity. However, a more subtle 
correlation of anti-F or even anti-G antibody may emerge if a larger sample size was 
used. Despite the small sample size, the significantly higher antibody level in the index 
group relative to the comparison group suggests that these findings that reject the 
hypothesis is unlikely to be false. 
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Chapter 12 Appendix 
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12.1 List of Suppliers 
Applied Biosystems, Carlsbad, California, USA 
Astell Scientific Ltd, Kent, DA14 5DT, UK 
BDH, VWR International, Leicestershire, UK 
Bioline, London, UK 
Bio-Rad Laboratories Ltd. Hertfordshire, UK 
Cargille Laboratories, Cedar Grove, NJ, USA 
Coleman Technologies Inc., Wilmington, USA 
Corning, New York, USA 
Dade-Behring, Illinois, USA. 
Dako, Cambridgeshire, UK 
Decon Laboratories Ltd, East Sussex, UK 
DuPont (U.K.) Ltd, Herts, UK 
Eurofins MWG Operon, http://www.eurofinsdna.com/ 
Fermentas, York, UK 
Fisher Scientific, Leicestershire, UK 
Fisons, Leicestershire., UK 
Fluka, http://www.sigmaaldrich.com/ 
GATC Biotech, Lake Constance, Germany 
Genevision Ltd, Newcastle upon Tyne, UK 
Gibco, Paisley, UK 
Hendley Ltd, Essex, UK 
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Lonza, Rockland, ME, USA  
Macherey-Nagel, Düren, Germany 
Medichem Int, Kent, UK 
Melford Laboratories Ltd, Suffolk, UK 
Millipore, Billerica, MA 
MJ Research Inc. Watham, MA, USA 
Nalgene, Roskilde, Denmark 
National Diagnostics, Atlanta, Georgia, USA 
Nikon, www. Europe-nikon.com/en_GB/ 
Northumbria Biologicals Ltd, Cramlington, UK 
Novocastra Laboratories, Newcastle upon Tyne, UK 
OXOID, Basingstoke, Hampshire, England 
PAA, Pasching, Austria 
Sigmaplot, www.sigmaplot.com 
SPSS Statistics, http://www.spss.com/uk/ 
Sigma-Aldrich, http://www.sigmaaldrich.com/united-kingdom.html 
Starlab Group, Milton Keynes, UK 
Swann-Morton® Ltd, Sheffield, England 
Weiss-Gallenkamp, Leicestershire, UK 
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12.2 Materials 
12.2.1 Sterilization 
Virkon 
1 tablet of Rely+On™ Virkon Tablet (Cat#D12557249) (DuPont) was dissolved in 500 
ml of distilled water. 
Trigene Advance 
Trigene Advance concentrate (Cat#TM305) (Medichem Int.) was diluted 1/100 in 
distilled water. 
12.2.2 Cell culture 
Phosphate Buffered Saline (PBS) 
1 tablet of phosphate buffered saline (Dulbecco A) (OXOID) was dissolved in 100 ml 
of water, sterilised and stored at ambient temperature. 
Heat inactivated Foetal Calf Serum (HI-FCS) 
Foetal Bovine Serum Standard Quality (Cat#A15-101) (PAA) was heat inactivated in a 
water bath at 56 °C for 30 minutes and stored as aliquots of 50 ml at -20 °C. 
Trypsin 
2.5 % trypsin was supplied as a stock and stored frozen at -20 °C. Stock trypsin was 
diluted 1/100 in versene and stored at 4 °C until use. 
L-glutamine 
L-glutamine (Cat# M11-004), (PAA) was purchased as a 200 mM stock and stored 
frozen at -20 °C. The stock solution was diluted 1/100 in media immediately before use. 
Penicillin/Streptomycin Solution 
PEN-STREP (Cat#DE17-603E) (LONZA) was purchased as a stock containing 5000 
U/ml of Penicillin and 5000 U/ml of Streptomycin and stored frozen at -20 °C. The 
stock was diluted 1/100 in media immediately before use. 
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Versene 
25g of Ethylenediaminetetraacetic acid (EDTA) was dissolved in 1 litre of PBS, 
aliquoted in 100 ml volumes, autoclaved and stored at 4°C until use. 
Tryptose Phosphate Broth (TPB) 
29.5g of TPB (Cat# CM0283) (OXOID) was dissolved in 1 litre of distilled water, 
aliquoted in 20 ml volumes, autoclaved and kept at ambient temperature. 
Non-essential amino acids (NEAA) 
Stock NEAA (Cat#M11-003) (PAA) was stored frozen at -20 °C. Stock was thawed to 
4 °C and diluted 1/100 in media before use. 
0.4 % (w/v) Phenol Red 
0.8 g of phenolsulfonphthalein sodium salt (Cat#P5530) (Sigma) was dissolved in PBS 
and stored at 4 °C until use. 
Gassed sodium bicarbonate buffer 
44 g of NaHCO3 (Cat#S/4240/60), Fisher Scientific and 2.5 ml of 0.4 % phenol red 
solution was dissolved in 1 litre of water and held on solid carbon dioxide. The solution 
was gassed by bubbling 5 % CO2 through it until a peach coloured solution was 
produced. It was then aliquoted in 5 ml volumes in glass bijou bottle, autoclaved and 
stored at ambient temperature. 
Tissue culture flasks 
All tissue culture flasks were purchased from Corning. T25, T75 and T225 were 
routinely used and the volume of medium used was 5 ml, 10 ml and 25 ml respectively.  
EMEM 
Eagle’s Minimum Essential Medium (EMEM) (Cat#BE12-684F) (LONZA) was 
purchased as a 10X stock solution without L-glutamine and NaHCO3 and stored at 4 °C. 
Stock solution was diluted 1/10 in sterile milli-Q water before use.  
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GMEM 
Glasgow Minimum Essential Medium (GMEM) (Cat#21710-025) (GIBCO) was 
purchased as a 1X ready to use solution with L-glutamine but without NaHCO3 and 
stored at 4 °C. 
OPTIMEM 
OPTI-MEM®I+GlutaMAXTM (OPTIMEM) (Cat#51985-026) (GIBCO) was purchased 
as a 1X ready to use solution and stored at 4 °C. 
HBSS 
Hanks Balanced Salt Solution (HBSS) (LONZA) was purchased as 500 ml ready to use 
1X solution with Phenol Red, without Calcium and Magnesium and stored at 4 °C until 
use. 
Embryo washing buffer 
90 ml of sterile water 
10 ml of 10X EMEM 
5 ml of Gassed 4.4% Sodium bicarbonate +0.4% phenol red 
Growth Medium (GM1) 
450 ml of sterile water 
50 ml of 10X EMEM 
5 ml of NEAA  
5 ml of L-glutamine  
20 ml of Gassed 4.4% Sodium bicarbonate +0.4 % phenol red 
50 ml of HI-FCS 
50 ml of TPB 
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Maintenance medium (MM1) 
450 ml of sterile water 
50 ml of 10X EMEM 
5 ml of NEAA 
5 ml of L-glutamine 
20 ml of Gassed 4.4% Sodium bicarbonate +0.4 % phenol red 
10 ml of HI-FCS 
50 ml of TPB 
Digestion buffer 
Trypsin 0.25 % (v/v) in versene  
Cryo buffer 
20 ml of FCS (non heat inactivated) 
10 ml of DMSO 
70 ml of 1X EMEM 
Growth medium (GM2) 
Formulated as for GM1 (see above) without TPB and NEAA 
Maintenance medium (MM2) 
Formulated as for MM1 (see above) without TPB and NEAA 
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Growth medium (GM3) 
10 ml of HI-FCS 
90 ml of 1X GMEM 
10 ml of TPB 
1 ml of Penicillin/streptomycin (100 µg/ml)  
Maintenance medium (MM3) 
2 ml of HI-FCS 
90 ml of 1X GMEM 
10 ml of TPB 
1 ml of Penicillin/streptomycin (100µg/ml) 
12.2.3 Immunofluorescent 
10X Phosphate buffered saline (PBS) 
160 g of Sodium chloride (Cat#S/3160/65), Fisher  
4 g of Potassium Dihydrogen orthophosphate (Cat#P/4800/60), Fisher  
23 g of Disodium hydrogen orthophosphate (Cat#S/45120/60), Fisher  
4 g Potassium chloride (Cat#101983K), BDH  
Mixed and dissolved in 1.5 litres of water and the pH was adjusted to 7.4 with HCl and 
volume adjusted to 2 litres at with distilled water. Stock PBS was sterilized and stored 
at ambient temperature. Dilute 1/10 in distilled water before use. 
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Evans blue counterstain 
Evan’s blue counterstain (0.5 % w/v) (Cat#E0133) was diluted 1/1000 in PBS, vortex 
mixed and stored at 4 °C until use. 
10X carbonate coating buffer 
15.898 g of Sodium carbonate (Cat#10240), BDH  
29.4 g of Sodium bicarbonate (Cat#30151), BDH  
Dissolved in 600 ml of distilled water and pH adjusted to 9.6 with 6N NaOH, 
autoclaved and stored at 4 °C. Diluted 1/10 in distilled water, readjust pH to 9.6 and use 
immediately.  
Serum and antibiotic free medium (SAF) 
Formulated as GM2 but without HI-FCS and antibiotics. 
12.2.4 ELISA 
Concanavalin A 
25 mg of lyophilized Concanavalin A (ConA) (cat#C2010-25MG) was dissolved in 10 
ml of PBS to make 2.5 mg/ml stock solution and stored as 500 µl aliquots at -20 °C 
until use. 
Wash buffer with 0.05% (v/v) Tween20 (PBST) 
500 µl of Tween®20 (Cat#P1379-500) dissolved in 1 L of PBS.  
Wash buffer with 0.1% Triton X-100 (PBSTx) 
1 ml of Triton X-100 (Cat#X-100) dissolved in 1L of PBS.  
Blocking buffer (PTF) 
10 ml of HI-FCS 
90 ml of sterile PBST 
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Mixed and stored as 20 ml aliquots in glass universal bottles at -20 °C and thawed to 
37 °C before use. 
Substrate buffer 
5.1 g of citric acid and 9.16 g of anhydrous Na2HPO4 were dissolved in 500 ml of 
distilled water and volume adjusted to 1 litre with distilled water, autoclaved and stored 
at ambient temperature. 
Ortho-phenylendiamine dihydrochloride (OPD) stock solution 
1.25 g of OPD was dissolved in 20 ml of substrate buffer to give a final concentration of 
62.5 mg/ml. Aliquots of 0.4 ml containing 25 mg of OPD were then stored at -20 °C. 
Developer solution 
400 µl of OPD was thawed and added to 24.6 ml of substrate buffer followed by 10 µl 
of 30 % (v/v) hydrogen peroxide (BDH) and used immediately. 
3M H2SO4 
50 ml of concentrated H2SO4 1.84 SG (Cat#450063S) (BDH) was gently titrated into 
150 ml of ice cold distilled water in an iced water bath.  
12.2.5 SDS-PAGE 
40% Acrylamide Solution 
Ready to use 40 % acrylamide solution (Cat#BP1408-1) (Fisher) was stored at 4 °C in 
the dark until use. 
Resolving buffer (1.5M Tris-Cl, pH8.8) 
272.3 g Tris base (Cat#B2005), (Melford Lab. Ltd.) was dissolved in 800 ml of water 
and the pH adjusted to 8.8 with concentrated HCl. The solution was sterilized and 
stored at ambient temperature until use. 
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Stacking buffer (0.5M Tris-HCl, pH6.8) 
30 g Tris base (Cat#B2005), (Melford Lab. Ltd.) was dissolved in 400 ml of water and 
the pH was adjusted to 6.8 with concentrated HCl. The solution was sterilized and 
stored at ambient temperature until use. 
10 % (w/v) SDS  
10 g of sodium dodecyl sulphate (Cat#L-4509) was dissolved in 80 ml of water and 
volume was adjusted to 100 ml in a volumetric flask. 
The solution was stored at ambient temperature until use.  
Blocking buffer 
10 g of Skimmed milk powder was dissolved in 100 ml of PBST to make 10 % (w/v) 
solution and used immediately. 
Tris buffered Saline (TBS) pH 7.4 
8 g NaCl 
0.2 g KCl 
0.3 g Tris base 
Dissolved in 800 ml of distilled water, pH adjusted to 7.4 with HCl, sterilized and 
stored at room temperature until use. 
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4X reducing sample buffer 
3.8 ml of distilled water 
1 ml of 0.5M Tris-HCl, pH6.8 
0.8 ml of glycerol 
1.6 ml of 10% SDS 
0.4 ml of 2-mercaptoethanol (Cat#63689) (Fluka)  
0.4 ml of 1 % (w/v) bromophenol blue 
Combined and stored as 1ml aliquots at -20 °C. Thaw to ambient temperature before use. 
1X reducing sample buffer 
65 µl of PBS,  
10 µl of protease inhibitor  
25 µl of 4X reducing sample buffer  
Combine and used immediately to treat for one sample. 
5X Electrode running buffer 
15 g of Tris base 
72 g of Glycine, Fisher (Cat#BP381-5) 
5 g of SDS 
Dissolved in water to make l litre solution and kept at ambient temperature. Diluted 1/5 
with distilled water and chilled to 4 °C before use. 
10 % (w/v) Ammonium Persulphate (APS) 
100 mg of APS (Cat#A/P470/46) (Fisher) was dissolved in 1 ml of water and stored at 
4 °C for a maximum of 2 weeks before use. 
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N,N,N’,N’-tetramethylethylenediamine (TEMED) 
Ready to use TEMED (Cat#EC503) (National Diagnostics)  
Substrate A 
0.15 g of 4-chloro-1-napthol (4CN) (Cat#C8890) 
150 ml of Methanol (Cat#M/4000/17), Fisher  
50 ml of TBS pH 7.4 
Dissolved and stored as aliquots of 10ml in universal bottles at -20 °C. Thawed to room 
temperature before use. 
Substrate B 
10 µl of 30% Hydrogen peroxide, BDH (Cat#101284N) 
10 ml of TBS pH7.4 
Substrate A and B 
Equal volumes of substrate A and substrate B were combined and used immediately.  
10 % Resolving gel 
2.5 ml of 40 % acrylamide 
2.5 ml of 1.5 M Tris pH 8.8 
0.1 ml of 10 % Ammonium persulphate 
0.1 ml of 10 % SDS 
0.004 ml of TEMED 
4.8 ml of water 
5 % Stacking gel 
0.625 ml of 40 % acrylamide 
0.625 ml of 1.5 M Tris pH 8.8 
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0.05 ml of 10 % Ammonium persulphate 
0.05 ml of 10 % SDS 
0.005 ml of TEMED 
3.65 ml of Water 
12.2.6 Western blotting 
10X Towbin buffer 
30.3 g Tris base 
144 g Glycine 
Dissolved in 1 liter of distilled water, sterilized and stored at ambient temperature. 
1X Towbin buffer 
100 ml of 10X Towbin buffer 
200 ml of Methanol 
Volume adjusted to 1 liter with distilled water and stored at 4 °C until use. 
12.2.7 Modified Lowry Assay 
Reagent A 
2 g of Na2CO3 (Cat#10240) (BDH)  
 0.4 g of NaOH (pearl) (Cat#104384F) (BDH)  
0.16 g of Sodium Tartrate dibasic dehydrate (Cat#4797-100G) 
1 g of SDS 
Dissolved in 80 ml of water and volume adjusted to 100 ml. 
Stored at ambient temperature until use. 
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Reagent B 
Dissolved 4 g of CuSO4.5H2O (Cat#C7631-250G) was dissolved in 100 ml of water 
and stored at ambient temperature. 
Reagent C 
100 parts of Reagent A + 1 part of Reagent B prepared fresh before use. 
Reagent D 
1 part of 2 N Folin Ciocalteu’s phenol reagent (Cat#F9252-500 ml) + 1 part of water. 
Prepared fresh before use. 
Lysis Buffer  
0.5% (v/v) Triton X-100 was dissolved in PBS, autoclaved and stored at ambient 
temperature. 
Protein standard 
500 mg of bovine serum albumin Cohn Fraction V, pH7.0 (Cat#422371X) (BDH) was 
dissolved in 50 ml of Lysis buffer as described above to make 10mg/ml stock and stored 
as 5 ml aliquot in plastic bijou bottle at -20 °C until use. 
Dilutions of 10, 5, 2.5, 1, 0.5, 0.3, 0.2, 0.1, 0.05 and 0 mg/ml were prepared as standards 
in 1 ml volumes with lysis buffer and used immediately. 
12.2.8 Biorad Protein Assay 
Protein Standard 
Protein standards were prepared as described in section 3.13 but was dissolved in PBS 
supplemented with 0.1 % (w/v) SDS. 
Biorad Assay reagent 
Biorad Protein Assay Dye reagent concentrate (Cat#500-0006) concentrate is stored at 
4 °C.  
1.75 ml of Biorad Reagent and 5.25 ml of water were mixed and used immediately.  
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12.2.9 Molecular Biology 
Diethyl pyrocarbonate treated water (DEPC-H20) 
All distilled water used in the molecular methodologies was treated with 0.1 % (v/v) 
diethyl pyrocarbonate (DEPC), BDH (Cat#44170 3D) overnight at 37 °C water bath, 
sterilized and stored at ambient temperature until use. 
10X Tris, Boric acid, EDTA (TBE) solution 
108 g of Tris base 
55 g of Boric acid (Cat#B6768) 
9.3 g of EDTA 
Autoclaved and stored at room temperature. Dilute 1/10 in distilled water before use. 
6X Loading dye 
30 ml Glycerol  
0.1 g bromophenol blue 
0.1 g xylene cyanole FF  
Dissolved in 100 ml of DEPC-H20 and stored as 1 ml aliquots at -20 °C and thawed to 
ambient temperature before use.  
dNTPs 
dNTPs stock was prepared from dNTP set (Cat#R0181) (Fermentas) by combining 250 
µl of each dNTPs together and mixed with 1500 µl of DEPC-H2O to make 10 mM stock 
solution and stored as aliquot of 200 µl at -20 °C until use. 
Ethidium bromide (EtBr) 
10 mg/ml (w/v) EtBr stock solution (E/P800/03) (Fisher) was stored at 4 °C and diluted 
in TBE buffer to 10 µg/ml working concentration immediately before use. 
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12.2.10 Bacteriology 
All chemicals in this section were purchased from OXOID unless stated otherwise.  
All restriction enzymes were purchased from Fermentas.  
T4 DNA ligase was purchased from Invitrogen.  
Luria-Bertani broth (LB) 
10 g of Tryptone (Cat#LP0021) 
5 g of Yeast extract (Cat#LP0042) 
10 g of Sodium chloride (Fisher Scientific) (Cat#2315983) 
The volume was adjusted with distilled water to 1 litre, autoclaved and stored at 
ambient temperature. 
Luria-Bertani Agar (LBA) 
4 g of Tryptone 
2 g of Yeast extract 
4 g of Sodium chloride 
6 g of Agar Technical (Agar No.3) (Cat#LP0013) 
The volume was adjusted to 400 ml with distilled water in a 500 ml Duran bottle, 
sterilized and stored at ambient temperature. 
LBA was melted in a boiling waterbath, equilibrated to 60 °C in a waterbath set at that 
temperature. Ampicillin was added to the final concentration of 100 µg/ml where 
necessary at this stage before pouring. Agar plates were prepared by pouring directly on 
the petri dish until the molten agar covers the whole surface (Approximately 15-20 
ml/dish). Agar plates were cooled to ambient temperature in a biological safety cabinet 
for 1 hour before storeing in sealed plastic bags at 4 °C until use.  
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SOB medium 
20 g of tryptone  
5 g of yeast extract 
0.5 g of NaCl 
0.186 g of KCl  
The volume was adjusted to 1 litre, autoclaved and stored at 4°C. 
1 M MgCl2 
9.521 g of anhydrous MgCl2 (Cat#M8266) was dissolved in 50 ml of distilled water and 
the volume adjusted to 100ml in a volumetric flask, autoclaved and stored at 4 °C. 
1M MgSO4 
24.647 g of MgSO4.7H2O (Cat#BP213.1) (Fisher) was dissolved in 50 ml of distilled 
water and the volume adjusted to 100 ml in a volumetric flask, autoclave sterilized and 
stored at 4 °C. 
1 M glucose 
9.08 g of D-glucose (Cat#1011744) (BDH) was dissolved in 30 ml of distilled water and 
the volume adjusted to 50 ml, filter sterilized and stored at -20 °C in a 50 ml centrifuge 
tube until use. 
SOC medium 
100 ml of SOB was supplemented with 100 µl of 1 M MgCl2, 100 µl of 1 M MgSO4 
and 200 µl of 1 M D-glucose. The solution was stored at -20 °C in aliquots of 20 ml in 
disposable plastic universal bottles. 
Ampicillin 
1 g of Ampicillin sodium salt (Cat#A9518-5G) was dissolved in 10 ml of water to make 
100 mg/ml stock solution. The solution was filter sterilized and stored as 1 ml aliquot in 
2 ml vial at -20 °C until use. 
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Tfb1 solution 
0.296 g of CH3COOK (Cat#P1190) 
1.210 g of RbCl (Cat#R2252) 
0.148 g of CaCl2.2H2O (Cat#C3881) 
1.000 g of MnCl2.4H2O (Cat#13446-34-9) 
Dissolved in 50 ml of water and pH adjusted to 5.8 using acetic acid. 
15 ml of glycerol was added and volume adjusted to 100 ml with water in a volumetric 
flask. The solution was filter sterilized and stored at -20 °C until use. 
Tfb2 solution 
0.105 g of MOPS (Cat#M3183) 
0.060 g of RbCl (Cat#R2252)  
0.550 g of CaCl2.2H2O (Cat#C3881) 
Dissolved in 20 ml of water and the pH adjusted to 6.5 with KOH. 
7.5 ml of glycerol was added, mixed and the volume adjusted to 50 ml in a volumetric 
flask. 
12.2.11 Cell titration and plaquing 
10% formal saline 
9 g of sodium chloride was dissolved in 800 ml of distilled water and 100 ml of 
formaldehyde was added. The volume was adjusted to 1 litre with distilled water and 
the solution was stored at ambient temperature. 
Crystal violet solution 
0.1 g of crystal violet was dissolved in 80 ml of distilled water and the pH was adjusted 
to 7.0 with ammonia. The solution was stored at ambient temperature. 
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Neutral red agarose 
Neutral red (Cat# N4638) was diluted 1:3 in PBS to make 1.5 ml solution and combined 
with 13 ml of molten 2 % Agarose Type VII.  
2% (w/v) Agarose type VII 
2 g of Agarose type VII (Cat#A9045) was added to 80 ml of distilled water in 100 ml 
Duran bottle, autoclave sterilized and stored at ambient temperature. 
For use, agarose was melted in a boiling waterbath and held in a 37 °C incubator in its 
molten state until use. 
2X EMEM 
20 ml of 10X EMEM 
20 ml of TPB 
10 ml of gassed sodium bicarbonate buffer 
2 ml of 100X Penicillin/streptomycin  
4 ml of HI-FCS 
42 ml of water 
The solution was stored at 4 °C up to 3 months. For use, the desired volume was 
aliquoted into a plastic universal bottle and L-glutamine was added to the final 
concentration of 2 µg/ml (2X concentration). The solution was then warmed to 37 °C 
before use. 
Xgal 
1 mg/vial of Xgal, Fermentas (Cat#R404) was dissolved in 10ml of dimethylformamide 
(DMF) (Cat#D4551) to make 100mg/ml stock. The solution was stored at -20 °C in 2 
ml aliquots in glass bijou bottle until use.  
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Agarose overlay 
Combine equal volume of 2 % (w/v) Agarose type VII and 2 X EMEM as described 
above, mixed by gentle inversion immediately before use. The minimum agarose 
overlay required for 24 wells plate and 6 wells plate is 500 µl and 1000 µl per well 
respectively.  
Xgal Agarose overlay 
Xgal stock was diluted to 400 µg/ml in 2X EMEM and formulate as described in 
Agarose overlay (see above). 
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12.3 Isolates 
Table 24 Summary of the isolation and subgrouping of HRSV isolated during the 
2007/2008 epidemic in Newcastle upon Tyne 
 
No. Isolate NPS 
Anti-RSV 
Mabpool Subgroup 
1 40/08  + A 
2 41/08  + A 
3 42/08  + A 
4 44/08  + A 
5 45/08  + B 
6 46/08  + A 
7 48/08 + A 
8 49/08 + A 
9 50/08 + A 
10 51/08 + A 
11 53/08 + A 
12 54/08 + B 
13 55/08 + A 
14 56/08 + B 
15 57/08  + A 
16 58/08 + A 
17 59/08 + A 
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Table 25 Summary of the isolation and subgrouping of HRSV isolated during the 
2008/2009 epidemic in Newcastle upon Tyne 
 Isolate IF Genotyping 
1 0309 + BA4 
2 0409 + GA5 
3 0609 + BA4 
4 0709 + GA2 
5 0909 + GA2 
6 1109 + BA4 
7 1209 - Not RSV 
8 1309 N/A Isolation negative 
9 1409 + GA2 
10 1509 N/A Isolation negative 
11 1709 N/A Isolation negative 
12 1809 N/A Isolation negative 
13 1909 N/A Isolation negative 
14 2009 N/A Isolation negative 
15 2109 + BA4 
16 2209 N/A Isolation negative 
17 2409 + GA2 
18 2509 + BA4 
19 2709 N/A Isolation negative 
20 2809 + GA2 
21 2909 + GA2 
22 3009 + unknown 
23 3109 + GA2 
24 3209 N/A Isolation negative 
25 3309 N/A Isolation negative 
26 3409 N/A Isolation negative 
27 3609 - Not RSV 
28 3909 + GA2 
29 4009 + GA2 
N/A- not attempted  
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Table 26 Summary of specimens obtained from infant volunteers over epidemic 
2009/2010 
# St
u
dy
 
N
o
.
 
Date of Birth 
Date of 
collection A
ge
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m
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e 
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x
 
se
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m
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M
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o
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1 16 17/10/2009 02/12/2009 46 serum 50ul       
      02/12/2009   NS 200ul P1 GA2  POS 
      03/12/2009   NPS 200ul P1 GA2 POS 
2 27 24/10/2009 06/12/2009 43 serum 60ul      
      06/12/2009   NS 500ul P1 GA2  POS 
3 41 14/10/2009 23/12/2009 70 serum 30ul     
    14/10/2009     NPS 150ul P1 GA2 POS 
4 51 18/11/2009 11/01/2010 54 serum 50ul     NEG 
          NS 500ul NEG GA2φ    
5 30 24/10/2009 07/12/2009 44 NPS 200ul P1 BA POS 
    24/10/2009 07/12/2009 44 serum 50ul       
    24/10/2009 09/12/2009 46 serum         
6 35 15/10/2009 16/12/2009 62 serum 60ul    
          NPS 150ul P1 BA POS 
7 44 08/10/2009 28/12/2009 81 serum 50ul    
                                                                                                                                 NS 500ul P1/P2 BA  POS 
8 45 19/08/2009 30/12/2009 133 serum 70ul      
          NS 500ul P1 BA POS 
9 47 05/07/2009 03/01/2010 182 serum      
          NS 500ul P1/P2 BA POS 
          NPS ~1ml P1 BA POS 
10 49 19/07/2009 11/01/2010 176 Blood      
          NS   P1 BA  POS 
11 53 12/09/2009 20/01/2010 130 NPS   P1 BA  POS 
          Blood 120ul       
12 52 13/12/2009 18/01/2010 36 blood 50ul     
          NS    NEG BAφ   NEG 
13 54 10/12/2009 18/01/2010 39 blood 20ul NEG   NEG 
          NS     BAφ   
14 29 29/10/2009 07/12/2009 39 NS   NEG BAφ NEG 
      09/12/2009   serum 50ul       
15 32 11/07/2009 12/12/2009 154 NS 500ul NEG BAφ  NEG 
          serum 40ul       
16 46 20/10/2009 30/12/2009 71 serum 50ul NEG BAφ NEG 
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          NS 500ul       
17 50 18/11/2009 17/01/2010 60 NS   NEG BAφ  NEG 
          blood         
18 21 15/01/2010 07/02/2010 23 serum 50ul       
        0 NS 500ul NEG BAφ   
19 40 09/08/2009 23/12/2009 136 serum 60ul NEG NEG NEG 
          NS 500ul       
20 33 21/10/2009 14/12/2009 54 NS 500ul NEG NEGφ  NEG 
          serum 200ul       
21 28 19/10/2009 06/12/2009 48 NS   NEG NEGφ  NEG 
          serum 50ul       
22 43 13/11/2009 27/12/2009 44 serum 15ul       
          NS 500ul NEG NEGφ  NEG 
23 48 10/09/2009 03/01/2010 115 serum        
          NS   NEG                                                                                                                          NEGφ  NEG
24 31 11/07/2009 09/12/2009 151 NS 500ul NEG NEG No serum 
25 36 02/12/2009 19/12/2009 17 serum 60ul N/A  N/A   No 
NPS/NS 
26 37 07/12/2009 19/12/2009 12 serum 30ul N/A  N/A   No 
NPS/NS 
27 38 09/08/2009 22/12/2009 135 serum 120ul N/A   N/A   No 
NPS/NS 
28 39 21/10/2009 22/12/2009 62 serum 70ul N/A   N/A   No 
NPS/NS 
29 15 03/08/2009 27/12/2009 146 serum 150ul N/A   N/A   No 
NPS/NS 
30 19 22/07/2009 14/12/2009 145 NS 500ul NEG NEG No serum 
31 34 10/11/2009 13/12/2009 33 serum 70ul N/A   N/A   No 
NPS/NS 
φ by nested PCR 
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Table 27 Passage history of isolates. 
 
No. Isolate NPS Genotype 
Date of 
collection P1 P2 comment 
1 40/08  GA2 N/A 16-21/1 11-18/2 2007/2008 
2 41/08  GA2 N/A 16-24/1 24-28/1 2007/2008 
3 42/08  GA2 N/A 16-24/1 13-15/2 Mix virus present 
4 44/08  GA2 N/A 28-4/2 8-18/2 2007/2008 
5 45/08  GA2 N/A 7-14/2 7-14/2 2007/2008 
6 46/08  GA2 N/A 7-14/2 7-14/2 2007/2008 
7 48/08 GA5 N/A 22-28/2 29-3/3 2007/2008 
8 49/08 GA5 N/A 28-10/3 11-18/3 2007/2008 
9 50/08 GA2 N/A 28-17/3 20-25/3 2007/2008 
10 51/08 GA2 N/A 28-17/3 20-25/3 2007/2008 
11 53/08 GA2 N/A 11-19/3 20-25/3 2007/2008 
12 54/08 GA2 N/A 20-3/4 4-10/4 2007/2008 
13 55/08 GA2 N/A 20-3/4 4-10/4 2007/2008 
14 56/08 GA2 N/A 17-24/4 24-28/4 2007/2008 
15 57/08  GA2 N/A 8-15/5 15-19/5 2007/2008 
16 58/08 GA2 N/A 13-23/5 23-30/5 2007/2008 
17 59/08 GA2 N/A 20-27/5 27-30/5 2007/2008 
18 03/09 BA4 17/11/08 4-11/2 N/A 2008/2009 
19 04/09 GA5 17/11/08 4-11/2 22-2/2 2008/2009 
20 06/09 BA4 19/11/08 N/A 8-14/4 2008/2009 
21 07/09 GA2 19/11/08 28-30/1 N/A 2008/2009 
22 09/09 GA2 28/11/08 28-2/2 4-11/2 2008/2009 
23 11/09 BA4 28/11/08 28-2/2 4-11/2 2008/2009 
24 14/09 GA2 4/2/09 4-16/2 4/3-8/3 2008/2009 
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Reading the Isolate name: Isolate 40/08 means isolate from NPS #40 isolated in year 
2008 in season 2007/2008. 
Dates stated for isolates season 2007/2008-2008-2009 corresponds to the day of 
inoculation till the day of harvest. 
Dates stated for isolates from season 2009/2010 corresponds to the day where the 
specimen was taken. 
  
25 21/09 BA4 11/2/09 11-24/2 8-17/4 2008/2009 
26 24/09 GA2 18/2/09 18-26/2 1/3-8/3 2008/2009 
27 25/09 BA4 18/2/09 18-4/3 N/A 2008/2009 
28 28/09 GA2 4/3/09 4-9/3 N/A 2008/2009 
29 29/09 GA2 4/3/09 4-10/3 N/A 2008/2009 
30 30/09 BA4 4/3/09 4-10/3 N/A 2008/2009 
31 31/09 GA2 4/3/09 4-10/3 N/A 2008/2009 
32 39/09 GA2 7/4/09 8-17/4 N/A 2008/2009 
33 40/09 GA2 15/4/09 15-19/4 N/A 2008/2009 
34 16/10 GA2 2/12/09 2-7/12 N/A 2009/2010 
35 27/10 GA2 06/12/09 14-28/12 N/A 2009/2010 
36 41/10 GA2 23/12/09 23-5/1 N/A 2009/2010 
37 30/10 GA2 07/12/09 7-10/12 N/A 2009/2010 
38 35/10 BA4 16/12/09 16-24/12 N/A 2009/2010 
39 44/10 BA4 28/12/09 28-12/1 N/A 2009/2010 
40 45/10 BA4 30/12/09 30-12/1 N/A 2009/2010 
41 47/10 BA4 03/01/10 4-21/1 N/A 2009/2010 
42 49/10 BA4 11/01/10 12-20/1 N/A 2009/2010 
43 53/10 BA4 20/01/10 20-4/2 N/A 2009/2010 
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12.4 Sequences used in the construction of the subgroup A 
phylogenetic tree  
>NCL/51/10 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
CAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/57/10 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCATAAAACCAAAGGAAGTACTCACCACCAAGCCCACAAAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAATACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAAGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/16/10 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGCACTCACCACCAAGCCCACAGAAAAGCCAACC
ATCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATC
CAGAACACACAAGTCAAGAGGAAACCCCCCACTCAACCACCTCCGAAGGCAATCTAAGCCC
ATCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAA
AATGATAG 
>NCL/27/10 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
CAACCTCAAACCACAAAACCAAAGGAAGTACTCACCTCCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/41/10 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
CAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/14/09 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGCACTCACCACCAAGCCCACAGAAAAGCCAACC
ATCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATC
CAGAACACACAAGTCAAGAGGAAACCCCCCACTCAACCACCTCCGAAGGCAATCTAAGCCC
ATCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAA
AATGATAG 
>NCL/24/09AAGAAAACAACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAA
AGATCCCAAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCTCACAGAAAAG
CCAACCATCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCCCCAACACCACAG
GAAATCCAGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACATCCGAAGGCAATCT
AAGCCCATCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCGTCTTCATCCAACA
CAACAAAATGATAG 
>NCL/29/09 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/4/09 
AAGAAAACCACCACCAAGCCCACGAAAAAACAAACCATCAAGACAACCAAAAAAGATCTC
AAACATCAAACTACAAAACCAAAGGAAGCACCTACCACCAAGCCTACAAAAAAGCCAACTA
TCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAGGAAATCT
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AGAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTCCGAAAGCAATACAAGCCCT
TCACAAATCTATACAACATCCGAGTACCTATCACAACCTCCATCTCCATCCAACATAACAGA
TCAGTAG 
>NCL/7/09 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGGCAACCAAAAAAGATCCT
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAATCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCATCACAACAAA
ATGATAG 
>NCL/9/09 
AAGAAAACCACCACCAAGCCCACAAAAAAATCAACCATCAAGACAACCAAAGAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/15/09 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/28/09 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/40/09 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCAAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/31/09 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/39/09 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCAAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/51/08 
AAGAAAACCACCACCAAGCCCACAAAAAAATCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/40/08 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAGAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
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TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/41/08 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/42/08 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCTCCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/44/08 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/46/08 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCGAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>NCL/48/08 
AAGAAAACCACCACCAAGCCCACGAAAAAACAAACCATAAAGACAACCAAAAAAGATCTC
AAACCTCAAACTACAAAACCAAAGGAAGCACCTACCACCAAGCCCACAGAAAAGCCAACCA
TCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAGGAAATCT
AGAACACACGAGTCAAGAGGAAACCCTCTATTCAACCTCCTCCGAAGGCAATACAAGCCCT
TCACAAATCTATACAACATCCGAGTACCTATCACAACCTCCATCTCCATCCAACATAACAGA
CTAGTAG 
>NCL/49/08 
AAGAAAACCACCACCAAGCCCACGAAAAAACCAACCATCAAAACAACCAAAAAAGATCTC
AAACCTCAAACCACAAAACCCAAGGAAGCACCTTCCACCAAGCCCACAGATAAGCCAACCA
TCAACACCACCAAACCAAACATAAGAACCACACTGCTCACCAACAGCACCACAGGAAATCT
AGAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTCCGAAGGCAACACAAGCCCT
TCACAAATCTATACAACATCCGAGTACCTATCACAACCTCAATCTCCATCCAACATAACAGA
CCAGTAG 
>NCL/50/08 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAGAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCGACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATCTAAGCCCA
TCACAAGTCTATACAACATCCAAGTACCTATCACAATCTCCATCTTCATCCAACACAACAAA
ATGATAG 
>RS89-1734 
AAGAGAACCACCACCAAGCCCACAAAGAAGCCAACCCTAAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACTAAATCAGAGGAGGTACCCACCACCAAGCTCACAGAAGAGCCAACTA
TCAACACCACCAAAACAAACATCATAACCACACCACTCACCTCCAACACCGCGAGAAATCC
AGAACTCACAAGTCAAATGGAAACCTTCCACTCAACCTCCTCCGAAGGTAATCCAAGCCCTT
CTCAAGTCTCCATTACATCCGAGTACCCACCACAACCCTCATCTCCACCCAACACACCACGC
TAGTAG 
>RS89-5857 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCTC
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AAACCTCAAACCACAAAACCAAAGGAAGTACTTACCACCAAGCCCACAGAAAAGCCAACCA
TCAACACCACCAGAACAAACATCAGAACTACACTGCTCACCACCAATACCACAGGAAATCC
AGAATACACAAGTCAAAAGGAAACCCTCCACTCAACCTCCCCCGAAGGCAATCCAAGCCCT
TCACAAGTCTATACAACATCCGAGTACCCATCACAACCTCCATCTCCATCCAACACAACAAA
CTAGTAG 
>RS89-6190 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCAC
AAACCTCAAACCACAAAACCAAAGGAAGCACCCACCACCAAGCCCACAGAAAAGCCAACC
ATCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAGGAAATC
TAGAACACACAAGTCAAGAGGAAACCCTCCACTCAACCTCCTCCGAAGGCAATACAAGCCC
TTCACAAGTCTATACAACATCCGAGTACCTATCACAACCTACATCTCCATCCAACATAACAA
ACCAGTAG 
>RS89-6256 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGTACTTACCACCAAGCCCACAGAAAAGCCAACCA
TCAACACCACCAGAACAAACATCAGAACTACACTGCTCACCACCAATACCACAGGAAATCC
AGAATACACAAGTCAAAAGGAAACCCTCCACTCAACCTCCCCCGAAGGCAATCCAAGCCCT
TCACAAGTCTATACAACATCCGAGTACCCATCACAACCACCATCTCCATCCAACACAACAAA
CTAGTAG 
>RS89-642 
AAGAGAACCACCACCAAGCCCACAAAAAAACCAACCCCAAAGACAACCAAAAAAGGTCCC
AAGCCTCAAACCACTAAATCAAAGGAGGCACCCACCACCAAGCCCACAGAAGAGCCAACTA
TCAATACCACCAAAACAAACATCATAACTACACTACTCACCTCCAACACCACGAGAAATCCA
GAACTCACAAGTCAAATGGAAACTTTCCACTCAACCTCCTCAGAAGGTAATCCAAGCCCTTC
TCAAGTCTCCATAACATCCGAGTACCCATCACAACCCTCATCTCCACCCAACACGCCACGCT
AGTAG 
>RS89-6614 
AAGAAAACTACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGTACTTACCACCAAGCCCACAGAAAAGCCAACCA
TCAACACCACCAAAACAAACATCAGAACTACACTGCTCACCACCAATACCACAGGAAATCC
AGAATACACAAGTCAAAAGGAAACCCTCCACTCAACCTCCCCCGAAGGCAATCCAAGCCCT
TCACAAGTCTATACAACATCTGAGTACCCATCACAACCTCCATCTCCATCCAACACAACAGA
CTAGTAG 
>NCL/26151/96 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAAACAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGCACCTACCACCAAGCCCACAGAAAAGCCAACC
ATCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAAGAAATC
TAGAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTCCGAAGGCAATACAAGCCC
TTCACAAGTCTATACAACATCCGAGTACCTATCACAACCTCCATCTTTATCCAACATAACAA
ACCAGTTG 
>NCL/25316/96 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAAACAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGCACCTACCACCAAGCCCACAGAAAAGCCAACC
ATCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAAGAAATC
TAGAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTCCGAAGGCAATACAAGCCC
TTCACAAGTCTATACAACATCCGAGTACCTATCACAACCTCCATCTTTATCCAACATAACAA
ACCAGTTG 
>NCL/15401/96 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAAACAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGCACCTACCACCAAGCCCACAGAAAAGCCAACC
ATCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAAGAAATC
TAGAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTCCGAAGGCAATACAAGCCC
TTCACAAGTCTATACAACATCCGAGTACCTATCACAACCTCCATCTTTATCCAACATAACAA
ACCAGTTG 
>NCL/24702/96 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATATC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCTCACAGAAAAGCCAACCA
TCAACACTACCAAAACAAACATCAGAACCACACTGCTCACCACCAATACTACAGAAAATCC
AGAACACACAAGTCAAAAGGAAACCCTCCACTCAACTTCTTCCGAAGGCAATTCAAGCCCTT
CACAAGTCTATCCAACATCCGAGTACCTATCACAATCTCCATCTCCATCCAACACAACAAAC
TTGTTG 
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>NCL/20714/97 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGCACCTCCCACCAAGCCCACAGAAAAGCCAACCA
TCAACATCACCAAACCAAACATCAGAACTACACTGGTCACCAACAGTACCACAGGAAATCT
AGAACACACAAGTCAAGAGGAAACCCTCCATACAACCTCCTCCGAAGGCAATACAAGCCCT
TCACAAATTTATTCAACATCCGAGTCCCTATCCAAACCTCCATCTTCATCCAACATAACAAAC
CAAGTT 
>NCL/1734/97 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGCACCTCCCACCAAGCCCACAGAAAAGCCAACCA
TCAACATCACCAAACCAAACATCAGAACTACACTGGTCACCAACAGTACCACAGGAAATCT
AGAACACACAAGTCAAGAGGAAACCCTCCATACAACCTCCTCCGAAGGCAATACAAGCCCT
TCACAAATTTATTCAACATCCGAGTCCCTATCCAAACCTCCATCTTCATCCAACATAACAAAC
CAAGTT 
>NCL/21540/97 
AAGAAAACCACCACCAAGCCCACAAGAAAACCAACCACCAAGATAACCAAAAAAGATCTC
AGACCTCAGACCACAGAACCAAGGGAGGTGCCTACCACCAAGCCCACGGAGAGGTCAACCA
TCAACACCACCAAAACAAACATCAGAACTACACTGCTCACCAACAACACCACAGGGAATCC
AGAACACACAAGTCAAAAGGAAACCCTCCACTCAACCTTTTCCGAAGGCAATCCAAGCCCTT
CACAAGTCCACACAACATCCGAGTACCTATGACAACCCCCATCTTCATCCGACACAACAAAC
TAGTTG 
>NCL/2567/97 
AAGAAAACCACCACCAAGCCCACAAGAAAACCAACCACCAAGATAACCAAAAAAGATCTC
AGACCTCAGACCACAGAACCAAGGGAGGTGCCTACCACCAAGCCCACGGAGAGGTCAACCA
TCAACACCACCAAAACAAACATCAGAACTACACTGCTCACCAACAACACCACAGGGAATCC
AGAACACACAAGTCAAAAGGAAACCCTCCACTCAACCTTTTCTGAAGGCAATCCAAGCCCTT
CACAAGTCTATACAACATCCGAGTACCTATGACAACCCCCATTTCCATCCAACACAACAAAC
TAGTTG 
>NCL/25137/96 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACTATCAAGACAACCAAAATAGATCTCA
AACCTCAAACCACAAAACCAAAGGAAGTACTTACCACCAAGCCCACAGAAAAGCCAACTAT
CAACACCACCAGAACAAACATCGGAACTACACTGCTCACCACCAATACCACAGGAAATCCA
GAATTCACAAGTCAAAAGGAAACCCTTCACTCAACCTTCCCCGAAGGCAATCCAAGCCCTTC
ACAAGTCTATACAACATCCGAGTACCCATCACAACCTCCATCTCCATCCAACACAACAAACT
AGTAG 
>NCL/17063/97 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACTATCAAGACAACCAAAATAGATCTCA
AACCTCAAACCACAAAACCAAAGGAAGTACTTACCACCAAGCCCACAGAAAAGCCAACTAT
CAACACCACCAGAACAAACATCGGAACTACACTGCTCACCACCAATACCACAGGAAATCCA
GAATTCACAAGTCAAAAGGAAACCCTTCACTCAACCTTCCCCGAAGGCAATCCAAGCCCTTC
ACAAGTCTATACAACATCCGAGTACCCATCACAACCTCCATCTCCATCCAACACAACAAACT
AGTAG 
>NCL/8923/97 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCCC
AAACCTCAAACCACAAAACCAAAGGAAGTACTCACCACCAAGCCCACAGAAAAGCCAACCA
TCAACACCACCAAAACAAACATCAGAACTACACTGCTCACCTCCAACACCACAGGAAATCC
AGAACACACAAGTCAAAAGGAAACCCTCCACTCAACCACCTCCGAAGGCAATTTAAGCCCT
TCACAAGTTTATACAACATCCGAGTACCTATCACAATCTTTATCTCCATCCAACACAACAAA
ATGGTTG 
>NCL/24650/96 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGCACCTACCACCAAGCCCACAGAAAAGCCAACC
ATCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAGGAAATC
TAGAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTCCGAAGGCAATACAAGCCC
TTCACAAGTCTATACAACATCCGAGTACCTATCACAACCTCCATCTTTATCCAACATAACAA
ACCAGTTG 
>NCL/24869/96 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGCACCTACCACCAAGCCCACAGAAAAGCCAACC
ATCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAGGAAATC
TAGAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTCCGAAGGCAATACAAGCCC
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TTCACAAGTCTATACAACATCCGAGTACCTATCACAACCTCCATCTTTATCCAACATAACAA
ACCAGTTG 
>NCL/11297/97 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGCACCTACCACCAAGCCCACAGAAAAGCCAACC
ATCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAGGAAATC
TAGAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTCCGAAGGCAATACAAGCCC
TTCACAAGTCTATACAACATCCGAGTACCTATCACAACCTCCATCTTTATCCAACATAACAA
ACCAGTTG 
>NCL/24845/96 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGCACCTACCACCAAGCCCACAGAAAAGCCAACC
ATCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAGGAAATC
TAGAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTTCGAAGGCAATACAAGCCC
TTCACAAGTGTATTCAACATTCGAGTCCTTATGACAACCTCCATCTTTATCCAACATAACAAA
CCAGTTT 
>NCL/24882/96 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGCACCTACCACCAAGCCCACAGAAAAGCCAACC
ATCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAGGAAATC
TAGAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTTCGAAGGCAATACAAGCCC
TTCACAAGTGTATTCAACATTCGAGTCCTTATGACAACCTCCATCTTTATCCAACATAACAAA
CCAGTTT 
>NCL/25115/96 
AAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATCAAGACAACCAAAAAAGATCTC
AAACCTCAAACCACAAAACCAAAGGAAGCACCTACCACCAAGCCCACAGAAAAGCCAACC
ATCAACATCACCAAACCAAACATCAGAACTACACTGCTCACCAACAGTACCACAGGAAATC
TAGAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTTCGAAGGCAATACAAGCCC
TTCACAAGTGTATTCAACATTCGAGTCCTTATGACAACCTCCATCTTTATCCAACATAACAAA
CCAGTTT 
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12.5 Sequences used in the construction of the subgroup B/BA 
phylogenetic tree 
>NCL/54/10 
TGTGGCAGCAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CAAAAACACCAGCCAAAACACCGAAAAAAGAACCCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAACCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTTACAATCTATGGTGCTCGACACAAC
CACATCAAAACACACAAT 
>NCL/52/10 
TGTGGCAACAATCAACTCTGCAAATCCATCTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCCACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CTAAAACACTAGCCAAAACACCGAAAAAAGAAACCACCATCAACCCAACAAAAAAA---
CCAACCCCCAAAACCACAAAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAGGAGACACCAGCACCCTACAATCCATTGCACTTGACACAAC
CACATCAAAACACACAAT 
>NCL/50/10 
TGTGGCAGCAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CAAAAACACCAGCCAAAACACCGAAAAAAGAACCCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAACCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCCCACAATCTACTGTGCTCGACACAAC
CACATCAAAACACACAAT 
>NCL/46/10 
TGTGGCAACAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACTATAAAACCCACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CTAAAACACTAGCCAAAACACCGAAAAAAGAAACCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTCACAATCCATTGCGCTTGACACAAC
CACATCAAAACACACAAT 
>NCL/32/10 
TGTGGCAGCAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CAAAAACACCAGCCAAAACACCGAAAAAAGAACCCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAACCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTTACAATCTATTGTGCTCGACACAAC
CACATCAAAACACACAAT 
>NCL/29/10 
TGTGGCAGCAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CAAAAACACCAGCCAAAACACCGAAAAAAGAACCCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAACCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTTACAATCTATTGTGCTCGACACAAC
CACATCAAAACACACAAT 
>NCL/21/10 
TGTGGCAACAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCCACAAACAAACCACCAACCAAAACCACAAACAAAAGAGACC
CCAAAACACCAGCCAAAACACCGAAAAAAGAAACCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCGAAACACACAGAAAGAGACACCAGCACCCCACAATCCATTGCGCTTGACACAAC
CACATCAAAACACACAAT 
>NCL/49/10 
TGTGGCAACAATCAACTCTGCAAATCCATCTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCCACAAACAAGCCACCCACCAAAACCACAAACAAAAGAGACC
CTAAAACACTAGCCAAAACACCGGAAAAAGAAACCACCATCAACCCAACAAAAAAA---
CCAACCCCTAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTTACAATCCATTGCGCTTGACACAAC
CACATCAAAACACACAA 
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>NCL/23/10 
TGTGGCAGCAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CAAAAACACCAGCCAAAACACCGAAAAAAGAACCCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAACCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTTACAATCTACTGCGCTCGACACAAC
CACATCAAAACACACAAT 
>NCL/47/10 
TGTGGCAGCAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CAAAAACACCAGCCAAAACACCGAAAAAAGAACCCACCATTAACTCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAACCCACTGTGCTCAACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTTACAATCTATTGTGCTTGACACAAC
CACATCAAAACACACAAT 
>NCL/53/10 
TGTGGCAGCAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CAAAAACACCAGCCAAAACACCGAAAAAAGAACCCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAACCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAGGAGACACCAGCACCTTACAATCTATTGTGCTCGACACAAC
CACATCAAAACACACAAT 
>NCL/45/10 
TGTGGCAACAATCAACTCTGCAAATCCATCTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCCACAAACAAGCCACCCACCAAAACCACAAACAAAAGAGACC
CTAAAACACTAGCCAAAACACCGGAAAAAGAAACCACCATCAACCCAACAAAAAAA---
CCAACCCCTAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTTACAATCCATTGCGCTTGACACAAC
CACATCAAAACACACAAT 
>NCL/35/10 
TGTGGCAGCAATCAACTCTGCAAATCCATTTGCAAAACAATAGCAAGCAATAAGCCAAAGA
AAAATCCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAACAAAAGAAACC
CAAAAACACCAGCCAAAACACCGAAAAAAGAACCCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAACCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTTACAATCTATTGTGCTCGACACAAC
CACATCAAAACACACAAT 
>NCL/44/10 
TGTGGCAACAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CAAAAACACTAGCTAAAACACCGAAAAAAGATACCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTCACAATCTATTGTGCTCGACACAAC
CACATCAAAACACACAAT 
>NCL/30/10 
TGTGGCAACAATCAACTCTGCAAATCCATTTGCAAAACTATACCAAGCAACAAACCAAAGA
AAAAACCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAGCAAAAGAGACC
CAAAAACACTAGCTAAAACACCGAATAAAGATACCACCACCAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTCACAATCTATTGTGCTCGACACAAC
CACATCAAAACACACAAT 
>NCL/56/08 
TGTGGCAACAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CAAAAACACTAGCTAAAACACCGAAAAAAGATACCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCTCCTCACAATCTATTGTGCTCGACACAAC
CACATCAAAACACACAAT 
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>NCL/45/08 
TGTGGCAACAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCACAAAACCCACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CAAAAACACTAGCCAAAACACCGAAAAAAGAAACCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAAACACCAGCACCTCACAATCCATTGTGCTCGACACAAC
CACATCAAAACACACAAT 
>NCL/54/08 
TGTGGCAACAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCAACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CAAAAACACTAGCTAAAACACCGAAAAAAGAAACCACTATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTCACAATCTATTGTGCTCGACACAAC
CACATCAAAACATACAAT 
>NCL/06/09 
TGTGGCAACAATCAACTCTGCAAATCCATCTGCAAAACAATACCAAGCAACAAACCAAAGA
AAAAACCAACCATAAAACCCACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CTAAAACACTAGCCAAAACACCGAAAAAAGAAACCACCATCAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTTACAATCCATTGCACTTGACACAAC
CACATCAAAACACACAAT 
>NCL/11/09 
TGTGGCAACAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACTATAAAACCCACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CTAAAACACTAGCCAAAACACCGAAAAAAGAAACCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTCACAATCCATTGCGCTTGACACAAC
CACATCAAAACACACAAT 
>NCL/25/09 
TGTGGCAACAATCAACTCTGCAAATCCATTTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACTATAAAACCCACAAACAAACCACCCACCAAGACCACAAACAAAAGAGACC
CTAAAACACTAGCCAAAACACCGAAGAAAGAAACCACCATTAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAACACCCCACAATCCACCGTGCTTGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTCACAATCCATTGCGCTTGACACAAC
CACATCAAAACACACAAT 
>NCL/03/09 
TGTGGCAACAATCAACTCTGCAAATCCATCTGCAAAACAATACCAAGCAATAAACCAAAGA
AAAAACCAACCATAAAACCCACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CTAAAACACTAGCCAAAACACCGAAAAAAGAAACCATCATCAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACAAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCCTACAATCCATTGCACTTGACACAAC
CACATCAAAACACACAAT 
>NCL/30/09 
TGTGGCAACAATCAACTCTGCAAATCCATCTGCAAAACAATACCAAGCAACAAACCAAAGA
AAAAACCAACCATAAAACCCACAAACAAACCACCCACCAAAACCACAAACAAAAGAGACC
CTAAAACACTAGCCAAAACACCGAAAAAAGAAACCACCATCAACCCAACAAAAAAA---
CCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCACAATCCACTGTGCTCGACACAA
CCACATCAAAACACACAGAAAGAGACACCAGCACCTTATAATCCATTGCACTTGACACAAC
CACATCAAAACACACAAT 
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12.6 Complete G and F in pSC11 
>25173G2/pSC11_1 (GA7G) 
CCCATAAATAATAAATACAATAATTAATTTCTCGTAAAAGTAGAAAATATATTCTAATTTAT
TGCACGGTAAGGAAGTAGAATCATAAAGAACAGTGACGGATCCCCGGGGCAATTGCAAACA
TGTCCAAAACCAAGGATCAACGCACCGCCAAGACACTAGAAAGGACCTGGGACACTCTCAA
TCATCTATTATTCATATCATCGTGCTTATACAAGTTAAATCTTAAATCTATAGCACAAATCAC
ATTATCCATTTTGGCAATGATAATCTCAACTTCACTTATAATTGCAGCCATCATATTCATAGC
CTCAGCAAACCACAAAGTCACACTAACAACTGCAATCACACAAGATGCAACAAGCCAGATC
AAGAACACAACCCCAACATACCTCACCCAGAATCCCCAGCTTGGAATCAGCTTCTCCAATCT
GTCTAAAACCACATCACAACCCACCACCACACCAGCTCTAGCAACACCAAGTGCTGAGTCA
ACCTCACAATCCACAACAGTCAAGACCAAAAACACAACAACAACCCAAATACAACCCAGCA
AGTCCACCACAAAACAACGCCAAAACAAACCACCAAATAAACCCAACAATGATTTTCACTT
TGAAGTGTTCAACTTTGTACCCTGCAGCATATGCAGCAACAATCCAACCTGCTGGGCTATCT
GCAAAAGAATACCAACCAAAAAACCTGGAAAGAAAACCACCACCAAGCCCACAAAAAAAC
CAACTATCAAGACAACCAAAATAGATCTCAAACCTCAAACCACAAAACCAAAGGAAGTACT
TACCACCAAGCCCACAGAAAAGCCAACTATCAACACCACCAGAACAAACATCGGAACTACA
CTGCTCACCACCAATACCACAGGAAATCCAGAATACACAAGTCAAAAAGGAAACCCTCCAC
TCAACCTCCCCCGAAGGCAGTCCAGGCCCTTCACAAGTCTATACAACATCTGAGTACCCATC
ACAACCTCCATCTCCATCCAACACAACAAACGAGTAGTCATTAAAAAGCGTATTCCTGAGGA
AACCCGGGAATTCTG 
 
>4208G/pSC11_4 (GA2G) 
GTAGTTTTTCCCCATAAATAATAAATACAATAATTAATTTCTCGTAAAAGTAGAAAATATAT
TCTAATTTATTGCACGGTAAGGAAGTAGAATCATAAAGAACAGTGACGGATCCCCGGGGCA
ATTGCAAACATGTCCAAAACCAAAGACCAACGCACCGCCAAGACACTAGAAAAGACCTGGG
ACACTCTCAATCATCTATTATTCATATCATCGTGCTTATACAAGTTAAATCTTAAATCTATAG
CACAAATCACATTATCCATTCTGGCAATGATAATCTCAACTTCACTTATAATCGTAGCTATCA
TATTCATAGCCTCAGCAAACAACAAAGTCACACTAACAACTGCAATCATACAAGATGCAAC
AAGCCAGATCAAGAACACAACCCCAACATACCTGACCCAGGATCCCCAGCTTGGAATCAGC
TTCTTCAATCTGTCTGGAACTATATCACAAACCACCGCCATACTAGCTCCAACAACACCAAG
TGTCGAGCCAATCCTGCAATCTACAACAGTCAAGACCAAAAACACAACAACAACCCAAATA
CAACCCAGCAAGCTCACCACAAAACAACGCCAAAACAAACCACCAAACAAACCCAATGATG
ATTTTCACTTTGAAGTGTTCAACTTTGTACCCTGCAGCATATGCAGCAACAATCCAACTTGCT
GGGCCATCTGCAAAAGAATACCAAGCAAAAAACCTGGAAGGAAAACCACCACCAAGCCCA
CGAAAAAACAAACCATAAAGACAACCAAAAAAGATCTCAAACCTCAAACTACAAAACCAA
AGGAAGCACCTACCACCAAGCCCACAGAAAAGCCAACCATCAACATCACCAAACCAAACAT
CAGAACTACACTGCTCACCAACAGTACCACAGGAAATCTAGAACACACGAGTCAAGAGGAA
ACCCTCTATTCAACCTCCTCCGAAGGCAATACAAGCCCTTCACAAATCTATACAACATCCGA
GTACCTATCACAACCTCCATCTCCATCCAACATAACAGACTAGTAGTCATTAAAAAGCGTAT
TCCTGAGGAAACCCGGGAATTCTGTGAGCGTATGGCAAACGAAG 
 
>5608G/pSC11_2 (BAG) 
TATTGCACGGTAAGGAAGTAGAATCATAAAGAACAGTGACGGATCCCCGGGGCAATTGCAA
ACATGTCCAAAAACAAGAATCAACGCACTGCCAGGACTCTAGAAAAGACCTGGGATACTCT
TAATCATCTAATTGTAATATCCTCTTGTTTATACAAATTAAATTTAAAATCTATAGCACAAAT
AGCACTATCAGTTTTGGCAATGATAATCTCAACCTCTCTCATAATTGCAGCCATAATATTCAT
CATCTCTGCCAATCACAAAGTTACACTAACAACTGTCACAGTTCAAACAATAAAAAAACCAC
ACTGAGAAAAACATAACCACTTACCTTACTCAAGTCTCACCAGAAAGGGTTAGCCCATCCAA
ACAACTCACAACCACACCACCAATCCACACAAATTCAGCCACAATATCACCTAATACAAAAT
CAGAAACACACCATACAACAGCACAAACCAAAGGCAGAACCTCTACTCCAACACAGAACAA
CAAACCAAGCACAAAACCACGTCCAAAAAATCCACCAAAAAAAGATGATTACCATTTCGAA
GTGTTCAACTTCGTTCCCTGCAGTATATGTGGCAACAATCAACTCTGCAAATCCATTTGCAAA
ACAATACCAAGCAATAAACCAAAGAAAAAACCAACCATAAAACCAACAAACAAACCACCC
ACCAAAACCACAAACAAAAGAGACCCAAAAACACTAGCTAAAACACCGAAAAAAGATACC
ACCATTAACCCAACAAAAAAACCAACCCCCAAGACCACAGAAAGAGACACCAGCACCCCAC
AATCCACTGTGCTCGACACAACCACATCAAAACACACAGAAAGAGACACCAGCTCCTCACA
ATCTATTGTGCTCGACACAACCACATCAAAACACACAATCCAACAGCAATCCCTCCACTCAA
TCACCCCCGGAAACACACCCAACTCCACACAAACACCCACAGCATCCGAGCCCTCCACATCA
AATTCTACCTA 
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>GA2F_pSC11_4 (GA2F) 
TTCTAATTTATTGCACGGTAAGGAAGTAGAATCATAAAGAACAGTGACGGATCCCCGGGGC
AAATAACAATGGAGTTGCCAATCCTCAAAACAAACGCAATCACTGCAATCCTTGCTGCAGTC
TCACTCTGTTTCGCTTCCAGTCAAAACATCACTGAAGAATTTTATCAATCAACCTGCAGTGCA
GTTAGCAAAGGCTATCTTAGTGCTTTAAGAACTGGTTGGTATACTAGTGTTATAACTATAGA
ATTAAGTAATATCAAGGAAAATAAGTGTAATGGAACCGATGCTAAGGTAAAATTGATAAAA
CAAGAATTAGATAAATATAAAAATGCTGTAACAGAATTGCAGTTGCTCATGCAAAGCACAC
CAGCAGCCAACAATCGAGCCAGAAGAGAACTACCAAGGTTTATGAATTATACACTCAACAA
TACCAAAAATAACAATGTAACATTAAGCAAGAAAAGGAAAAGAAGATTTCTTGGCTTTTTGT
TAGGTGTTGGATCTGCAATCGCCAGTGGCATTGCTGTATCTAAAGTCCTGCACCTAGAAGGA
GAAGTGAACAAAATCAAAAGTGCTCTACTATCCACAAACAAGGCTGTAGTCAGCTTATCAA
ATGGAGTTAGTGTCTTAACCAGCAAAGTGTTAGACCTCAAAAACTATATAGATAAACAGTTG
TTACCCATTGTGAACAAGCAAAGCTGCAGCATATCAAACATTGAAACTGTGATAGAATTCCA
ACAAAAGAACAACAGACTACTAGAGATTACCAGGGAATTTAGTGTTAATGCAGGTGTAACT
ACACCTGTAAGCACTTATATGTTAACAAATAGTGAATTATTATCATTAATCAATGATATGCCT
ATAACAAATGATCAGAAAAAGTTAATGTCCAACAATGTTCAAATAGTTAGACAGCAAAGTT
ACTCTATCATGTCCATAATAAAGGAGGAAGTCTTAGCATATGTAGTACAATTACCACTATAT
GGTGTAATAGATACACCTTGTTGGAAACTACACACATCCCCTCTATGCACAACCAACACAAA
GGAAGGGTCCAACATCTGTTTAACAAGAACCGACAGAGGATGGTACTGTGACAATGCAGGA
TCAGTTTCTTTCTTCCCACAAGCTGAAACATGCAAAGTTCAATCGAATCGAGTATTTTGTGAC
ACAATGAACAGTTTAACATTACCAAGTGAAGTAAATCTCTGCAACATTGACATATTCAACCC
TAAATATGATTGCAAAATTATGACTTCAAAAACAGATGTAAGCAGCTCCGTTATCACATCTC
TAGGAGCCATTGTGTCATGCTATGGCAAAACTAAATGCACAGCATCCAATAAAAATCGTGG
AATCATAAAGACATTTTCTAACGGGTGTGATTATGTATCAAATAAAGGGGTGGACACTGTAT
CTGTAGGTAATACATTATATTATGTAAATAAGCAAGAAGGAAAAAGTCTCTATGTAAAAGGT
GAACCAATAATAAATTTCTATGACCCATTAGTGTTCCCTTCTGATGAATTTGATGCATCAATA
TCTCAAGTCAATGAGAAGATTAACCAGAGCCTAGCATTTATTCGTAAATCTGATGAATTATT
ACATAATGTAAATGTTGGTAAATCCACCACAAATATCATGATAACTACTATAATTATAGTGA
TTATAGTAATATTGTTATTATTAATTGCAGTTGGGCTGTTCCTATACTGCAAGGCCAGAAGCA
CACCAGTCACACTAAGCAAGGATCAACTGAGTGGTATAAATAATATTGCATTTAGTAACTGA
ATAAAAATA  
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12.7 Truncation 
Engineered restriction sites, NcoI and BamHI are boxed. 
>284G-pTM3 
CTTTGAAAAACACGATAATACCATGGCCAAAACCAAGGATCAACGCACCGCCAAGACACTA
GAAAGGACCTGGGACACTCTCAATCATCTATTATTCATATCATCGTGCTTATACAAGTTAAA
TCTTAAATCTATAGCACAAATCACATTATCCATTTTGGCAATGATAATCTCAACTTCACTTAT
AATTGCAGCCATCATATTCATAGCCTCAGCAAACCACAAAGTCACACTAACAACTGCAATCA
CACAAGATGCAACAAGCCAGATCAAGAACACAACCCCAACATACCTCACCCAGAATCCCCA
GCTTGGAATCAGCTTCTCCAATCTGTCTAAAACCACATCACAACCCACCACCACACCAGCTC
TAGCAACACCAAGTGCTGAGTCAACCTCACAATCCACAACAGTCAAGACCAAAAACACAAC
AACAACCCAAATACAACCCAGCAAGTCCACCACAAAACAACGCCAAAACAAACCACCAAAT
AAACCCAACAATGATTTTCACTTTGAAGTGTTCAACTTTGTACCCTGCAGCATATGCAGCAA
CAATCCAACCTGCTGGGCTATCTGCAAAAGAATACCAACCAAAAAACCTGGAAAGAAAACC
ACCACCAAGCCCACAAAAAAACCAACTATCAAGACAACCAAAATAGATCTCAAACCTCAAA
CCACAAAACCAAAGGAAGTACTTACCACCAAGCCCACAGAAAAGCCAACTATCAACACCAC
CAGAACAAACATCGGAACTACACTGCTCACCACCAATACCACAGGAAATCCAGAATACACA
AGTCAAAAGGAAACCCTCCACTCAACCTCCCCCGAAGGCAGTCCAGGCCCTTCACAAGTCTA
TACAACATCTGAGGATCCCTGCAGCTCG 
 
>G172-pTM3-clone 2  
GTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAG
TGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAA
CAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGG
TGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGG
GGACGTGGTTTTCCTTTGAAAAACACGATAATACCATGGCCAAAACCAAGGATCAACGCAC
CGCCAAGACACTAGAAAGGACCTGGGACACTCTCAATCATCTATTATTCATATCATCGTGCT
TATACAAGTTAAATCTTAAATCTATAGCACAAATCACATTATCCATTTTGGCAATGATAATCT
CAACTTCACTTATAATTGCAGCCATCATATTCATAGCCTCAGCAAACCACAAAGTCACACTA
ACAACTGCAATCACACAAGATGCAACAAGCCAGATCAAGAACACAACCCCAACATACCTCA
CCCAGAATCCCCAGCTTGGAATCAGCTTCTCCAATCTGTCTAAAACCACATCACAACCCACC
ACCACACCAGCTCTAGCAACACCAAGTGCTGAGTCAACCTCACAATCCACAACAGTCAAGA
CCAAAAACACAACAACAACCCAAATACAACCCAGCAAGTCCACCACAAAACAACGCCAAA
ACAAACCACCAAATAAACCCAACAATGATTTTCACTTTGAAGTGTTCAACTTTGTACCCTAG
GGATCCCTGCAGCTCGAGAGGCCTAATTAATTAAGTCGACGATCCGGCTGCTAACAAAGCC
CGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGG
CCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGGTCCGGAGTT
AACTCGACATCTATATACTATATAGTAATACCAATACTCAAGACTACGAAACTGATACAATC
TCTTATCATGTGGGTAATGTTCTCGATGTCGATAGCCATATGCCCGGTAGTTGCGATATACAT
AAACTGATCACTAATT 
 
>G177-pTM3-clone 2 
AGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTC
AACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCCATTGTATGGGATCTGATCTGGGGCCT
CGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACAC
GGGGACGTGGTTTTCCTTTGAAAAACACGATAATACCATGGCCAAAACCAAGGATCAACGC
ACCGCCAAGACACTAGAAAGGACCTGGGACACTCTCAATCATCTATTATTCATATCATCGTG
CTTATACAAGTTAAATCTTAAATCTATAGCACAAATCACATTATCCATTTTGGCAATGATAAT
CTCAACTTCACTTATAATTGCAGCCATCATATTCATAGCCTCAGCAAACCACAAAGTCACAC
TAACAACTGCAATCACACAAGATGCAACAAGCCAGATCAAGAACACAACCCCAACATACCT
CACCCAGAATCCCCAGCTTGGAATCAGCTTCTCCAATCTGTCTAAAACCACATCACAACCCA
CCACCACACCAGCTCTAGCAACACCAAGTGCTGAGTCAACCTCACAATCCACAACAGTCAA
GACCAAAAACACAACAACAACCCAAATACAACCCAGCAAGTCCACCACAAAACAACGCCA
AAACAAACCACCAAATAAACCCAACAATGATTTTCACTTTGAAGTGTTCAACTTTGTACCCT
GCAGCATATGCTAGGGATCCCTGCAGCTCGAGAGGCCTAATTAATTAAGTCGACGATCCGG
CTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGC
ATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATAT
CCGGGTCCGGAGTTAACTCGACATCTATATACTATATAGTAATACCAATAC 
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>G190-pTM3 
GGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACG
TCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATAATACCATGGCC
AAAACCAAGGATCAACGCACCGCCAAGACACTAGAAAGGACCTGGGACACTCTCAATCATC
TATTATTCATATCATCGTGCTTATACAAGTTAAATCTTAAATCTATAGCACAAATCACATTAT
CCATTTTGGCAATGATAATCTCAACTTCACTTATAATTGCAGCCATCATATTCATAGCCTCAG
CAAACCACAAAGTCACACTAACAACTGCAATCACACAAGATGCAACAAGCCAGATCAAGAA
CACAACCCCAACATACCTCACCCAGAATCCCCAGCTTGGAATCAGCTTCTCCAATCTGTCTA
AAACCACATCACAACCCACCACCACACCAGCTCTAGCAACACCAAGTGCTGAGTCAACCTC
ACAATCCACAACAGTCAAGACCAAAAACACAACAACAACCCAAATACAACCCAGCAAGTCC
ACCACAAAACAACGCCAAAACAAACCACCAAATAAACCCAACAATGATTTTCACTTTGAAG
TGTTCAACTTTGTACCCTGCAGCATATGCAGCAACAATCCAACCTGCTGGGCTATCTGCAAA
AGAATACCATGAGGATCCCTGCAGCTCGAGAGGCCTAATTAATTAAGTCGACGATCCGGCT
GCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCA 
CCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTT 
TGCTG 
 
>151-284-pTM3-clone 2 
AAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGT
GCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGG
GACGTGGTTTTCCTTTGAAAAACACGATAATACCATGGAACGCCAAAACAAACCACCAAAT
AAACCCAACAATGATTTTCACTTTGAAGTGTTCAACTTTGTACCCTGCAGCATATGCAGCAA
CAATCCAACCTGCTGGGCTATCTGCAAAAGAATACCAACCAAAAAACCTGGAAAGAAAACC
ACCACCAAGCCCACAAAAAAACCAACTATCAAGACAACCAAAATAGATCTCAAACCTCAAA
CCACAAAACCAAAGGAAGTACTTACCACCAAGCCCACAGAAAAGCCAACTATCAACACCAC
CAGAACAAACATCGGAACTACACTGCTCACCACCAATACCACAGGAAATCCAGAATACACA
AGTCAAAAGGAAACCCTCCACTCAACCTCCCCCGAAGGCAGTCCAGGCCCTTCACAAGTCTA
TACAACATCTGAGGATCCCTGCAGCTCGAGAGGCCTAATTAATTAAGTCGACGATCCGGCTG
CTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATA
ACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCG
GGTCCGGAGTTAACTCGACATCTATATACTATATAGTAATACCAATACTCAAGACTACGAAA
CTGATACAATCTCTTATCATGTGGGTAATGTTCTCGATGTCGATAGCCATATGCCCGGTAGTT
GCGATATACATAAACTGATCACTAATTCCAAACCCACCCGCTTTTTATAGTAAGTTTTTCACC
CATAAATAATAAATACAATAATTAATTTCTCGTAAAAGTAGAAAATATATTCTAATTTATTG
CACGGTAAGGAAGTAGAAT 
 
>155-284-pTM3-clone 2 
CACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCA
AGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCT
GGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCC
CGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATAATACCATGGAACCACCAAATA
AACCCAACAATGATTTTCACTTTGAAGTGTTCAACTTTGTACCCTGCAGCATATGCAGCAAC
AATCCAACCTGCTGGGCTATCTGCAAAAGAATACCAACCAAAAAACCTGGAAAGAAAACCA
CCACCAAGCCCACAAAAAAACCAACTATCAAGACAACCAAAATAGATCTCAAACCTCAAAC
CACAAAACCAAAGGAAGTACTTACCACCAAGCCCACAGAAAAGCCAACTATCAACACCACC
AGAACAAACATCGGAACTACACTGCTCACCACCAATACCACAGGAAATCCAGAATACACAA
GTCAAAAGGAAACCCTCCACTCAACCTCCCCCGAAGGCAGTCCAGGCCCTTCACAAGTCTAT
ACAACATCTGAGGATCCCTGCAGCTCGAGAGGCCTAATTAATTAAGTCGACGATCCGGCTGC
TAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAA
CCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGG
GTCCGGAGTTAACTCGACATCTATATACTATATAGTAATACCAATACTCAAGACTACGAAAC
TGATACAATCTCTTATCATGTGGGTAATGTTCTCGATGTCGATAGCCATATGCCCGGTAGTTG
CGATATACATAAACTGATCACTAATTCCAAACCCACCCGCTTTTTATAGTAAGTTTTTCACCC
ATAAATAATAAATACAATAATTAATTTCTCGTAAAAGTAGAAAATATATTCTAATTTATTGC
ACGGTAAGGAAGTAGAATCATAAAGAACAGTGACGGATCGATCCCCCAAGCTTGGACAC 
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>158-284-pTM3-clone 2 
GCCTCTGCGGCCAAAAGCCACGGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGT
GCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAAC
AAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGT
GCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGG
GACGTGGTTTTCCTTTGAAAAACACGATAATACCATGGATAAACCCAACAATGATTTTCACT
TTGAAGTGTTCAACTTTGTACCCTGCAGCATATGCAGCAACAATCCAACCTGCTGGGCTATC
TGCAAAAGAATACCAACCAAAAAACCTGGAAAGAAAACCACCACCAAGCCCACAAAAAAA
CCAACTATCAAGACAACCAAAATAGATCTCAAACCTCAAACCACAAAACCAAAGGAAGTAC
TTACCACCAAGCCCACAGAAAAGCCAACTATCAACACCACCAGAACAAACATCGGAACTAC
ACTGCTCACCACCAATACCACAGGAAATCCAGAATACACAAGTCAAAAGGAAACCCTCCAC
TCAACCTCCCCCGAAGGCAGTCCAGGCCCTTCACAAGTCTATACAACATCTGAGGATCCCTG
CAGCTCGAGAGGCCTAATTAATTAAGTCGACGATCCGGCTGCTAACAAAGCCCGAAAGGAA
GCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACG
GGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGGTCCGGAGTTAACTCGACAT
CTATATACTATATAGTAATACCAATACTCAAGACTACGAAACTGATACAATCTCTTATCATG
TGGGTAATGTTCTCGATGTCGATAGCCATATGCCCGGTAGTTGCGATATACATAAACTGATC
ACTAATTCCAAACCCACCCGCTTTTTATAGTAAGTTTTTCACCCATAAATAATAAATACAATA
ATTAATTTCTCGTAAAAGTAGAAAATATATTCTAATTTATTGCAC 
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12.8 ELISAs 
Table 28 Direct IgA ELISA with infant sera. 
 A2   HeLa   CORRECTED    
ID Read1 Read2 Read3 Read1 Read2 Read3 Read1 Read2 Read3 Mean SD 
21 1.767 1.788 1.633 0.333 0.353 0.437 1.434 1.435 1.196 1.355 0.1377 
58 0.242 0.285 0.247 0.255 0.264 0.290 -0.013 0.021 -0.043 -0.012 0.03202 
55 0.282 0.284 0.304 0.260 0.258 0.302 0.022 0.026 0.002 0.017 0.01286 
56 0.408 0.315 0.332 0.284 0.314 0.276 0.124 0.001 0.056 0.060 0.06161 
65 0.300 0.287 0.251 0.316 0.306 0.305 -0.016 -0.019 -0.054 -0.030 0.02113 
20 0.310 0.287 0.288 0.239 0.225 0.284 0.071 0.062 0.004 0.046 0.03636 
16 0.277 0.237 0.233 0.281 0.283 0.281 -0.004 -0.046 -0.048 -0.033 0.02485 
27 0.525 0.452 0.441 0.365 0.341 0.339 0.160 0.111 0.102 0.124 0.03121 
51 0.275 0.218 0.218 0.221 0.226 0.235 0.054 -0.008 -0.017 0.010 0.03866 
30 0.238 0.246 0.245 0.279 0.274 0.290 -0.041 -0.028 -0.045 -0.038 0.00889 
52 1.853 1.945 1.840 0.345 0.345 0.418 1.508 1.600 1.422 1.510 0.08902 
54 0.487 0.496 0.511 0.491 0.525 0.526 -0.004 -0.029 -0.015 -0.016 0.01253 
29 0.274 0.274 0.283 0.280 0.280 0.303 -0.006 -0.006 -0.020 -0.011 0.00808 
50 0.235 0.236 0.250 0.280 0.267 0.336 -0.045 -0.031 -0.086 -0.054 0.02858 
33 0.763 0.741 0.692 0.296 0.311 0.316 0.467 0.430 0.376 0.424 0.04576 
28 0.366 0.258 0.246 0.248 0.255 0.242 0.118 0.003 0.004 0.042 0.06611 
43 0.648 0.606 0.640 0.284 0.289 0.342 0.364 0.317 0.298 0.326 0.03398 
22 0.397 0.397 0.383 0.331 0.337 0.378 0.066 0.060 0.005 0.044 0.03362 
60 0.289 0.303 0.308 0.304 0.300 0.344 -0.015 0.003 -0.036 -0.016 0.01952 
24 0.343 0.357 0.382 0.322 0.339 0.384 0.021 0.018 -0.002 0.012 0.0125 
61 0.612 0.497 0.474 0.330 0.323 0.337 0.282 0.174 0.137 0.198 0.07534 
41 0.428 0.334 0.326 0.308 0.325 0.325 0.120 0.009 0.001 0.043 0.06652 
35 0.292 0.256 0.254 0.237 0.236 0.243 0.055 0.020 0.011 0.029 0.02325 
44 0.391 0.357 0.361 0.422 0.428 0.461 -0.031 -0.071 -0.100 -0.067 0.03465 
46 0.339 0.267 0.249 0.252 0.276 0.271 0.087 -0.009 -0.022 0.019 0.05953 
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18 0.476 0.431 0.415 0.387 0.370 0.354 0.089 0.061 0.061 0.070 0.01617 
17 0.450 0.340 0.341 0.315 0.321 0.338 0.135 0.019 0.003 0.052 0.07204 
48 0.532 0.554 0.561 0.279 0.277 0.371 0.253 0.277 0.190 0.240 0.04493 
2 0.279 0.283 0.287 0.321 0.331 0.395 -0.042 -0.048 -0.108 -0.066 0.0365 
25 0.393 0.315 0.303 0.311 0.314 0.314 0.082 0.001 -0.011 0.024 0.05059 
26 0.464 0.353 0.313 0.279 0.272 0.260 0.185 0.081 0.053 0.106 0.06955 
45 0.370 0.254 0.266 0.292 0.294 0.305 0.078 -0.040 -0.039 0.000 0.06784 
53 0.403 0.413 0.409 0.356 0.353 0.432 0.047 0.060 -0.023 0.028 0.04464 
40 0.714 0.695 0.653 0.349 0.339 0.334 0.365 0.356 0.319 0.347 0.02438 
59 0.274 0.271 0.271 0.301 0.310 0.385 -0.027 -0.039 -0.114 -0.060 0.04715 
49 0.389 0.344 0.329 0.296 0.294 0.295 0.093 0.050 0.034 0.059 0.03051 
32 0.292 0.306 0.305 0.271 0.280 0.373 0.021 0.026 -0.068 -0.007 0.05289 
47 0.323 0.286 0.287 0.310 0.332 0.320 0.013 -0.046 -0.033 -0.022 0.031 
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Table 29 Maternal antibody against the fusion glycoprotein (GA2F) of HRSV GA2 
genotype. 
 GA2F   BGAL   CORRECTED    
ID Read1 Read2 Read3 Read1 Read2 Read3 Read1 Read2 Read3 Mean SD 
21 1.178 1.174 1.078 0.298 0.294 0.487 0.880 0.880 0.591 0.784 0.167 
58 2.026 1.976 1.856 0.222 0.222 0.330 1.804 1.754 1.526 1.695 0.148 
55 1.521 1.289 1.245 0.341 0.328 0.336 1.180 0.961 0.909 1.017 0.144 
56 2.708 2.465 2.330 0.266 0.269 0.255 2.442 2.196 2.075 2.238 0.187 
65 2.239 2.243 2.143 0.400 0.407 0.514 1.839 1.836 1.629 1.768 0.120 
20 2.821 2.514 2.394 0.157 0.146 0.160 2.664 2.368 2.234 2.422 0.220 
16 1.609 1.567 1.486 0.200 0.209 0.306 1.409 1.358 1.180 1.316 0.120 
27 1.892 1.643 1.600 0.610 0.530 0.517 1.282 1.113 1.083 1.159 0.107 
51 2.676 2.793 2.652 0.233 0.234 0.374 2.443 2.559 2.278 2.427 0.141 
30 2.682 2.458 2.383 0.500 0.494 0.484 2.182 1.964 1.899 2.015 0.148 
52 1.895 1.509 1.481 0.223 0.217 0.218 1.672 1.292 1.263 1.409 0.228 
54 2.462 2.132 1.976 0.240 0.237 0.240 2.222 1.895 1.736 1.951 0.248 
29 2.635 2.446 2.331 0.216 0.212 0.198 2.419 2.234 2.133 2.262 0.145 
50 0.786 0.554 0.536 0.170 0.166 0.174 0.616 0.388 0.362 0.455 0.140 
33 2.487 2.423 2.458 1.644 1.591 1.609 0.843 0.832 0.849 0.841 0.009 
28 1.196 1.007 1.000 0.139 0.139 0.143 1.057 0.868 0.857 0.927 0.112 
43 1.427 1.361 1.342 0.412 0.385 0.520 1.015 0.976 0.822 0.938 0.102 
22 0.744 0.701 0.715 0.171 0.178 0.246 0.573 0.523 0.469 0.522 0.052 
60 1.087 1.031 1.009 0.185 0.190 0.325 0.902 0.841 0.684 0.809 0.112 
24 2.509 2.472 2.349 0.458 0.468 0.560 2.051 2.004 1.789 1.948 0.140 
61 1.566 1.567 1.479 0.566 0.570 0.735 1.000 0.997 0.744 0.914 0.147 
41 1.864 1.505 1.484 0.380 0.387 0.391 1.484 1.118 1.093 1.232 0.219 
35 1.171 1.188 1.211 0.338 0.287 0.397 0.833 0.901 0.814 0.849 0.046 
44 1.156 0.990 0.995 0.422 0.458 0.445 0.734 0.532 0.550 0.605 0.112 
46 1.610 1.320 1.354 0.312 0.300 0.282 1.298 1.020 1.072 1.130 0.148 
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18 0.705 0.610 0.613 0.125 0.118 0.125 0.580 0.492 0.488 0.520 0.052 
17 0.485 0.448 0.441 0.319 0.435 0.320 0.166 0.013 0.121 0.100 0.079 
48 1.146 0.988 0.962 0.315 0.315 0.317 0.831 0.673 0.645 0.716 0.100 
2 0.282 0.285 0.294 0.112 0.102 0.178 0.170 0.183 0.116 0.156 0.036 
25 0.519 0.510 0.524 0.575 0.581 0.653 -0.056 -0.071 -0.129 -0.085 0.039 
26 0.043 0.045 0.051 0.054 0.056 0.085 -0.011 -0.011 -0.034 -0.019 0.013 
45 0.341 0.336 0.322 0.103 0.105 0.197 0.238 0.231 0.125 0.198 0.063 
53 2.971 2.735 2.609 0.502 0.474 0.462 2.469 2.261 2.147 2.292 0.163 
40 0.280 0.188 0.186 0.168 0.159 0.195 0.112 0.029 -0.009 0.044 0.062 
59 1.907 1.755 1.617 0.115 0.120 0.127 1.792 1.635 1.490 1.639 0.151 
49 0.478 0.474 0.524 0.383 0.371 0.481 0.095 0.103 0.043 0.080 0.033 
32 0.858 0.628 0.630 0.304 0.311 0.304 0.554 0.317 0.326 0.399 0.134 
47 1.675 1.511 1.407 0.599 0.602 0.575 1.076 0.909 0.832 0.939 0.125 
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Table 30 Maternal antibody against the G glycoprotein of HRSV genotype GA2. 
 GA2G   BGAL   CORRECTED    
ID Read1 Read2 Read3 Read1 Read2 Read3 Read1 Read2 Read3 Mean SD 
21 0.546 0.387 0.383 0.348 0.235 0.215 0.198 0.152 0.168 0.173 0.023 
58 1.354 1.358 1.352 0.190 0.189 0.296 1.164 1.169 1.056 1.130 0.064 
55 0.327 0.286 0.296 0.275 0.273 0.539 0.052 0.013 -0.243 -0.059 0.160 
56 2.712 2.686 2.638 0.246 0.247 0.340 2.466 2.439 2.298 2.401 0.090 
65 3.222 3.237 3.268 0.349 0.341 0.563 2.873 2.896 2.705 2.825 0.104 
20 1.664 1.535 1.458 0.147 0.146 0.144 1.517 1.389 1.314 1.407 0.103 
16 1.741 1.545 1.517 0.270 0.247 0.253 1.471 1.298 1.264 1.344 0.111 
27 1.352 0.890 0.798 0.359 0.368 0.447 0.993 0.522 0.351 0.622 0.332 
51 1.454 1.265 1.299 0.200 0.194 0.193 1.254 1.071 1.106 1.144 0.097 
30 1.761 1.641 1.673 0.581 0.548 0.627 1.180 1.093 1.046 1.106 0.068 
52 0.659 0.612 0.601 0.174 0.171 0.177 0.485 0.441 0.424 0.450 0.031 
54 2.058 2.009 1.924 0.178 0.184 0.184 1.880 1.825 1.740 1.815 0.071 
29 2.524 2.483 2.479 0.277 0.280 0.349 2.247 2.203 2.130 2.193 0.059 
50 0.965 0.605 0.834 0.201 0.209 0.181 0.764 0.396 0.653 0.604 0.189 
33 2.349 2.180 2.132 1.668 1.646 1.581 0.681 0.534 0.551 0.589 0.080 
28 0.573 0.564 0.569 0.126 0.124 0.157 0.447 0.440 0.412 0.433 0.019 
43 3.092 3.201 2.870 0.275 0.267 0.272 2.817 2.934 2.598 2.783 0.171 
22 0.517 0.534 0.516 0.174 0.176 0.238 0.343 0.358 0.278 0.326 0.043 
60 0.594 0.590 0.622 0.121 0.124 0.188 0.473 0.466 0.434 0.458 0.021 
24 2.348 2.365 2.249 0.193 0.195 0.310 2.155 2.170 1.939 2.088 0.129 
61 1.769 1.527 1.517 0.461 0.417 0.378 1.308 1.110 1.139 1.186 0.107 
41 1.096 1.105 1.081 0.299 0.289 0.396 0.797 0.816 0.685 0.766 0.071 
35 1.219 1.235 1.216 0.195 0.202 0.419 1.024 1.033 0.797 0.951 0.134 
44 0.352 0.347 0.345 0.252 0.253 0.445 0.100 0.094 -0.100 0.031 0.114 
46 1.150 1.131 1.280 0.212 0.231 0.469 0.938 0.900 0.811 0.883 0.065 
18 0.520 0.443 0.442 0.124 0.122 0.122 0.396 0.321 0.320 0.346 0.044 
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17 0.306 0.210 0.193 0.201 0.193 0.193 0.105 0.017 0.000 0.041 0.056 
48 0.797 0.789 0.763 0.231 0.221 0.332 0.566 0.568 0.431 0.522 0.079 
2 1.070 0.800 0.827 0.292 0.250 0.290 0.778 0.550 0.537 0.622 0.136 
25 0.805 0.588 0.588 0.434 0.427 0.430 0.371 0.161 0.158 0.230 0.122 
26 0.110 0.069 0.067 0.064 0.061 0.073 0.046 0.008 -0.006 0.016 0.027 
45 0.509 0.327 0.301 0.148 0.141 0.152 0.361 0.186 0.149 0.232 0.113 
53 2.943 2.783 2.680 0.228 0.220 0.223 2.715 2.563 2.457 2.578 0.130 
40 0.382 0.398 0.370 0.157 0.153 0.274 0.225 0.245 0.096 0.189 0.081 
59 0.353 0.352 0.339 0.105 0.108 0.211 0.248 0.244 0.128 0.207 0.068 
49 0.422 0.292 0.257 0.178 0.171 0.183 0.244 0.121 0.074 0.146 0.088 
32 0.298 0.290 0.285 0.215 0.210 0.283 0.083 0.080 0.002 0.055 0.046 
47 0.717 0.538 0.536 0.220 0.215 0.210 0.497 0.323 0.326 0.382 0.100 
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Table 31 Maternal antibody to the G glycoprotein of HRSV genotype BA4. 
 BAG   BGAL   CORRECTED    
ID Read1 Read2 Read3 Read1 Read2 Read3 Read1 Read2 Read3 Mean SD 
21 0.403 0.404 0.409 0.191 0.188 0.268 0.212 0.216 0.141 0.190 0.042 
58 1.786 1.837 1.815 0.195 0.194 0.237 1.591 1.643 1.578 1.604 0.034 
55 0.289 0.247 0.255 0.290 0.291 0.301 -0.001 -0.044 -0.046 -0.030 0.025 
56 3.244 3.215 3.013 0.254 0.257 0.250 2.990 2.958 2.763 2.904 0.123 
65 3.328 3.387 3.201 0.323 0.303 0.300 3.005 3.084 2.901 2.997 0.092 
20 1.676 1.650 1.656 0.158 0.157 0.201 1.518 1.493 1.455 1.489 0.032 
16 1.742 1.769 1.693 0.205 0.205 0.241 1.537 1.564 1.452 1.518 0.058 
27 0.973 0.825 0.789 0.371 0.387 0.406 0.602 0.438 0.383 0.474 0.114 
51 1.525 1.484 1.560 0.164 0.156 0.212 1.361 1.328 1.348 1.346 0.017 
30 1.997 2.009 1.950 0.524 0.526 0.611 1.473 1.483 1.339 1.432 0.080 
52 0.860 0.777 0.738 0.172 0.163 0.170 0.688 0.614 0.568 0.623 0.061 
54 2.481 2.268 2.149 0.183 0.181 0.190 2.298 2.087 1.959 2.115 0.171 
29 2.750 2.851 2.772 0.268 0.319 0.318 2.482 2.532 2.454 2.489 0.040 
50 0.958 0.874 0.782 0.131 0.128 0.138 0.827 0.746 0.644 0.739 0.092 
33 2.140 2.237 2.100 1.489 1.505 1.619 0.651 0.732 0.481 0.621 0.128 
28 0.786 0.804 0.794 0.135 0.132 0.159 0.651 0.672 0.635 0.653 0.019 
43 3.301 3.387 3.071 0.263 0.267 0.278 3.038 3.120 2.793 2.984 0.170 
22 0.571 0.561 0.587 0.149 0.154 0.166 0.422 0.407 0.421 0.417 0.008 
60 0.798 0.804 0.784 0.137 0.136 0.155 0.661 0.668 0.629 0.653 0.021 
24 3.119 3.027 2.821 0.302 0.287 0.291 2.817 2.740 2.530 2.696 0.149 
61 1.636 1.690 1.652 0.351 0.350 0.402 1.285 1.340 1.250 1.292 0.045 
41 1.278 1.212 1.223 0.344 0.346 0.410 0.934 0.866 0.813 0.871 0.061 
35 1.549 1.466 1.460 0.119 0.108 0.119 1.430 1.358 1.341 1.376 0.047 
44 0.619 0.681 0.547 0.324 0.332 0.334 0.295 0.349 0.213 0.286 0.068 
46 1.688 1.484 1.467 0.170 0.167 0.166 1.518 1.317 1.301 1.379 0.121 
18 0.716 0.522 0.534 0.114 0.113 0.125 0.602 0.409 0.409 0.473 0.111 
17 0.224 0.231 0.233 0.125 0.126 0.157 0.099 0.105 0.076 0.093 0.015 
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48 1.342 1.139 1.096 0.235 0.221 0.212 1.107 0.918 0.884 0.970 0.120 
2 0.764 0.766 0.762 0.197 0.189 0.221 0.567 0.577 0.541 0.562 0.019 
25 0.778 0.581 0.590 0.441 0.449 0.439 0.337 0.132 0.151 0.207 0.113 
26 0.053 0.060 0.068 0.059 0.060 0.061 -0.006 0.000 0.007 0.000 0.007 
45 0.481 0.395 0.382 0.155 0.159 0.169 0.326 0.236 0.213 0.258 0.060 
53 3.108 3.137 2.830 0.203 0.201 0.207 2.905 2.936 2.623 2.821 0.172 
40 0.499 0.453 0.446 0.137 0.131 0.138 0.362 0.322 0.308 0.331 0.028 
59 0.494 0.451 0.436 0.099 0.097 0.108 0.395 0.354 0.328 0.359 0.034 
49 0.385 0.275 0.315 0.169 0.166 0.171 0.216 0.109 0.144 0.156 0.055 
32 0.646 0.433 0.383 0.304 0.329 0.307 0.342 0.104 0.076 0.174 0.146 
47 0.490 0.457 0.490 0.186 0.186 0.230 0.304 0.271 0.260 0.278 0.023 
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